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It is even so - Nature is nowhere accustomed more openly to display her secret 
mysteries than in cases where she shows traces of her workings apart from the beaten 
path; nor is there any better way to advance the proper practice of medicine than to 
give our minds to the discovery of the usual law of Nature by careful investigation of 
rarer forms of disease. For it has been found in almost all things, that what they contain 
of useful or applicable is hardly perceived unless we are deprived of them, or they 
become deranged in some way. 
 
William Harvey (1578-1657) 
 
In a letter written six weeks before his death to a Dutch physician, Johannes Vlackveld of Haarlem, who 
had asked his advice about an unusual presentation of disease in one of his patients, 1657.  
Willis R. (ed.): The Works of William Harvey. London: Sydenham Society, 1847, p.616 
Harvey W. The Circulation of the Blood. Everyman’s Library 262. London, England: 
J.M.Dent &Sons;1966:209-210. 
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The publication of this thesis occurs exactly twenty years after the first description 
of the hyper-immunoglobulinaemia D (IgD) and periodic fever syndrome (HIDS) 
was published [1], and five years after the discovery of the genetic background of 
this autoinflammatory syndrome [2,3]. This last event was the final confirmation 
for the existence of HIDS as a distinct entity and has improved diagnosis. But at 
the same time it raised numerous questions on the pathogenesis – how can a 
genetic metabolic defect result in periodic inflammation? – which called for 
further investigation. The current thesis is filled with our exploits into the field of 
HIDS and auto-inflammation in the past four years. These will be briefly outlined 
here. 
 
This thesis starts off with a clinical review on the current knowledge of familial 
auto-inflammatory syndromes (chapter 1). This offers an introduction to these 
rare hereditary disorders for clinicians.  
 
The next four chapters deal with issues involving diagnosis of HIDS. The 
questions that we asked ourselves were: 
• What are the genotypes found in a cohort of HIDS patients, and can we 
develop an effective molecular testing strategy for diagnosis? (chapter 2) 
• What is the role of mevalonate kinase in HIDS, and can the subgroup of 
HIDS patients without mevalonate kinase deficiency be distinguished 
clinically? (chapter 3) 
• Is the clinical phenotype of mevalonate kinase deficiency truly a 
continuous spectrum between mevalonic aciduria and classical type HIDS? 
(chapter 4) 
• What are the characteristics of the acute phase response during 
inflammatory attacks in HIDS, and can these be used to discriminate 
between (serious bacterial) infection and a HIDS attack? (chapter 5) 
More fundamental research questions prompted the following two studies: 
• Why are classical type HIDS families, especially those carrying a V377I 
mutation in the MVK gene, clustered in the Netherlands? (chapter 6) 
• What is the effect of an excessive amount of mevalonic acid on the 
function of peripheral blood mononuclear cells in classical type HIDS 
patients as well as in healthy controls? (chapter 7) 
In the search for an effective treatment of the inflammatory attacks in HIDS, we 
performed two clinical trials to study the effect of two medications on the 
frequency, intensity and duration of these HIDS attacks:  
- Thalidomide, a drug known to inhibit production of several cytokines, 
beneficial in a large variety of inflammatory disorders (chapter 8) 
- Simvastatin, an inhibitor of HMG-CoA reductase which reduces the 
formation of mevalonic acid (chapter 9).  
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In chapter 10, the scope is broadened from HIDS to all hereditary 
autoinflammatory syndromes, to try and answer the question: would more rigorous 
and unlimited genetic screening allow further classification of patients with 
periodic fever attacks, who could not be diagnosed previously? An additional 
question raised here is whether combinations of mutations from different 
autoinflammatory syndromes occur regularly, as is suggested by some. 
 
We take a closer look at TNF-receptor associated periodic syndrome (TRAPS) in 
the subsequent three chapters in the form of clinical observations: 
• Diagnosis of two patients with TRAPS, after a delay of more than 40 years 
– and what is the effect of short course etanercept, a soluble TNF-receptor 
preparation, in the treatment of the inflammatory attacks? (chapter 11). 
• Could the cessation of inflammatory attacks in a TRAPS patient who 
developed amyloidosis be related to her renal insufficiency? (chapter 12) 
• How to treat a patient with severe TRAPS, refractory to etanercept? 
(chapter 13) 
Chapter 14 is a clinical review on the subject of abdominal pain in familial 
Mediterranean fever (FMF), in which we try to answer the question: what is the 
best approach and treatment for abdominal attacks in FMF?  
 
The thesis ends with a general summary of the research described and a look at 
future perspectives. 
 
  
Chapter 1 
Familial Autoinflammatory 
Syndromes 
Anna Simon, Jos W.M. van der Meer, Joost P.H. Drenth 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kelley’s Textbook of Rheumatology, 7th Edition, 2004: chapter 112 (in press) 
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
The familial auto-inflammatory syndromes, otherwise known as hereditary 
periodic fever syndromes, form a group of rare disorders with a common 
phenotype of lifelong recurrent inflammatory episodes with fever, usually 
accompanied by other inflammatory symptoms such as abdominal pain, diarrhea, 
rash or arthralgia, and separated by symptom-free intervals [4]. In between the 
fever episodes, patients feel healthy and can generally function normally. Routine 
laboratory investigations during a fever attack invariably reveal a severe acute 
phase response with a high sedimentation rate, leukocytosis and high 
concentrations of acute phase proteins such as C-reactive protein (CRP), serum 
amyloid A (SAA) and several proinflammatory cytokines.The fever episodes most 
often arise without an obvious trigger, although some patients note a relation with 
physical stimulus (exposure to cold), emotional stress, or with the menstrual cycle 
in women. They resolve spontaneously after a number of days or weeks. Patients 
with periodic fever very often go undiagnosed for years. That represents a high 
level of discouragement and frustration for patients and physicians because in 
many instances elaborate clinical investigations fail to substantiate the diagnosis 
[5,6]. The term “auto-inflammatory”, coined by McDermott et al. in 1999 for these 
disorders [7],  adequately describes the phenotype of recurrent acute inflammatory 
responses. It is preferable to “auto-immune” in these cases, since autoimmune 
phenomena are not found. 
At the moment, four distinct subtypes of hereditary periodic fever are recognized, 
if we take a genetical basis for the classification. Despite the common phenotype 
described above, these subtypes can often be differentiated clinically by a number 
of specific characteristics; in particular the mode of inheritance, age of onset, 
average duration of the fever episodes and the fever-free interval, geographical 
region of origin of the patients family, and occurrence of long-term complications 
like amyloidosis or deafness (table 1; figure 1).  
Since the end of the 1990s, when three of these subtypes were genetically 
characterized (the fourth followed in 2001), they have obtained a more definite 
foothold in medicine, because for the first time a positive diagnosis became 
possible instead of a diagnosis per exclusionem. However, there still remains a 
significant number of patients with periodic fever phenotypes who do not fit into 
this classification. It is probable that there are more (genetic) defects that can lead 
to periodic fever, which have not yet been recognized. Another disappointing 
aspect is the lack of efficacious therapy for these disorders. Hopefully, a further 
characterization of the distinct pathogenetic mechanisms in the near future will 
give us a clue on treatment of these debilitating disorders.   
In this chapter, we will describe the six major subtypes of familial auto-
inflammatory syndromes: Familial Mediterranean fever (FMF), the hyper-IgD and 
periodic fever syndrome (HIDS), the TNF-receptor associated periodic syndrome 
(TRAPS), Familial cold autoinflammatory syndrome (FCAS), Muckle-Wells 
syndrome (MWS) and Chronic infantile neurological cutaneous and articular 
syndrome (CINCA) or the neonatal onset multisystemic inflammatory disease 
(NOMID) as it is known in Anglo-Saxon literature. 
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Table 1. Differential diagnosis of familial auto-inflammatory syndromes.  
* duration may be variable; here given is a typical duration; aut. = autosomal. Adapted from Hull et al. [8] 
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Figure 1. Characteristic patterns of body temperature during inflammatory attacks in the familial auto-
inflammatory syndromes. However, there is considerable interindividual variability for each syndrome and and 
even for the individual patient, the fever pattern may vary greatly from episode to episode. Please note the 
different time scales on the X axes. 
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Recently, it has been proposed to include a number of other syndromes in the 
group of autoinflammatory disorders. These include Crohn’s disease, Blau 
syndrome and also the inherited syndrome “Pyogenic sterile Arthritis, Pyoderma 
gangrenosum and Acne” (PAPA), which has been genetically characterised as well 
[9]. We will discuss PAPA and Blau syndrome briefly at the end of the chapter. 
%&&"
When do we consider the diagnosis periodic fever? When a patient has had 
recurrent fever episodes for more than two years, it is increasingly unlikely that 
these are caused by an infection or a malignant disorder. The differential diagnosis 
at that time may include numerous inflammatory disorders such as juvenile 
rheumatoid arthritis, adult-onset Still’s disease, inflammatory bowel disease, Blau 
syndrome, Schnitzler syndrome and Behçet’s disease, besides the hereditary 
periodic fever syndromes (table 2). Since the hereditary syndromes are rare 
(except for Familial Mediterranean fever in people with a distinct ethnical 
background), the more common diagnoses need to be sought for first.  
 
Table 2. Differential diagnosis of periodic fever 
Hereditary – see table 1 
Non-hereditary 
infectious:  
hidden infectious focus (e.g. aorta-enteral fistula, Caroli syndrome) 
recurrent reinfection (e.g. chronic meningococcemia; host defense defect) 
specific infection (e.g. Whipple’s disease, malaria) 
non-infectious inflammatory disorders: 
adult onset Still’s disease 
juvenile chronic rheumatoid arthritis 
periodic fever, aphtous stomatitis, pharyngitis and adenitis (PFAPA) 
Schnitzler syndrome 
Behçet syndrome 
Crohn’s disease 
sarcoidosis 
extrinsic alveolitis 
humidifier lung, polymere fume fever 
neoplastic: 
lymphoma (Hodgkin’s disease, angioimmunoblastic lymphoma (AILD)) 
solid tumour (pheochromocytoma, myxoma, colon carcinoma) 
vascular: 
recurrent pulmonary embolism 
hypothalamic 
psychogenic periodic fever [10] 
factitious / fraudulent 
 
The mainstay of the diagnosis of hereditary periodic fever is clinical assessment 
with a detailed medical history (which includes family history) and preferably at 
least once observation of the patient during a fever episode, as physical 
examination of the patient in a remission period is seldom abnormal. This clinical 
assessment will often yield enough information for the first differential diagnosis 
of the specific familial autoinflammatory syndromes (table 1). The next step is to 
try for a more definite, genetic diagnosis. A specific diagnosis within the group of 
familial autoinflammatory syndromes is important as it will yield information on 
prognosis, treatment and genetic counselling.  
 1 
Chapter 1 
 
18 
'
"'(
 	")
Familial Mediterranean Fever (FMF, MIM 249100) is the most prevalent disorder 
among the hereditary autoinflammatory syndromes, with more than 10,000 
patients affected worldwide. It occurs mostly in people originating from the 
Mediterranean basin, including Armenians, Sephardic Jews, Arabs and Turks. 
FMF is an autosomal recessively inherited disorder. Most families reported with 
an apparent autosomal dominant inheritance pattern of FMF [11] represent 
examples of pseudodominant inheritance due to consanguinity and the high carrier 
frequency of FMF mutations in certain populations [11-13]; at least three families 
do seem to show a true dominant inheritance even after extensive genetic analysis 
[13]. 
 )
In 1997, two groups independently traced the genetic background of familial 
Mediterranean fever to a hitherto unknown gene on the short arm of chromosome 
16, which was dubbed MEFV gene. At least 67 disease-linked mutations in the 
MEFV gene have been described so far, most of which are clustered in the tenth 
exon of this gene. Most of the mutations are missense mutations, leading to a 
single amino acid change in the protein (figure 2).  
 
There are 6 common mutations, accounting for almost 99% of all FMF 
chromosomes; these are M694V (occurring in 20 to 65 percent of cases, depending 
on the population examined [14]), V726A (in 7 to 35 percent), M680I, M694I, 
V694I and E148Q. For the first three mutations mentioned here, a founder effect 
has been established [15], pointing to common ancestors at least 2500 years ago. 
The high frequency of the mutated MEFV gene in more than one Middle Eastern 
population has led to the hypothesis that heterozygous carriers have an as yet 
unknown advantage, possibly a heightened (inflammatory) resistance to an 
endemic pathogen of the Mediterranean basin [15]. Such a pathogen has not been 
identified so far.  
 
Figure 2. Schematic representation of pyrin (marenostrin) protein, with 4 conserved domains, including a 
pyrin domain (yellow), a coiled-coil domain (white) and a B30.2 domain (red). Indicated are the mutations 
as found in FMF, with the 5 most common missense mutations in bold type. 
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The MEFV gene encodes for a protein of 781 amino acids known as pyrin or 
marenostrin, which is mainly expressed as a cytoplasmic protein in mature 
neutrophils and monocytes [16], in association with microtubuli [17]. The 
expression of pyrin is effectively stimulated by inflammatory mediators such as 
interferon-γ and tumor necrosis factor [18]. The pyrin domain is shared by a 
number of proteins involved in apoptosis and inflammation and is a member of the 
six-helix bundle death-domain superfamily that includes death domains, death 
effector domains, and caspase recruitment domains.  Pyrin binds specifically to 
other proteins that contain a pyrin domain. There is increasing evidence for a 
function of pyrin as mediator of apoptosis [19]. Another hypothesis on 
pathogenesis of FMF implicates a specific inhibitor of chemotaxis, a serine 
protease that inactivates the complement factor C5a and interleukin 8, which can 
be found in peritoneal and synovial fluids [19-21]. It is thought that this inhibitor 
acts to prevent inappropriate inflammation [20]. Activity of this C5a-inhibitor was 
greatly reduced in serosal fluid from FMF patients [19,21], which might contribute 
to the development of a severe inflammatory response after a rather innocuous 
stimulus. A relationship between pyrin and C5a-inhibitor is hypothetical and has 
not been established so far. 
&
In approximately 90 percent of patients, symptoms start before the age of 20 years 
[22]. The inflammatory attacks of FMF usually last only 1 to 3 days, and 
frequency of the attacks can be very variable, though 2 to 4 weeks is the most 
common interval (figure 1). Fever is the main feature of the attacks in FMF, and is 
usually accompanied by symptoms of serositis (either peritonitis, pleuritis or 
synovitis). Abdominal pain of one or two days’ duration occurs in 95 percent of 
patients [23], varying in severity from severe peritonitis resembling acute abdomen 
to only mild abdominal pain without overt peritonitis [24]. Arthritis is often 
confined to one large joint, such as the knee, ankle or wrist, and may also be the 
sole manifestation of an attack. Chronic destructive arthritis and migratory 
polyarthritis are rare. Chest pain due to pleuritis is usually unilateral, and 
associated with diminished breathing sounds, a friction rub or transient pleural 
effusion. Skin involvement occurs in approximately 30 percent of patients, most 
often as an erysipelas-like skin lesions on the shins or feet (figure 3) [25]. Other, 
more uncommon, symptoms are pericarditis, occurring in less than 1 percent [26], 
acute scrotal swelling and tenderness [27], aseptic meningitis and severe protracted 
myalgia, especially of the legs. 
 1 
  
Figure 3. Erysipelas like 
eruption in a patient with a 
FMF attack. Picture courtesy 
of Professor A. Livneh, 
Heller Institute of Medical 
Research, Tel Hashomer, 
Israel 
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Recurrent attacks of peritonitis may lead to intraabdominal or pelvic adhesions, 
resulting in  complications such as small bowel obstruction or reduced fertility in 
female patients. Another serious long-term complication of FMF is AA 
amyloidosis, which is found primarily in the kidneys, but also in the 
gastrointestinal tract, liver and spleen, and eventually in the heart, testes and 
thyroid, leading to organ dysfunction. The prevalence of amyloidosis is variable, 
especially according to the population, but generally high in untreated patients. It 
is common among Sephardic Jews but rare in Ashkenazi Jews [28]. 
 ("
There is no specific biologic marker for FMF available. During an inflammatory 
attack there will be a polymorphonuclear leukocytosis and serum markers of acute 
phase response are found to be elevated. These include serum amyloid A (SAA), 
C-reactive protein (CRP) and plasma fibrinogen. Proteinuria in patients with FMF 
is highly suggestive of amyloidosis [24].  
FMF is a clinical diagnosis, and there is a set of validated diagnostic criteria (table 
3) [29], with a reported sensitivity and specificity of 96-99%. However, this was 
validated in a population with a very high prevalence of FMF and low prevalence 
of the other auto-inflammatory disorders, and it is not known whether this also 
applies to other populations [4].  
Since the location of FMF mutations is known, it is possible to establish a 
molecular diagnosis of FMF, but there are some limitations [4]. Genetic 
laboratories usually screen for the five most common mutations, and those that are 
more rare will be missed. Furthermore, MEFV mutations occur on both alleles in 
only 70 percent of typical cases [30], while in the remaining 30 percent only one 
or no mutation can be detected, even after sequencing. There is also evidence of 
reduced penetrance. Despite these limitations, molecular testing can be used as a 
confirmatory test in cases in which there is a high index of suspicion. Whether or 
not the results are positive, treatment with colchicine is warranted in symptomatic 
cases fulfilling the diagnostic criteria [31-34]. 
An issue of some importance in the management are the fertility problems 
encountered in FMF. For a variety of reasons, including peritoneal adhesions and 
ovulatory dysfunction, subfertility in females is not rare [35]. In males, subfertility 
due to azoospermia (sometimes secondary to testicular amyloidosis) or impairment 
of sperm penetration has been noted [36]. 
Table 3. Diagnostic criteria for diagnosis of FMF (Tel-Hashomer) [29] 
Major criteria: 
Typical attacks with peritonitis (generalized) 
Typical attacks with pleuritis (unilateral) or pericarditis 
Typical attacks with monarthritis (hip, knee, ankle) 
Typical attacks with fever alone 
Incomplete abdominal attack 
Minor criteria: 
Incomplete attacks involving chest pain 
Incomplete attacks involving monarthritis 
Exertional leg pain 
Favorable response to colchicine 
 
Requirements for diagnosis of FMF are 1 major criteria or 2 minor criteria. 
Typical attacks are defined as recurrent (3 of the same type), febrile (38°C) and short (between 
12 hours and 3 days). Incomplete attacks are defined as painful and recurrent attacks not fulfilling 
the criteria for a typical attack. 
Familial Autoinflammatory Syndromes 
 
21 
*
Colchicine is the first-line of treatment for patients with FMF. Its efficacy has been 
established in two controlled clinical trials in 1974 [33,34]. Colchicine will prevent 
inflammatory attacks in 60 percent of patients, and significantly reduces the 
number of attacks in another 20 to 30 percent [22]. The average dose in adults is 1 
mg daily, but this may be increased up to 3 mg in cases where no response is seen 
at the low dose. This regimen is usually well tolerated, and gastrointestinal side 
effects including diarrhea or abdominal pain will generally resolve with dose 
reduction. More serious side effects, such as myopathy, neuropathy and leukopenia 
are rare, and occur mainly in patients with renal or liver impairment. During a 
fever attack, diclofenac (75 mg administered intramuscularly) may be used for 
pain relief. Other agents (e.g. reserpine, steroids) have limited efficacy. 
Compliance with colchicine use is very important, since colchicine has been 
shown to prevent the occurrence of amyloidosis. Since the introduction of 
colchicine treatment, the incidence of amyloidosis in FMF has dropped 
dramatically, while in areas with a high prevalence of FMF where colchicine is not 
routinely available, such as Armenia, amyloidosis is still common.  
Colchicine’s main effect at the cellular level occurs by its interaction with tubulin 
at the microtubules, inhibiting motility and exostosis of intracellular granules. 
Furthermore, it has a powerful antimitotic effect by causing  metaphase arrest. 
Therefore it has been speculated, in cases of infertility in patients treated with 
colchicine, that this medication causes azoospermia. However, colchicine does not 
have a significant adverse effect on sperm production or function [37]. Unfounded 
fear of teratogenic effects of colchicine often wrongly leads to cessation of this 
drug in young women who wish to get pregnant, with a subsequent increased 
frequency and severity of attacks, which enhances problems with fertility and 
pregnancy. Colchicine has proven safe even in early pregnancy and treatment 
should not be interrupted for this reason [35,38]; it can also be used while breast 
feeding [36].  
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The hyper-IgD syndrome (HIDS, MIM 260920) is also an autosomal recessively 
inherited disorder, but is far less prevalent than FMF. The International Hyper-IgD 
syndrome Registry, based at Nijmegen, the Netherlands, in which clinical 
information is actively collected from physicians worldwide, currently holds data 
on some 190 patients. More than 80% of these stem from Western Europe, 55% 
originate from the Netherlands and France. Almost all of the hyper-IgD patients 
are of Caucasian origin. These observations can at least in part be explained by a 
founder effect [39]. In the Netherlands the carrier frequency of a hyper-IgD 
mutation is estimated to be 1:350. There are equal numbers of men and women 
affected. Based on the genotype and phenotype we now distinguish classic HIDS 
and variant HIDS [40]. 
 )
The hyper-IgD syndrome in its classic form is caused by mutations in the gene 
encoding for the enzyme mevalonate kinase, located on the long arm of 
chromosome 12 [2,3,40]. Mevalonate kinase is part of the isoprenoid pathway; it is 
the next step after 3’5’-hydroxymethylglutaryl-coenzyme A (HMG-CoA) 
reductase, and phosphorylates mevalonic acid. The isoprenoid pathway has a 
number of very diverse endproducts, which include cholesterol, dolichol and 
ubiquinone. It also leads to isoprenylation of proteins, which is a post-translational 
modification directing these proteins, such as Rho and Ras, to the cell membrane 
[41]. 
Patients with classic hyper-IgD syndrome are most often compound heterozygotes 
for two different missense mutations in the mevalonate kinase gene (figure 4). 
Two mutations (leading to a valine-to-isoleucine change, V377I, and to a 
isoleucine-tyrosine change, I268T) together account for more than 85% of patients 
described so far [41,42]. The mutations lead to a constantly diminished activity of 
mevalonate kinase to about 5-15% of normal, which appears to be further reduced 
during a fever attack [43]. 
Because of this reduced enzyme activity, its substrate mevalonic acid can 
accumulate in serum and urine. This accumulation of mevalonic acid is 
predominantly observed during the fever episodes. There does not appear to be a 
dramatic shortage of a specific end-product; concentrations of cholesterol, 
Figure 4. Mevalonate kinase, with four conserved domains represented by colored boxes. Indicated are the 
missense mutations, nonsense mutations and two deletions which have been identified in mevalonate 
kinase deficiency. In bold, mutations found in mevalonic aciduria patients, in bold and italic mutations 
found in both classical HIDS and mevalonic aciduria. 
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ubiquinone and dolichol in patients are normal to low-normal. How this metabolic 
defect in the isoprenoid pathway leads to the inflammatory phenotype of the 
hyper-IgD syndrome is still unknown. The cause of the characteristic high serum 
concentrations of immunoglobulin D in this syndrome, which have led to its name, 
are also still unexplained. 
Another syndrome was already linked to mutations in the mevalonate kinase gene 
before the hyper-IgD syndrome [44]. Mevalonic aciduria patients carry specific 
mutations which cause a more severe reduction of mevalonate kinase enzyme 
activity, often to undetectable limits. These patients constantly accumulate large 
amounts of mevalonic acid, and often have more than thousand times as much 
mevalonic acid in the urine than hyper-IgD patients [45]. They also have a more 
severe phenotype, which will be described later. Evidence is emerging that 
mevalonic aciduria and the hyper-IgD syndrome are not two sides of a dichotomy, 
but rather two extremes of a continuous spectrum of disease related to mevalonate 
kinase deficiency. 
Not all patients with HIDS appear to have an increased urinary excretion of 
mevalonic acid and a gene defect of mevalonate kinase. We have designated these 
patients as variant HIDS (table 1) [40].  
&
Ninety percent of patients with classic HIDS will experience the first fever episode 
in the first year of life [46]. These episodes tend to be most frequent in childhood 
and adolescence, and the high fever may result in febrile seizures, especially in 
young children. Vaccination, minor trauma, surgery and physical or emotional 
stress are factors which seem able to provoke a fever episode, though often a 
 1 
Figure 5. Facial erythematous 
macules and papules in a HIDS 
patient during an attack 
  
Figure 6. Petechiae on the leg of 
a HIDS patient during a febrile 
attack. 
Figure 7. Aphthous ulceration 
detected on the tongue in a 
patient with HIDS. Picture 
courtesy of Dr. K. Antila, North 
Carelian Central Hospital, 
Joensuu, Finland. 
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triggering factor is not obvious. The fever episode often starts with cold chills and 
a sharp rise in body temperature [4]. It is almost always accompanied by (cervical) 
lymphadenopathy and abdominal pain with vomiting and diarrhea. Other frequent 
symptoms are headache, myalgia and arthralgia. Apart from the lymphadenopathy, 
physical signs frequently consist of splenomegaly and a skin rash with 
erythematous macules and papules (figure 5) or petechia (figure 6) [47]. 
Sometimes there are also signs of frank arthritis, mostly of large joints, and 
hepatomegaly. About forty percent of patients report painful aphthous ulcers in the 
mouth, vagina or on the scrotum (figure 7). The fever will disappear spontaneously 
after 3 to 5 days, though it may take longer before the symptoms of joints or skin 
disappear completely. These inflammatory attacks occur on average once every 4 
to 6 weeks although this may be very variable from patient to patient or in an 
individual patient (figure 1). The phenotype of variant HIDS differs slightly from 
and is milder than that of classic HIDS [40]. 
Patients with mevalonic aciduria, the metabolic disorder which is also caused by 
mevalonate kinase gene mutations, experience similar inflammatory episodes as 
hyper-IgD patients, but these are often of lesser importance in comparison with the 
severity of the rest of the phenotype. This phenotype consists of psychomotor 
retardation, ataxia, failure to thrive, cataracts and dysmorphic facies, and patients 
usually die in early childhood [45]. 
The long-term outcome in both classic and variant hyper-IgD syndrome is 
relatively benign. No cases of amyloidosis have been reported in the literature, nor 
has this occurred in the 190 patients in the International Nijmegen HIDS registry 
since its initiation in 1992 [4]. There is no excess mortality in this patient group. In 
many patients, the fever episodes occur less frequently and become less severe 
later in life. Joint destruction is extremely rare. Abdominal adhesions are more 
frequently seen, resulting from repeated abdominal inflammation and/or 
(unnecessary) diagnostic laparotomy because of suspected “acute abdomen”. 
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"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HIDS is diagnosed on a combination of characteristic clinical findings and 
continuously elevated immunoglobulin D (IgD) concentrations (more than 100 
IU/mL) (table 4). However, IgD values may be normal in very young patients 
(especially those less than three years old) [48] and persistently low levels have 
been reported in a small number of patients with typical clinical findings and the 
genotype for HIDS [3]. More than 80 percent of HIDS patients combine a high 
concentration of IgD with high IgA levels [48,49]. During fever attacks, a brisk 
acute-phase response is observed, which includes leukocytosis, high levels of SAA 
and CRP, and activation of the cytokine network [50]. The diagnosis of classic 
HIDS can be confirmed by DNA analysis of the mevalonate kinase gene. The best 
approach is to start with screening for the two most prevalent mutations, V377I 
and I268T. If this screening is negative but the clinical suspicion remains very 
high, sequencing of the entire gene can be considered. An alternative is the 
measurement of urinary mevalonic acid concentrations during an attack, which are 
slightly elevated. However, gas chromatography–mass spectroscopy is necessary 
to detect this slight increase [51]. The measurement of mevalonate kinase enzyme 
activity is complicated and time-consuming, and is mostly reserved for scientific 
research purposes. 
 
Familial Autoinflammatory Syndromes 
 
25 
Table 4. Diagnostic indicators of HIDS 
At attacks 
Elevated ESR and leukocytosis 
Abrupt onset of fever (38.5°C) 
Recurrent attacks 
Lymphadenopathy (cervical) 
Abdominal distress: vomiting, diarrhoea, pain 
Skin manifestations (erythematous macules and papules) 
Arthralgias / Arthritis 
Splenomegaly 
 
Constantly present 
Elevated IgD ( 100 U/mL) measured at 2 occasions with at least one month aparta 
Elevated IgA (2.6 g/L) 
Classic HIDS: mutations in mevalonate kinase gene 
Classic HIDS: decreased mevalonate kinase enzyme activity 
a(Extremely) high serum concentrations of IgD are characteristic but not obligatory. 
*
There is no efficacious therapy for the hyper-IgD syndrome. Some individual 
patients have been reported to have benefited from treatment with corticosteroid, 
colchicine, intravenous immune globulin or cyclosporin, but these results can not 
be repeated in the majority of patients [46]. Thalidomide did not have an effect on 
disease activity in a recent placebo-controlled trial [52]. Preliminary results of a 
double-blind placebo-controlled trial that we performed with the HMG-CoA 
reductase inhibitor simvastatin in a small group of HIDS patients indicate a 
beneficial effect of this drug, reducing the number of days illness by 
approximately 50 percent. 
*-',	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TNF-receptor associated periodic syndrome (TRAPS, MIM142680) has an 
autosomal dominant inheritance pattern. It was originally described in a large 
family from Irish and Scottish descent as “Familial Hibernian Fever” [53]. It is 
primarily found in patients originating from north-western Europe, but has also 
been described in families from Australia, Mexico, Puerto Rico, Portugal, and the 
Czech Republic [54], and it is clear that any ethnic group may be affected. Other 
previous nomenclature for this syndrome include “autosomal dominant familial 
periodic fever” [55] and “familial perireticular amyloidosis” [56]. 
 )
Mutations are found in the gene for the type I TNF-receptor (TNFRSF1A), which 
is located on the short arm of chromosome 12 [7]. These are mainly single-
nucleotide missense substitutions, located in exons 2, 3 and 4, which encode for 
the extracellular domain of TNFRSF1A. Many disrupt one of the highly conserved 
cysteine residues involved in extracellular disulfide bonds of the 55-kD protein 
(figure 8). 
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These mutations are supposed to be gain-of-function mutations, leading to 
increased TNF-α signalling through the TNF-receptor. TNF-α is a pleiotropic 
molecule, which induces cytokine secretion, activation of leukocytes, fever and 
cachexia [57]. Activation of the receptor by TNF-α causes cleavage and shedding 
of its extracellular part into the circulation, where it acts as an inhibitor of TNF-α. 
It has been suggested that the mutations in the TNFRSF1A found in TRAPS 
interfere with receptor shedding, leading to continuous TNF-α signaling and, 
hence, uncontrolled inflammation. An in vitro shedding defect has been 
demonstrated in the case of a number of TRAPS mutations, but not in all of them 
[7,58]. Also, serum concentrations of the shedded soluble TNFRSF1A in TRAPS 
patients during periods without symptoms are often found to be significantly 
reduced compared to normal subjects [54,58,59], but not in all cases. Thus, the 
hypothesis of reduced shedding, although attractive by its simplicity, is not 
supported as the sole cause of the fever attacks in TRAPS, and additional 
mechanisms seem to be at work. 
There are some general genotype-phenotype correlations, especially when 
mutations are grouped in cysteine and non-cysteine mutations. Non-cysteine 
mutations have overall a lower penetrance than cystein mutations, and amyloidosis 
is seen far more often in association with cystein mutations [58]. Two missense 
mutations in TNFRSF1A, P46L and R92Q, have a particularly low penetrance, 
and are found in approximately 1% of control chromosomes [58,58]. Especially 
R92Q has been observed in higher prevalence in for example a group of patients 
with arthritis. It is thought that the clinical manifestations of patients with an R92Q 
mutation depend on other so far unidentified modifying genes and/or 
environmental factors [58,58].  
 
Figure 8. Schematic representation of the TNF-receptor type 1 protein (TNFRSF1A), depicting all 
mutations found in TRAPS up to this time (except for one intron mutation affecting a splice site). 
Mutations disrupting cysteine residues are in blue italics. 
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The clinical features can vary much more between individual TRAPS patients than 
is generally seen in FMF or HIDS [54]. The age of onset can be very variable, 
even within the same family, with a range of 2 weeks to 53 years of age [54,60]. 
There is also a large variation in duration and frequency of the fever episodes in 
TRAPS. On average, attacks last 3 to 4 weeks and recur 2 to 6 times each year, but 
episodes may also be limited to a few days (figure 1). While the index patient 
through whom the diagnosis is made often displays well-defined inflammatory 
attacks, affected family members may suffer from less typical symptoms such as 
episodic symptoms of mild arthritis. 
During inflammatory attacks, a high spiking fever can be accompanied by skin 
lesions, myalgia and arthralgia, abdominal distress and ocular symptoms. The most 
common cutaneous manifestation is a centrifugal migratory, erythematous patch, 
which may overlie a local area of myalgia (figure 9) [61], but urticaria-like plaques 
may also be seen. Myalgia is often located primarily in the thigh muscles, but may 
also migrate during the fever episode. It may effect limbs and torso, but also face 
and neck [54]. Arthralgia primarily affects large joints, including hips, knees and 
ankles. Frank synovitis is more rare, and when it does occur it is non-erosive, 
asymmetric and monoarticular [54]. Abdominal pain occurs in 92% of TRAPS 
patients during inflammatory attacks; other gastrointestinal symptoms often seen 
include vomiting and constipation. Ocular involvement is characteristic in TRAPS, 
and it may involve conjunctivitis, periorbital edema or periorbital pain, in one or 
both eyes. Severe uveitis and iritis has been described, and any TRAPS patient  
with ocular pain should be examined for these complications [54,61]. Other less 
frequently observed symptoms during fever attacks in TRAPS are chest pain, 
breathlessness, pericarditis and testicular and scrotal pain, which may be caused by 
inflammation of the tunica vaginalis [54,60]. It has been suggested from 
observation in one of the first families with TRAPS that this disorder is associated 
with an increased incidence of indirect inguinal hernias [59], but this has not been 
demonstrated in other patients. Lymphadenopathy is rare in TRAPS. 
Reactive AA amyloidosis is the main determinant for the prognosis in TRAPS. It 
occurs in about 15-25% of patients [58,62], and generally leads to renal 
impairment. Amyloidosis in a patient with TRAPS places other affected family 
members at high risk for this complication. It is mainly associated with 
TNFRSF1A mutations affecting cysteine residues [58].  
Figure 9. 
 Migrating erythematous rash 
during a TRAPS attack. Picture 
courtesy of Dr. T. Fiselier, 
University Medical Center St. 
Radboud, Nijmegen, The 
Netherlands. 
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As in the other familial auto-inflammatory syndromes, laboratory investigations 
during inflammatory attacks show a clear acute phase response, and again even in 
between fever attacks such an inflammatory response may be measured. 
Autoantibodies are generally not detected in TRAPS. The IgD level may be 
elevated, but the value is almost always less than 100 IU/mL[59,60]. Most patients 
exhibit a significantly lower concentration of soluble TNFRSF1A, most 
prominently in symptom-free intervals, compared with appropriate controls[59], 
although this does not appear to be a universal rule[54]. Also, since soluble 
TNFRSF1A is cleared by the kidneys, TRAPS patients with renal insufficiency 
(e.g. due to renal amyloidosis) may have normal or elevated plasma concentrations 
of this protein[63]. 
A set of clinical diagnostic criteria was proposed by Hull et al. [54] as indicators of 
TRAPS (table 5). These are not validated by epidemiological measures, but may 
be used as a first step in evaluation of patients. TRAPS is ultimately a genetic 
diagnosis, defined by a missense mutation in the gene for TNFRSF1A. However, it 
must be borne in mind that clinical penetrance of TRAPS mutations is not 100%, 
even for cysteine mutations, and asymptomatic carriers are not uncommon.  
Since proteinuria is the initial manifestation of renal amyloidosis, it is advisable to 
screen urine samples from TRAPS patients regularly by dipstick examination, 
especially affected family members from a TRAPS patient with amyloidosis. 
 
Table 3. Diagnostic indicators of TRAPS [54] 
Recurrent episodes of inflammatory symptoms spanning a period of >6 months duration  
(several symptoms generally will occur simultaneously) 
fever 
abdominal pain 
myalgia (migratory) 
rash (erythematous macular rash occurs with myalgia) 
conjunctivitis/periorbital edema 
chest pain 
arthralgia or monoarticular synovitis 
Episodes last >5 days on average (although variable) 
Responsive to glucocorticosteroids but not colchicine 
Affect family members in autosomal dominant pattern (although may not always be present) 
Any ethnicity may be affected 
 
*
Both nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoids in 
relatively high doses (more than 20 mg oral prednisone) are able to alleviate the 
symptoms of fever and inflammation in most TRAPS patients, although they do 
not alter the frequency of attacks. They can be used beneficially at times of attack, 
and glucocorticoids can usually be tapered in the course of one or two weeks, as 
tolerated. There is no response to colchicine or immunosuppresive drugs such as 
azathioprine, cyclosporin, thalidomide or cyclophosphamide [54]. 
With regard to the pathogenesis of TRAPS, intravenous infusion of a synthetic 
TNFRSF1A fusion protein was tried in one patient by Drewe et al. [54], but this 
seemed to provoke a severe attack. Use of etanercept, a fusion product of 
TNFRSF1B (the receptor that is not defective!), has been more successful 
[54,58,64]. A pilot study with twice weekly administration of etanercept, in a dose 
Familial Autoinflammatory Syndromes 
 
29 
of 25 mg for adults or 0,4 mg/kg for children, in 9 TRAPS patients with various 
mutations revealed an overall 66% reponse rate as determined by decreased 
number of attacks over a 6 months period [54]. A similar regimen of etanercept 
reversed the nephrotic syndrome in a patient with amyloidosis [65]. We have 
shown that use of etanercept 25 mg at the time of an attack may abort the 
symptoms and induce a long-lasting remission [63]. Drewe et al. have described 
one patient whose symptoms were resistant to administration of etanercept, who 
responded favourably to use of oral sirolimus (4-6 mg) [54]. Infliximab, a 
monoclonal antibody against TNF, has been shown to be less effective than 
etanercept in TRAPS. 
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These three syndromes have all been traced back to mutations in one common 
gene, but their phenotypes differ, at least to some degree. After the recognition of 
the genetic defect it became clear that there is considerable overlap between these 
three disorders. Most notably families have been described with features of both 
Muckle-Wells syndrome and FCAS [66].  It has been suggested that FCAS, MWS, 
and CINCA/NOMID appear to represent a spectrum of disease with FCAS the 
mildest and NOMID/CINCA the most severe form. Given their common genotype, 
they will be discussed under one heading here. 
 	")
All three are rare, autosomal dominantly inherited syndromes. Since its original 
description in 1940, FCAS has been described in some 20 published reports. Most 
articles describe large families from Europe and Northern America with extensive 
pedigrees but sporadic cases have been described. There appears to be a founder 
effect in American families of Northern European extraction [67]. MWS has been 
described for the first time in 1962 and has since described in large families 
although it is seen in isolated cases and small nuclear families. Most families come 
from France and the United Kingdom[68]. CINCA/NOMID is rare and to date 
some 70 cases, and only a few families, have been described. Most patients stem 
from France and Argentina, but cases are seen in other European countries and the 
United States [69,70]. 
 )
The first indications that MWS and FCAS are allelic stem from early linkage 
studies demonstrating that both FCAS and MWS were linked to the same region 
on the long arm of chromosome 1 (1q44) [68,71]. In 2001 the gene for FCAS and 
MWS was identified. In a large scale positional cloning effort using 3 families 
with FCAS and one family with MWS, missense mutations in a new gene were 
found. This gene, CIAS1 (synonyms are NALP3 and PYPAF), encodes for a 
protein denoted as cryopyrin, which consists of three recognized protein domains, 
including an N-terminal pyrin domain, a central nucleotide binding site (NBS) 
domain, and a leucine-rich repeat domain [72]. The protein is predominantly 
expressed in granulocytes and monocytes. It has been shown that overexpressed 
crypoyrin interacts with apoptosis-associated-specklike protein and activated NF-
κB and caspase1, suggesting a proinflammatory effect. Later studies demonstrated 
that CIAS1 mutations were also associated with CINCA/NOMID[70,73]. All 
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mutations ascertained so far can be found in exon 3 of the CIAS1 gene which 
encodes the NBS domain of crypopyrin, lending support to the suggestion that this 
domain is crucial in cryopyrin function. So far 21 missense mutations have been 
identified in these 3 disorders [8]. Some mutations occur in MWS as well as in 
FCAS (R260W) or in both MWS and NOMID/CINCA (D303N) (figure 10) [70]. 
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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Familial cold autoinflammatory syndrome (FCAS; MIM 120100) is 
characterized by episodes of rash, fever and arthralgia after generalized exposure 
to cold (figure 1). The disease occurs in large families as an autosomal dominant 
inherited disorder with an almost complete penetrance [67]. The rash usually starts 
on the exposed extremities, and in most episodes extends to the remainder of the 
body. It consists of erythematous macules and plaques (figure 11, 12), urticarial 
lesions and sometimes petechiae [74] and can cause a burning or “itchy” sensation. 
In some cases, localized edematous swelling of extremities is reported. The 
arthralgias, present in 93% of cases, most often affect the hands, knees and ankles, 
but can also involve feet, wrists and elbows [75]. Frank arthritis is not seen. The 
majority of patients (84%) also report conjunctivitis during a fever episode. Other 
symptoms which have been reported are myalgia, profuse sweating, drowsiness, 
headache, extreme thirst and nausea. 
 
Figure 10. Cryopyrin protein, containing an N-terminal pyrin domain (yellow), a nucleotide binding site 
(NBS or NACHT, green), and a leucine-rich repeat domain (blue). Indicated are the missense mutations 
identified in patients with FCAS (red), MWS (green) or CINCA (blue), and mutations which are found in 
common in two or all of these clinical syndromes. 
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Figure 11. Fine confluent erythematous macules in FCAS on the upper leg. Picture courtesy of Dr. 
Johnstone, Medical College of Georgia, Augusta, Georgia, USA. 
Figure 12. Detail of  upper leg with fine confluent erythematous macules in FCAS. Picture 
courtesy of Dr. Johnstone, Medical College of Georgia, Augusta, Georgia, USA 
Figure 13. Urticarial skin rash in a MWS patient. Picture courtesy of Dr. D.L. Kastner, National 
Institute of Health, Bethesda, USA 
Figure 14. Urticarial skin rash on the arm of a MWS patient. Picture courtesy of Dr. D.L. Kastner, 
National Institute of Health, Bethesda, USA 
Figure 15. Severe deformative arthropathy of the knees in a patient with CINCA/NOMID. Picture 
courtesy of Dr. A.M. Prieur, Hopital Necker-Enfants Malades, Paris, France 
Figure 16. Radiograph of the knee in CINCA/NOMID showing greatly enlarged epiphyses and 
patella with punctate increased density. Picture courtesy of Dr. A.M. Prieur, Hopital Necker-
Enfants Malades, Paris, France 
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A typical feature of FCAS is the requirement of cold exposure to elicit the 
symptoms; the delay between cold and onset of symptoms reported in a study by 
Hoffman et al [75] varied from 10 min to 8 hours. The subsequent fever attack can 
be variable in length, also depending on the degree of cold exposure; generally it 
will last a few hours to a maximum of three days. These episodes will start at an 
early age, 95% of patients having had their first fever episode in the first year of 
life; 60% even within the first days. The symptoms tend to become less severe 
with advancing age [74]. Type AA amyloidosis complicated by renal insufficiency 
has been described in 3 FCAS families [75]. 
 
Muckle-Wells syndrome (MWS; MIM 191900) is a rare autosomal dominant 
inflammatory disorder with incomplete penetrance. Patients suffer from recurrent 
episodes with fever, abdominal pain, myalgia, urticarial rash (figure 13, 14) and 
conjunctivitis frequently accompanied by arthralgias and/or arthritis with limb 
pain. Attacks start in adolescence and can be provoked by hunger, tiredness, and 
sometimes by exposure to cold [76]. The inflammatory episodes generally last 24 
to 48 hours (figure 1) and start with ill-defined malaise and transient chills and 
rigour followed by aching and lancinating pains in distal limbs and larger joints. 
Arthralgia is a common feature of the attacks, but synovitis of the large joints is 
less common [77]. The rash consists of usually aching and sometimes pruritic 
erythematous papules of 1-7 cm in diameter. In a few cases genital and buccal 
aphthous ulcers have been seen [78]. Ocular symptoms may  include uveitis and 
conjunctivitis. Symptoms typically start in adolescence, although debut at earlier 
age can be seen. Late onset development of perceptive deafness is common in 
MWS. Bone involvement such as clubbing of nails and pes cavus can be seen as 
well. Most often, patients have a positive family history for the disease indicative 
for autosomal dominant inheritance, but isolated cases have been reported. The 
most feared complication of the inflammatory attacks is type AA amyloidosis 
which mostly affects the kidneys first and will lead to proteinuria and subsequent 
rapid progression to renal failure. 
 
Chronic infantile neurological cutaneous and articular syndrome (CINCA; 
MIM 607115) is a rare congenital disorder defined by the presence of a triad of (a) 
neonatal onset of skin lesions, (b) chronic aseptic meningitis and (c) recurrent 
fever along with joint symptoms [79]. CINCA is also known in the Anglo-Saxon 
literature as the “neonatal onset multisystemic inflammatory disease (NOMID) ” 
and appears to be an autosomal dominant inherited disorder [70]. The key clinical 
feature of CINCA is a skin rash accompanied by peculiar joint manifestations and 
central nervous system involvement.  
The symptoms in CINCA/NOMID present right after birth or in the first monts of 
life most notably with a generalised skin rash. The disease follows an 
unpredictable course with persistent non-pruritic and migratory rash with fever, 
hepatosplenomegaly and lymphadenopathies. Central nervous sytem involvement 
is not clear from the outset, unless patients present with symptoms such as 
seizures, spasticity, or transient episodes of hemiplegia. In the majority of patients 
there are signs of chronic persistent aseptic meningitis [80]. Cerebral fluid analysis 
may show mild pleiocytosis and there may be an increased intracranial pressure. 
Brain  imaging shows mild ventricular dilatation, prominent sulci and central 
atrophy, and in longstanding cases calcifications of faulx and dura. In older 
children, headache is often a prominent feature as a sign of chronic meningitis. 
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There is mental retardation in almost all cases. Progressive sensoneural 
impairment leading to high frequency hearing loss can be seen in a minority. 
Ocular manifestations are prominent with optic disc changes such as optic disc 
edema, pseudopapilledema and optic atrophy, and anterior segment manifestations 
such as chronic anterior uveitis [69]. These symptoms may lead to visual 
impairment. Hoarseness, especially in older children, is typical. Osteoarticular 
symptoms are a prominent feature of CINCA and these present as bone 
inflammation giving rise to major arthropathies due to epiphyseal and metaphyseal 
disorganisation. Growth cartilage alterations such as enlarged epiphyses and 
patellar overgrowth can be an impressive feature of the disease (figure 15, 16). 
Erosive changes occur, especially in the phalanges of hands and feet. There are 
typical dysmorphic features such as frontal bossing and a saddle nose. These 
common physical features are the reason that CINCA/NOMID patients give the 
impression that (totally) unrelated patients are siblings. The prognosis of these 
patients is grave as 20% die in childhood because of infections, vasculitis and 
amyloidosis [79]. 
 ("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Again, most important for diagnosis are patient and family history (table 1). 
Hoffman et al suggested a set of diagnostic criteria for FCAS [75] after studying 
six large families with this syndrome (table 6), but these have not been validated in 
an independent cohort. Laboratory examination during a fever episode in FCAS, 
but also MWS and NOMID/CINCA will show an acute phase response with 
polymorphonuclear leukocytosis and raised sedimentation rate but this will not 
differentiate between theperiodic fever disorders. Symptoms such as an urticarial 
rash after cold exposure highly favor a diagnosis of FCAS.. The ice cube test, i.e. 
holding an ice cube to a patch of skin to provoke urticaria, which is diagnostic in 
acquired cold urticaria, however is negative in FCAS. Typical facial features as 
frontal bossing and a long pediatric history including chronic aseptic meningitis 
will point to NOMID/CINCA There appears to be genetic heterogeneity in 
NOMID/CINCA since not all patients have CIAS1 mutations. 
 
Table 6. Diagnostic criteria for Familial cold autoinflammatory syndrome (FCAS) [75] 
Recurrent intermittent episodes of fever and rash that primarily follow generalized cold exposures. 
Autosomal dominant pattern of disease inheritance. 
Age of onset <6 months of age. 
Duration of most attacks <24 hours. 
Presence of conjunctivitis associated with attacks. 
Absence of deafness, periorbital edema, lymphadenopathy, and serositis. 
*
No specific treatment can be offered for patients suffering from FCAS, MWS or 
CINCA/NOMID. In FCAS, some patients benefit from high-dose corticosteroids, 
and NSAIDs may be effective in selective cases [75]. Most effective is the 
avoidance of precipitating factors such as exposure to cold. In MWS colchicine 
was effective in controlling arthritic events in one patient [81] but failed in other 
patients [76,82]. Oral corticosteroids may provide relief for relief of skin and joint 
symptoms  but the role for  azathioprine and ciclosporin is less clear [76,83]. 
CINCA/NOMID is a chronic remitting disease and while corticosteroids may have 
a beneficial effect on fever, pain and general wellbeing they will not induce a 
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remission. NSAIDs, disease modifying antirheumatic drugs and cytostatics do not 
affect the disease course.  
5&,&))"
Two recent suggested additions to the group of familial autoinflammatory 
syndromes are Blau syndrome and PAPA syndrome. 
Blau syndrome (MIM 186580) is an autosomal dominant disorder characterized 
by recurrent granulomatous inflammation with a varying age of onset [84]. Typical 
granulomatous inflammations are acute anterior uveitis, arthritis and skin rash; 
other symptoms include camptodactyly, cranial neuropathies, fever, and arteritis 
[85]. Blau syndrome is caused by mutations in the NOD2/CARD15 gene [85,86]. 
The NOD2/CARD15 protein is thought to have a function in regulation of 
apoptosis. Polymorphisms in the same NOD2/CARD15 gene on chromosome 16 
are associated with a susceptibility to Crohn’s disease [87]; the risk of developing 
Crohn’s disease is increased up to 40-fold in persons homozygous for these 
polymorphisms. There are certainly some shared features between the two 
diseases: both are characterized by granulomatous inflammation, and while bowel 
inflammation is not seen in Blau syndrome, Crohn’s disease can present with 
uveitis, arthritis and skin rash. 
PAPA syndrome (MIM 604416) is an acronym for Pyogenic sterile Arthritis, 
Pyoderma gangrenosum and Acne syndrome, an autosomal dominant disorder first 
described by Lindor et al. [88]. The episodic inflammation in this syndrome will 
lead to eventual destruction of joints, muscle and skin. Wise et al. identified 
mutations in the CD2-binding protein 1 (CD2BP1) gene linked with PAPA 
syndrome [9]. CD2BP1 has a role in actin reorganization during cytoskeletal-
mediated events, and as such is hypothesized to have a functional relationship with 
pyrin. 
 
0)"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
The familial auto-inflammatory syndromes are characterised by recurrent episodes 
of fever and inflammation. This group of disorders needs to be considered in a 
patient with a history of years of such inflammatory attacks with symptom-free 
intervals in between (except for CINCA/NOMID, in which some symptoms and 
morphological features will persist).  
The discovery of the causative genes has had an enormous impact in the field of 
periodic fever . This has been made possible only because of the accurate 
phenotypical characterisation of patients with periodic fever. Careful analysis and 
proper clustering of these patients is indispensable in order to allow the elucidation 
of the genetic background as well as the evaluation of possible treatment options. 
This is greatly stimulated by development of central periodic fever registries, 
which afford the opportunity to appreciate of previously unrecognised symptoms, 
to give insight in the long-term prognosis and to allow better evaluation of drug 
regimens.  Even yet, despite recent research, many periodic fever patients do not 
fall in one of the above-mentioned disease categories. It is to be expected that in 
the future other periodic fever syndromes and corresponding genes will be 
discovered. 
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HIDS.net - http://hids.net 
Online Mendelian Inheritance in Man –  
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM 
INFEVERS – the repertory of FMF and hereditary inflammatory disorders 
mutations - http://fmf.igh.cnrs.fr/infevers/ 
ORPHANET – a database dedicated to information on rare diseases and orphan 
drugs - http://orphanet.infobiogen.fr/ 
METAFMF – a meta-analysis for the study of FMF phenotype-genotype 
correlation - http://fmf.igh.cnrs.fr/metaFMF/ 
GeneDx – provide mutation testing in rare disorders – http://genedx.com 
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Hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) is an 
autosomal recessive inflammatory disorder characterized by recurrent episode of 
fever associated with lymphadenopathy, abdominal distress, joint involvement and 
skin lesions. We recently demonstrated that mutations in the mevalonate kinase 
gene (MVK) are associated with HIDS. Direct DNA sequencing was done to 
screen the entire coding region of MVK in 25 unrelated patients with HIDS. 
Mutations were detected in the coding region of the gene including 11 missense 
mutations, one deletion, the absence of expression of one allele, as well as 3 novel 
polymorphisms. Seven of these mutations are novel. The large majority of the 
patients were compound heterozygotes for two mutations. Of these, V377I (G->A) 
is the most common mutation occurring in 20 unrelated patients and was found to 
be associated with I268T in 6 patients. Mutations were associated with a decreased 
of mevalonate kinase (MK) (ATP: mevalonate 5-phosphotransferase, EC 2.7.I.36) 
enzymatic activity but not as profound as in mevalonic aciduria, a syndrome also 
caused by a deficient activity of MK. In HIDS the mutations are located all along 
the protein which is different from mevalonic aciduria where MK mutations are 
mainly clustered to a same region of the protein. On the basis of this study, we 
propose that the diagnostic screen of MVK in HIDS should be first directed on 
V377I and I268T mutations. Three patients are also described to illustrate the 
genotypic and phenotypic overlap with mevalonic aciduria.  
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The hyperimmunoglobulinemia D and periodic fever syndrome (HIDS [MIM 
260920], http://www.hids.net) is an autosomal recessive disorder with recurrent 
febrile attacks as its main feature [2,3,46,89]. During these attacks patients also 
suffer from a variable presence of lymphadenopathy, arthralgias, splenomegaly, 
skin lesions and headache. Symptoms start in early childhood and may persist 
during life. So far, 13 HIDS families with two or more affected siblings are known 
to us. The elevated serum IgD (to values beyond 100 IU/ml) serves as convenient 
biochemical marker [244,100]. The clinical presentation is rather homogeneous 
although severity and intensity of the febrile crises may differ among patients. A 
recent genome wide search linked HIDS to the long arm of chromosome 12 
(12q24) [2,245] and the linked interval contains the gene encoding for mevalonate 
kinase (MVK). MK, a homodimeric enzyme present in the peroxisomes of every 
mamalian cell, follows 3-hydroxy-3-methylglutaryl-CoA reductase in the 
cholesterol synthesis and converts mevalonate into 5-phosphomevalonate. A near 
complete deficiency of this enzyme causes mevalonic aciduria [MIM 251170]. 
This rare autosomal recessive disorder is characterised by developmental delay, 
failure to thrive, hypotonia, ataxia, myopathy, cataracts. Most notably, many 
patients suffer from recurrent febrile attacks with vomiting, diarrhoea, 
leukocytosis, elevated erythrocyte sedimentation rate, arthralgia and 
morbilliformic rash [44,45,246,247]. These phenotypical similarities with HIDS 
lead us to consider mevalonate kinase as a candidate gene for HIDS. Effective 
linkage and the serendipitous finding by others of minor elevated urinary 
excretions of mevalonic acid in a HIDS patient, led to the identification of MVK as 
the causative HIDS gene [2,3,249]. Preliminary molecular analysis revealed 4 
different missense mutations (V377I, I268T, H20P and P167L), the absence of 
expression of one allele and a 92bp deletion in the MVK gene. These mutations 
result in a functional defect of MK and preliminary studies indicated a residual 
activity of 5-15%, values higher than those observed in mevalonic aciduria. At 
present it is unclear whether HIDS and mevalonic aciduria are extremes of a 
continuous spectrum or that they are truly two different entities. For example, 2 
mutations (I268T and H20P) are common in HIDS and mevalonic aciduria 
patients, but have been reported heteroallelic with different mutations in both 
[100,245]. Therefore, the different nature of HIDS and mevalonic aciduria may be 
caused by a differential mutational spectrum, but information to this end is 
lacking. 
Therefore, we have undertaken studies in order to gain more insight in the 
genotypes in a large cohort of HIDS patients. We expected to shed light on the 
molecular pathology of HIDS and to aid the development of an effective molecular 
testing strategy for diagnosis and carrier testing.  
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Patients for this study were selected on the basis of previous inclusion in the 
Nijmegen HIDS registry [46] and the availability of Epstein-Barr immortalized 
cell lines. The Nijmegen HIDS registry was set up in 1992 and hosts clinical and 
laboratory data on these patients. Twenty five unrelated patients agreed to 
participate in the present study and in eight cases, father and mother were 
included. The numbering of the patients reflects the entry number in the Nijmegen 
HIDS registry. A thorough clinical examination was performed on all subjects and 
HIDS was diagnosed in concordance to set criteria. Biochemical proof of affected 
status was obtained by measurement of the IgD content in serum. The hereditary 
pattern in all included families was compatible with an autosomal recessive 
hereditary trait [46]. The study was carried out after informed consent from all 
individuals and formal approval was obtained by the Medical Ethical Comittee 
(CWOM) of the University Medical Center St. Radboud, Nijmegen, The 
Netherlands.  
%6
Online Mendelian Inheritance in Man (OMIM) is http://www.ncbi.nlm.nih.gov 
 (for HIDS [OMIM 260920] and mevalonic aciduria [OMIM 251170]). Blast 
searches of htgs (high throughput genomic sequences) database of the National 
Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov) were 
performed using the cDNA sequence of MVK (GeneBank M88468).  
0&
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RNA was extracted from Epstein-Barr immortalised cell lines according to 
established protocols. Total RNA was prepared using the RNA B reagent 
(Bioprobe) according to the instructions of the manufactor. Four microgrammes of 
RNA were used to synthetise cDNA with Superscript reverse transcriptase II 
(Gibco BRL), followed by PCR using Platinium Taq DNA polymerase (Gibco 
BRL) in a GeneAmp PCR system 9600 (Perkin Elmer). We determined the 
nucleotide sequences of the amplified fragments by standart semi-automated 
methods on an ABI PRISM 377 (Perkin Elmer). The primers used in this study 
have already been described [2]. The complete coding region of MVK was 
amplified from cDNA in two overlapping fragments using primers 29/788 and 
591/1381. Their sequences were determined using primers 29, 381, 535, 921, 1000 
and 1381. When the homozygous status of a mutation in a proband could not be 
controlled by the analysis of both parents an additional PCR was performed on 
cDNA using primers 381/1000 followed by sequence analysis to eliminate the 
presence of a short deletion spanning primers 788 and 591. 

89:))
Mevalonate kinase enzyme activity in extracts of cultured lymphocytes was 
performed by a radiometric assay. DL-[Mevalonic-2-14C], DBED salt was 
purchased from NEN Life Science Products, Inc. Boston. Non-isotopic DL-
mevalonolactone, from Sigma Chemical (St Louis, Mo.), was converted before use 
to the potassium salt as described [93]. Preparation of the lymphoblasts lysates was 
carried out as described by earlier [94]. Mevalonate kinase assay in lymphoblast 
Molecular analysis MVK gene 
 
41 
lysates, including separation of substrate and products by thin layer 
chromatography, was performed according to Gibson et al. [93]. 
/
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The study group consisted of 25 patients: 22 Dutch, 1 British, 1 Czech and 1 
Spanish. The mean age was 30.3± 16.4 years and there was an even male-female 
ratio (13 female and 12 male). The clinical features of the first 50 patients in the 
Nijmegen HIDS registry have been described in detail elsewhere [46]. Briefly, all 
patients had recurrent attacks of fever (38.5°C) with an acute phase response with 
elevated erythrocyte sedimentation rate and a brisk leukocytosis. All had a 
constantly elevated serum IgD (>100 U/mL) measured at 2 occasions with at least 
one month apart, and one or more of the following symptoms during attacks; 
lymphadenopathy; abdominal distress (vomiting, diarrhoea, pain); skin 
manifestations (erythematous macules and papules); arthralgias / arthritis; and 
splenomegaly. Although affected siblings were available for the study we elected 
to study unrelated patients in order to obtain a representative survey of mutational 
spectrum and enzyme activities of mevalonate kinase in HIDS.  
;&
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The genomic organization of the MVK gene is shown in figure 1 and was 
determined to help in the understanding of the deletion found in HIDS patients. 
We deduced it by comparison between a human genomic clone from the working 
draft sequencing database (accession number AC007623) and the human cDNA 
(accession number M88468). The gene contains 10 coding exons and one non 
coding exon spanning over 21kb. The size of the exons varies from 62 to 837 bp 
and the size of the introns from 378 to 4470 bp. The first and last base belonging 
to each exon is indicated in figure 1 and refers to the numbering of the human 
cDNA. The last exon contains 152 bp of the open reading frame (ORF) and 685 bp 
of the 3’ UTR.  
 
Figure 1. Genomic organization of the MVK gene. This structure has been deduced by comparison between a 
genomic clone (AC007623) and the human cDNA (M88468). In the large square are indicated the first and last 
nucleotide position belonging to each exon and refers to the numbering of the human cDNA. 
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Patient No 
 
Exon Nucleotide 
Change 
Amino Acid 
Changea 
MK Enzyme 
Activityb 
1 
 
10 
? 
1220G->A 
? 
V377I  
? 
8.9 
4 8 
10 
894T->C 
1220G->A 
I268T 
V377I 
5 
10 
 
9 
10 
1016G->A 
1220G->A 
G309S 
V377I 
3.6 
11 1 
10 
150A->C 
1220G->A 
H20P 
V377I 
8.5 
12 
 
2 
10 
207T->C 
1220G->A 
L39P 
V377I 
2.1 
13 
 
8 
10 
894T->C 
1220G->A 
I268T 
V377I 
7.2 
15 
 
10 
? 
1220G->A 
? 
V377I homo 
? 
4.5 
17 10 
ND 
1220G->A 
ND 
V377I homo 
Abs RNA 
28 
18 8 
10 
894T->C 
1220G->A 
I268T 
V377I 
4 
21 1 
10 
150A->C 
1220G->A 
H20P 
V377I 
11.4 
26 10 
ND 
1220G->A 
ND 
V377I homo 
Abs RNA 
11.3 
31 8 
10 
894T->C 
1220G->A 
I268T 
V377I 
15.3 
35 
 
10 
ND 
1220G->A 
ND 
V377I homo 
Abs RNA 
ND 
47 
 
1 
6 
149C->A 
735G->A 
H20N 
R215Q 
3.5 
52 
 
4 
5 
591C->T 
695G->A 
P167L 
G202R 
1.8 
55 8 
10 
894T->C 
1220G->A 
I268T 
V377I 
10.7 
56 8 
10 
894T->C 
1220G->A 
I268T 
V377I 
7.7 
61 
 
4 
10 
540C->T 
1220G->A 
 S150L 
V377I 
17.3 
66 
 
9 
10 
1067G->A 
1220G->A 
G326R 
V377I 
16.4 
71 
 
9 
? 
1091G->A 
? 
A334T 
? 
0 
72 
 
10 
? 
1220G->A 
? 
V377I homo 
? 
8 
89 
 
10 
? 
1220G->A 
? 
V377I homo 
? 
5.7 
100 4 
10 
465-619del 
1220G->A 
del exon 4 
V377I 
8.3 
103 
 
8 
? 
894T->C 
? 
I268T homo 
 ? 
7.3 
116 
 
4 
ND 
591C->T 
ND 
P167L homo 
abs RNA 
9.7    
Table 1. Mutations in the MVK cDNA. 
del = deletion, homo = homozygote, ND = not determined, abs RNA = absence of RNA expression. a = amino 
acids are given in single-letter code; b = enzyme activities are derived from experiments using cultured 
lymphoblasts and are expressed as percentage of control.  
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Of the 25 unrelated patients investigated for sequence variations in the coding 
region of the MVK gene, we were able to identify a total of 13 mutations and 3 
new polymorphisms. Seven mutations are novel and have never been described 
before. Mutations were detected in all exons except in exon 3 and 7 (table 1). Most 
of the mutations are missense mutations; nonsense mutations were not found. The 
position of the affected nucleotide refers to the human MVK cDNA (accession 
number M88468). Where available both parents were studied (patients: 17, 21, 26, 
31, 35, 47, 100, 116).  


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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We found 7 new mutations: R215Q, L39P, G202R, G326R, G309S, S150L and 
H20N. Each of them was detected on only one allele in 7 unrelated patients 
indicating that they are not very frequent in HIDS. Among the previously reported 
MVK mutations we detected the 4 known HIDS missense mutations V377I, I268T, 
H20P and P167L, and surprisingly one patient carried the A334T allele which 
previously only had been described in mevalonic aciduria. V377I, which is located 
at the C-terminal end of the protein, was found in 20 of 25 patients and therefore 
constitutes the most frequent mutation in HIDS. I268T occurred in 7 unrelated 
patients and is the second more frequent mutation in HIDS. V377I and I268T were 
found heteroallelic in 6 patients. Interestingly, one patient carrying I268T was 
found homozygous for that mutation. The status of the parents could not be 
determined as they both were dead at the start of the study. Patient 116 was found 
homozygous for P167L. 
!6&#	&
Analysis of the parents of this last patient (patient 116) showed that the mother 
was heterozygote for P167L and that the father displayed a normal allele, c 
suggesting that the second mutation in the proband led to the absence of 
expression of the second allele. In the group of the 20 patients carrying V377I 
([1220G->A]), six were found to be homozygous upon examination on cDNA. For 
only 3 of them, both parents were available (patients 17, 26 and 35) and tested. In 
these 3 families, one parent was heterozygous G/A at position 1220 whereas the 
other parent was found to be homozygous for the normal G at the same position. 
This reveals that in these three families one parent and the patient also carry an 
unknown mutation on the second allele that leads to the absence of expression of 
mRNA. This observation has been reported in our first study [2]. Unfortunately, 
patients 15, 72, 89 could not been investigated further because samples from their 
parents and genomic DNA from these 3 patients were not available. Additional 
RT-PCR using other sets of primers spanning primers 788 and 591 followed by 
sequencing analysis did not reveal any other alterations. However it cannot be 
excluded that these patients carry a mutation spanning the 5’ or 3’ end of the 
cDNA that would prevent the primer annealing.  
%
In patient 100 we found a deletion spanning from nucleotide 465 to 619. 
Comparison with the deduced genomic organization reveals that this mutation 
corresponds to the complete deletion of exon 4 suggesting that this patient would 
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carry a mutation affecting the splicing of the transcript. The same deletion was 
found in her healthy father, whereas the second mutation of the patient (V377I) 
was transmitted by her healthy mother. The determination of the genomic structure 
allowed us to conclude that the 92 bp deletion we reported for family 13 in our 
previous study [46] corresponds to a complete deletion of exon 1 suggesting that 
this patient would also carry a mutation affecting the splicing of one transcript.  
)	
Three novel polymorphisms were identified. A 601C->T transition within exon 4 
resulting in a silent change (170D->D) was found in 5% of the individuals 
analyzed. Another polymorphism, 246G->A with a resulting 52S->N, was detected 
in 10% of individuals. Although this modification changes the amino acid 
sequence, we expect it to be silent because it was found in one healthy mother and 
one independent healthy father (both carrying another heterozygous mutation). In 
addition, it did not segregate with HIDS as it was not transmitted to their 
respective affected children. The functional significance of this polymorphism is 
not known. In addition to these missenses, a 1336insG was found. This 
polymorphism was located 50 bp after the stop codon and therefore did not affect 
the coding sequence. It was found in 5% of individuals including a healthy father 
(carrying another heterozygous mutation) who did not transmit this polymorphism 
to his affected. None of these rare polymorphisms were specifically associated 
with a mutated allele and therefore did not give any information about a potential 
founder effect in the disease.  

9()
Analysis of the MK enzyme activities in cultured lymphoblasts were greatly 
affected in HIDS patients. When we excluded patient 71, who had a nearly absent 
MK activity, the average activity was decreased to 9.2% (SD 6%) of that of 
healthy controls (table 1). There was a great variation among HIDS patients and 
enzyme activities varied from 1.8% to even 28%.  
Figure 2. Summary of mutations identified in HIDS and mevalonic aciduria patients [1]. The bar depicts the MK 
protein. PTS2 homology domain and putative ATP binding domain are indicated. K13, E19, E193 and D204 are 
known important functional amino acids [12]. Deletion 1 refers to our previous report [1] and deletion 2 refers to 
this study. HIDS mutations are indicated in bold characters and mevalonic aciduria mutations (#) are summarized 
in the large square. 
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To analyze the distribution of mutations in the MK protein sequence, we combined 
our data with results from previous reports [2,3,44,100,245,247] and plotted 
mutations in HIDS and mevalonic aciduria against amino acids residues (fig. 2). 
This shows that the HIDS mutations are evenly distributed along the coding region 
of MVK, which contrasts to that of mevalonic aciduria which essentially clusters 
between amino acids 243 and 334. Except for H20P and I268T, none of the 
mutations are common between HIDS and mevalonic aciduria. MK contains a 
peroxisomes targeting sequence 2 (PTS2) domain in the N terminal part and an 
ATP binding site in the C terminal part. Four amino acids (K13, E19, E193 and 
D204) have been shown to play a crucial role in the enzymatic activity of the 
protein [248,249] and some of the HIDS mutations are very close to these 
important amino acids.  
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To evaluate the functional significance of the mutations identified we undertook a 
careful evaluation of the phenotypes and compared them with the different types 
of the mutations observed. Patients were evaluated for age of onset of disease, 
frequency and length of attacks and symptoms accompanying the attacks. 
Laboratory data with emphasis on immunoglobulins and parameters of the acute 
phase response were monitored.  
We compared the phenotype of those who were compound heterozygote for V377I 
to the 5 patients who did not carry this mutation. The frequency or severity of 
febrile attacks did not differ between V377I positive and negative patients, nor was 
there a difference in symptomatology during attacks. 
One patient, a 39-year-old woman (#71) carried an A344T mutation on one allele. 
This mutation is thought to be associated with mevalonic aciduria [247]. She had 
typical febrile attacks from birth onwards but also developed a tapetoretinal 
blindness and optical nerve atrophy at the age of 2. After an episode of measles 
with encephalitis she developed a clinical picture of severe mental retardation, 
cerebellar ataxia, athethosis, and microcephalia with epilepsy. She continued to 
have febrile attacks. Immunoglobulins are elevated: IgD (465 IU/ml) and IgA (4 
g/L). The MK enzyme activity was <1% and the excretion of mevalonic acid in 
urine was strongly elevated 7200 mmol/mol creatinine. On the basis of the massive 
urinary mevalonic acid excretion and the complete absence of enzymatic activity 
she must now be classified as having mevalonic aciduria instead of HIDS. It is 
likely that the severe neurological symptoms fit with mevalonic aciduria and 
cannot be attributed as a sequel to measles encephalitis.  
Another patient (#15) had a similar phenotype as patient 71 with mental 
retardation, tapetoretinal blindness, cataracts, and ataxia. In contrast he has the 
V377I mutation, the MK activity is 4.5% of controls and during remission there is 
no excretion of mevalonic acid. This labels him as HIDS. Patient 47, a 20-year-old 
man who is a compound heterozygote for H20N and R215Q has very severe 
phenotype. He has repetitive febrile attacks with deforming arthritis. Patient 52 
who was compound heterozygote for P167L and G202R died of staphylococcal 
pneumonia at the age of 30 but she did not have any attacks in the 18 months 
preceeding her death. Patient 103, a 40-year-old male is homozygote for I268T. 
Neurological examination is completely normal and he has no dysmorphic 
features. He has a very mild disease with only 3-4 febrile attacks per year. The 
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sequence variation has been reported before in mevalonic aciduria [100]. The last 
patient (#116) is a 10-year-old girl who is a compound heterozygote for the P167L 
mutation and has the absence of expression of the second allele. She has regular 
febrile attacks but growth and development is unremarkable.  
%
Our study presents detailed clinical and mutation analysis data on the largest 
cohort of patients with HIDS. Although affected siblings were available, we 
elected to study a total of 25 unrelated patients to obtain a representative survey of 
mutations in the MVK gene and enzyme activity. We identified 13 different 
mutations, 7 of which were novel, comprising 11 missense mutations, one deletion 
and the absence of expression of one allele. Three novel polymorphisms were 
found. Missense mutations of MVK were detected at the heterozygous stage on 
both alleles of 14 patients and on one allele of 2 patients (#1 and #71). In these two 
last patients the first heterozygous mutation was localized in the 3’ part of the 
cDNA and the second mutation could not be determined. The disease 
manifestation in these two patients may be explained by a short deletion 
overlapping the forward primer of the 5’ part of the cDNA or by a mutation in 
intronic sequences as these were not addressed in this study. We consider patient 1 
as typical HIDS because she possesses the most frequent MVK mutation (V377I) 
and displays the classical features of HIDS, being the first HIDS patient diagnosed 
[1]. This others studies allow us to draw a more complete picture of the 
biochemical and mutational differences between HIDS and mevalonic aciduria. In 
our HIDS cohort the MK enzyme activities vary widely and, as we previously 
observed [2], the lower values may overlap with those observed in mevalonic 
aciduria [45]. 
However, in mevalonic aciduria, there are very high concentrations of mevalonic 
acid present constitutively in all bodyfluids, most notably in urine. This is clearly 
different from HIDS, where only a minor elevated excretion of urinary mevalonic 
acid can be observed with attacks. In our cohort we detected a patient with grossly 
elevated urinary mevalonic acid excretion. This patient (#71), a 39-year-old 
woman presented with febrile attacks typical for HIDS but was heterozygous for 
A334T, an allele that already had been reported in patients with mevalonic 
aciduria. On basis of the increased excretion of mevalonic acid in urine we label 
her now with mevalonic aciduria. Another patient (#15) with similar phenotypical 
features carries the V377I mutation and lacks mevalonic aciduria. Both patients 
illustrate the phenotypic overlap between mevalonic aciduria and HIDS. Patient 
#71 probably represents a mild phenotype of mevalonic aciduria and most notably, 
she has an unusual long survival. The course of this syndrome is almost invariably 
fatal and although some patients may reach late adolescence, survival beyond 35 
years has not been described before [45]. Patient 15 is a prototype of a severe 
classical HIDS patient.  
Interestingly, mutations H20P and I268T which are shared by both HIDS and 
mevalonic aciduria diseases were detected in our sample. In most HIDS patients 
we found it in association with V377I which suggests that this mutation is 
responsible for the HIDS phenotype. This corroborates with data generated by 
expression of MVK cDNA’s in E. coli lysates which only showed a decrease of 
MK enzyme activity to approximately one-third of controls [3]. In previously 
reported mevalonic aciduria cases, H20P and I268T were found associated with 
A334T and N301T respectively [100,245] suggesting that these two last mutations 
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would determine the severity of the phenotype. However, our finding of a HIDS 
patient who is homozygous for I268T is puzzling given the fact that homozygosity 
for this mutation was previously found in a patient with very severe mevalonic 
aciduria. The patient had a nearly absent MK activity and died at the age of 4.5 
months [100]. It is intriguing that our HIDS patient lacks the phenotypical 
characteristics of mevalonic aciduria such as psychomotor retardation, hypotonia, 
myopathy and ataxia. He has a residual enzyme activity of 7.2%, far higher than 
that in mevalonic aciduria. These findings provide the first evidence that the two 
diseases can share the same MVK mutations. This suggests that not only these 
specific mutations but also other, as yet undetermined, factors are important for the 
resultant phenotype.  
Our study also clearly demonstrates that the V377I mutation, as a consequence of 
a G to A transition, is the most frequent HIDS mutation as it was detected in 20 
patients. We also provide evidence that this mutation is not systematically 
associated with the HIDS phenotype since 4 patients did not possess the mutant 
V377I allele. The second most frequent mutation in HIDS is I268T and was found 
in 7 patients. In 6 of them, patients were compound heterozygote with V377I. On 
basis of these findings we recommend that a diagnostic screen of the MVK gene 
for HIDS mutations should first be directed on V377I and I268T because they both 
constitute the most common mutations in HIDS. Since V377I abolishes a BsmAI 
site [2] the detection of V377I with restriction enzymes can be done rapidly and 
this probably represents a very useful tool for molecular diagnosis of HIDS. 
Seven patients were found to display a homozygous mutation using cDNA. For 4 
of them, analysis of the both parents allowed us to demonstrate that they carry a 
second unknown mutation that led to the absence of expression of the second 
allele. We previously reported such observation [2] and the detection of 4 
additional patients here suggests this is a relatively frequent event in HIDS. The 
finding of one common mutation (V377I) suggests however that our families are 
distantly related and suggests that it could be a founder mutation. Indeed most 
patients described in this report stem from the Netherlands that is in concordance 
with the founder hypothesis. Unfortunately the rare polymorphisms found in the 
cDNA could not address this question and therefore this issue must be directed by 
analyzing haplotypes generated by microsatellite markers or by single nucleotide 
polymorphisms within the gene. 
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Background: hyper-immunoglobulinemia D and periodic fever syndrome (HIDS) 
is characterized by recurrent attacks of fever, abdominal distress and arthralgia, 
and is caused by mevalonate kinase mutations. Objective: to ascertain the role of 
mevalonate kinase and usefulness of molecular diagnosis in HIDS. Design: cross-
sectional study. Setting: Nijmegen HIDS registry. Patients: 54 patients from 41 
families, who met the clinical criteria for HIDS. Measurements: clinical symptoms 
and signs, concentrations of immunoglobulins, and leukocytes, erythrocyte 
sedimentation rate, mutation analysis and mevalonate kinase enzyme activity 
assay. Results: There were two groups of patients: 41 patients with mevalonate 
kinase mutations ("classic type"), and 13 patients without mutations ("variant 
type"). Classic type HIDS patients had lower mevalonate kinase enzyme activities, 
higher IgD, and more additional symptoms with attacks. The IgD concentration 
did not correlate with disease severity, mevalonate kinase enzyme activity or 
genotype. This study suggests genetic heterogeneity in patients with a clinical 
diagnosis of HIDS. 
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Periodic fever encompasses a group of disorders characterized by limited periods 
of fever that recur for years in otherwise healthy subjects. It represents a high level 
of discouragement and frustration for physicians and patients alike, because in 
many instances elaborate clinical investigations fail to substantiate the diagnosis 
[5,6]. Over the last few years several distinct subtypes of periodic fever have 
emerged [7,15,89-91], one of which is the hyper-IgD and periodic fever syndrome 
(HIDS) [1]. Patients with HIDS suffer from recurrent episodes of high fever 
accompanied by lymphadenopathy, abdominal distress and arthralgia [46] (see 
also website hids.net), which last several days and recur every few weeks. Most 
patients are from West-European stock, but patients have been identified in the 
United States [92]. HIDS patients have constantly elevated serum immunoglobulin 
D (IgD). The diagnosis is made on clinical grounds and elevated serum IgD 
concentrations but requires a high index of suspicion.  
Two studies employing different genetic methods established that mutations in 
mevalonate kinase cause HIDS [2,3]. Mevalonate kinase is an enzyme which 
follows 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, early in 
the cholesterol synthesis. One study searched the genome using affected HIDS 
families and established linkage with the locus for mevalonate kinase [2]. Another 
study detected minor elevated urinary excretions of mevalonic acid and an 
impaired mevalonate kinase activity in a HIDS patient [3]. Both studies 
independently discovered disease-associated mutations in the mevalonate kinase 
gene in affected patients.  
To ascertain the role of mevalonate kinase in HIDS, we searched for mutations 
within the gene and examined the enzyme activity of mevalonate kinase in 54 
patients who all shared the typical clinical and laboratory features of HIDS.  
0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Patients were selected on the basis of previous inclusion in the Nijmegen HIDS 
registry, an international database which at present holds data on 176 patients [46], 
and the fact that DNA and lymphoblast cell lines were available to us. All patients 
met the following criteria: repeated episodes of fever (>38.5°C) with biochemical 
evidence of an acute phase response, including elevated erythrocyte sedimentation 
rate and leukocytosis; a constantly elevated serum IgD (>100 IU/ml) measured at 2 
separate occasions; and one or more of the following symptoms during attacks: 
lymphadenopathy, abdominal distress (vomiting, diarrhea, pain), skin lesions 
(erythematous macules and papules), arthralgia and/or splenomegaly.  
We included 54 patients from 41 families and 12 unaffected parents of patients. 
Nationalities of patients included 42 Dutch, 4 French, 2 British, 2 Czech, 2 
Spanish, 1 Belgian and 1 Turkish. Patients and family members were subjected to 
a thorough clinical examination during and in between attacks. Blood samples 
were collected during and in between fever episodes; laboratory results are from 
samples taken during remissions unless otherwise indicated. The study was carried 
out after informed consent from all individuals and formal approval was obtained 
by the Medical Ethical Committee of the University Medical Center St. Radboud, 
Nijmegen, The Netherlands.  
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RNA was extracted from Epstein-Barr immortalized lymphoblast cell lines and 
cDNA was produced using standard techniques.  The complete coding region of 
the mevalonate kinase gene was amplified by polymerase chain reactions and 
mutation detection was done by fluorescent sequencing as described earlier [2,42]. 
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Mevalonate kinase enzyme activity was determined in 36 of the 54 HIDS patients, 
and in 12 parents of classic HIDS patients who are (obligate) heterozygous for the 
mevalonate kinase mutation. We employed a radiometric assay using extracts of 
cultured lymphocytes from Epstein-Barr immortalized cell lines as described 
elsewhere [93,94].  
0)
Where appropriate, the Chi square test, unpaired nonparametric Mann-Whitney 
test or nonparametric Spearman correlation coefficients were used for statistical 
analysis. Significance level, the probability of a type I error, was set at 0.05. 
/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Mutation analysis revealed mutations in the gene for mevalonate kinase in 41 of 
the 54 tested patients, described in more detail elsewhere [2,42]. We detected a 
missense mutation that is a one-base pair exchange in the gene resulting in an 
amino-acid change in the protein, in 64 of 82 examined alleles. A deletion of a 
small number of base pairs was detected in 5 alleles, while RNA was absent from 
7 alleles. Of 6 alleles the pertinent mutation could not be determined. Thirty-seven 
of the 41 patients were compound heterozygous, that is, they possess a different 
mutation on each allele of the gene.  
In 13 of the 54 patients no mutation of the mevalonate kinase gene could be 
detected even though they did exhibit the clinical phenotype of HIDS and 
completely fulfilled the clinical criteria. In order to detect whether mutations in the 
mevalonate kinase gene result in a different clinical picture, we decided to separate 
our cohort in 2 groups. We designated HIDS patients who met the clinical criteria 
for HIDS and carried mutations in the  mevalonate kinase gene as "classic type 
HIDS", and the mutation negative patients, who did meet the clinical criteria for 
HIDS, as "variant type HIDS".  
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The left figure shows the mevalonate kinase enzyme activity in individual HIDS 
patients. In classic HIDS patients, the enzyme activity was greatly depressed to a 
mean of 0.42 nmol/min/mg protein (SD 0.25), compared to 2.8 nmol/min/mg 
protein (SD 1.3) in the variant HIDS patients (p=<0.0001). In both groups there 
was no significant correlation between enzyme activity and clinical disease 
severity as measured in number of febrile days per year (classic: rs=0.06, p=0.77, 
variant: rs=-0.15, p=0.63) or between enzyme activity and IgD levels (classic: 
rs=0.02, p=0.90, variant: rs=-0.11, p=0.73). Parents of classic HIDS patients, who 
are heterozygous for the mevalonate kinase mutation, have low enzyme activity 
(mean 1.7 nmol/min/mg protein, SD 0.77) when compared to variant type HIDS 
patients (p=0.008), although still significantly higher than their affected offspring 
(p<0.0001).  
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The table depicts the pertinent clinical variables. Age of onset of febrile attacks is 
higher in variant type HIDS patients. There is a tendency for longer attacks (mean 
number of days 6.9±5.7 vs. 4.7±1.7) and longer attack-free interval (mean number 
of weeks 9.3±9.2 vs. 5.6±3.8) in the variant type HIDS patients compared to 
classic HIDS patients, although this does not reach statistical significance (p=0.57 
and p=0.74 respectively). Of 13 variant type HIDS patients, one patient had a 
brother and mother with similar symptoms and one patient had an affected brother 
and daughter. As shown in table 2, a number of accompanying symptoms in HIDS 
is more likely to occur in classic type HIDS. 
The intensity of the acute phase response during attacks was greater in classic type 
HIDS patients, as evidenced by a significantly higher erythrocyte sedimentation 
rate (Table). When compared with variant type patients we observed higher IgA 
and IgG3 concentrations, but lower IgG4 values, in classic HIDS patients. We 
Figure. Mevalonate kinase enzyme activity and IgD levels in patients with classic-type or variant-
type hyper-IgD and periodic fever syndrome (HIDS). Left. Mevalonate kinase enzyme activity, as 
measured in lymphoblasts, in patients with classic-type (squares) and variant-type (circles) HIDS. 
The horizontal bars represent the mean. Right. Serum level of IgD in patients with classic-type versus 
variant-type HIDS. Horizontal bars represent the median of the groups. Normal range in healthy 
persons for serum IgD level is <100 kIU/L. 
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detected high serum concentrations of IgD in both groups of patients but the 
concentrations in classic type HIDS patients greatly exceeded those in variant 
patients (figure). However, in 2 affected siblings of separate classic HIDS patients 
we detected low values of IgD, although both patients carried the same mutations, 
had typical HIDS attacks, and had depressed activity of the mevalonate kinase 
enzyme similar to their affected sister and brother. Further, concentration of IgD 
did not correlate with mevalonate kinase enzyme activity (see above), nor was 
there a significant correlation between IgD concentrations and the number of 
febrile days per year (classic: rs=0.05, p=0.76; variant: rs=0.46, p=0.11).  
 
Table. Characteristics of patients with classical type versus variant type HIDS* 
Variable Patients with 
classical type 
HIDS (n=41) 
Patients with 
variant type 
HIDS (n=13) 
P value 
Clinical feature    
Mean age (yrs) 31.2 30.3 - 
Men/Women (n/n) 24/17 8/5 - 
Mean duration of attack (shortest-longest, dys) 4.0-5.4 6-7.8 - 
Mean attack-free interval (shortest-longest, wks) 4.8-6.5 8.7-10.5 - 
Median age at onset (range, in months) 3 (0-120) 24 (0-636) 0.02† 
Mean laboratory value ± SD    
Maximum IgD (IU/mL) 1168.8 ± 1090.3 311.8 ±143.9 <0.001† 
IgA (g/L) 5.37 ± 2.75 2.66 ± 0.82 0.001† 
IgG (g/L) 12.7 ± 3.6 13.9 ± 5.1  
IgG1 (g/L) 8.6 ± 2.4 7.9 ± 3.2  
IgG2 (g/L) 2.0 ± 0.9 2.6 ± 1.5  
IgG3 (g/L) 1.2 ± 0.7 0.5 ± 0.1 <0.001† 
IgG4 (g/L) 0.2 ± 0.2 0.5 ± 0.4 0.009† 
IgM (g/L) 1.4 ± 0.9 1.5 ± 0.8  
Erythrocyte sedimentation rate (mm/h)‡ 92.2 ± 29.3 63.5 ± 35.3 0.02† 
Leukocyte count (109/L)‡ 17.8 ±  7.2 14.4 ± 6.0  
Symptom, n (%)    
Attack after immunization 7 (100) 2  (33) <0.001§ 
Vomiting 36 (88) 4  (31) <0.001§ 
Diarrhoea 28 (68) 4  (31) <0.001§ 
Lymphadenopathy 40 (98) 7  (54) <0.001§ 
Splenomegaly 20 (49) 2  (15) <0.001§ 
Skin lesions 35 (85) 8  (62) <0.001§ 
Arthritis 29 (71) 6  (46) <0.001§ 
Serositis 5  (12) 0  (0) <0.001§ 
Abdominal pain 34 (83) 8  (62) <0.001§ 
Arthralgia 36 (88) 9  (69) 0.011§ 
Aphtous ulcers 4  (67) 2  (50) 0.015§ 
Cold chills 31 (76) 10 (77) - 
Headache 26 (63) 8  (62) - 
*HIDS = hyper-IgD and periodic fever syndrome.  
† Calculated by using the Mann-Whitney U test. 
‡ Measured during a fever episode. 
§ Calculated by using the chi-square test. 
Not unequivocally known in all patients; information on attacks after immunizations was 
obtained from 7 and 6 patients with for classical and variant type HIDS respectively, and on 
aphtous ulcers from 6 and 4 patients.  
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Recent localization and positional cloning efforts identified mevalonate kinase as 
the causative gene in HIDS [2,3]. This enabled us to develop and evaluate a 
molecular genetic test of the mevalonate kinase gene as a diagnostic tool. We 
could detect disease-associated mutations in 76% of patients in a large cohort of 54 
patients. Most patients were compound heterozygotes, that is, they carried a 
different mutation on each allele of the mevalonate kinase gene.  
The mutations have clear physiological consequences as evidenced by the 
considerably decreased activity of the enzyme mevalonate kinase in cultured 
lymphoblasts.  
We were able to delineate a substantial subgroup of patients (24% of our cohort) 
who had the typical clinical presentation of HIDS but lacked mutations in the 
mevalonate kinase gene. This suggests that there is genetic heterogeneity among 
patients with clinical symptoms indicative of HIDS. Although we did not rule out 
the possibility of mutations in the promotor or intronic sequences or the 
occurrence of very large deletions, this is unlikely because these patients display a 
normal level of mevalonate kinase enzyme activity. 
In order to establish if, apart from mutations in the mevalonate kinase gene, there 
are other distinctive features, we examined the two subgroups. HIDS patients who 
showed mutations in the gene for mevalonate kinase were denoted as "classic type 
HIDS", while patients who did not carry any mutation in this gene were designated 
as "variant type HIDS".  Subtle differences in symptoms, signs and laboratory 
values could be detected (table).  In general, classic type HIDS patients are 
younger at their first attack, tend to have shorter, but more frequent febrile attacks, 
and have more additional symptoms during attacks. Although variant type patients 
have high IgD and IgA concentrations, values are lower than those seen in classic 
type patients. It is intriguing that most of the variant type HIDS patients have a 
negative family history, which suggests that this type is sporadic. The early onset 
of symptoms however suggests a genetic predisposition. 
It can be hypothesized that, given the phenotypical similarities, both variant and 
classic HIDS patients share a common inflammatory pathway distal of mevalonate 
kinase which results in the febrile attacks. Earlier studies indicated the activation 
of cytokines during fever attacks in HIDS [50,95] which suggests the involvement 
of macrophage activation. At present it is unclear how a single enzyme defect in 
the isoprenoid pathway gives rise to an inflammatory disorder such as HIDS. 
Some insight might be gained from inhibitors of HMG CoA-reductase, the enzyme 
upstream of mevalonate kinase. These drugs do not only lower cholesterol but also 
have anti-inflammatory properties [96]. The anti-inflammatory effects of HMG 
CoA-reductase inhibitors seem contradictory to the pro-inflammatory phenotype 
of HIDS, which is caused by an enzyme defect one step downstream from HMG 
CoA-reductase.  
This study also raises questions on the significance of IgD in the pathophysiology 
of HIDS. The height of serum IgD concentrations could not be related to clinical 
disease severity. Although IgD levels in variant patients were lower than in classic 
patients, both groups had considerably elevated IgD. This suggests that high IgD 
values do not result directly from mutated mevalonate kinase. From the study of 
Houten et al. it appears that patients with periodic fever who do not have raised 
IgD concentrations may also have mutations in mevalonate kinase [3]. We have 
demonstrated before that symptoms in HIDS may antedate the rise of serum IgD in 
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childhood [46,48]. These findings might suggest that IgD acts as a secondary 
marker which can be found in most, but not all, HIDS patients.  Still, we think it is 
valuable to measure IgD in patients with periodic fever.  If the patient has an early 
onset of symptoms (before the end of the first year of life), has a sibling who is 
affected  with periodic fever and possesses an elevated IgD, the results of the 
current study indicate that it is likely that the patient suffers from classic type 
HIDS.  
We propose to diagnose HIDS using the clinical criteria as set before [46]. Using a 
genetic diagnostic tool, this group of HIDS patients can then be divided into a 
group of patients who have mutations in the gene for mevalonate kinase ("classic 
type"), and a group who lack mutations ("variant type"). The classic type HIDS 
patients are a relatively homogeneous group with a predictable inheritance pattern 
and clinical presentation, which facilitates the counseling of the individual patient. 
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Both mevalonic aciduria, characterized by psychomotor retardation, cerebellar 
ataxia, recurrent fever attacks and death in early childhood, and hyper-IgD 
syndrome, with recurrent fever attacks without neurological symptoms, are caused 
by a functional deficiency of mevalonate kinase. In a systematic review of known 
mevalonate kinase deficient patients we identified 5 adults with phenotypical 
overlap between these two syndromes, which argues for a continuous spectrum of 
disease. Mevalonate kinase deficiency should be considered in adult patients with 
fitting neurological symptoms, with or without periodic fever attacks. 
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Mevalonate kinase deficiency, caused by mutations in the mevalonate kinase gene, 
is associated with two disparate clinical syndromes. The hyper-IgD and periodic 
fever syndrome (HIDS, MIM 260920) is an autoinflammatory disease 
characterized by lifelong recurrent episodes of fever, abdominal distress, 
lymphadenopathy and skin rash [2-4], which usually start in the first year of life. 
There are no apparent neurologic or morphological abnormalities, and in between 
the febrile attacks patients are remarkably free of symptoms. Mevalonic aciduria 
(MVA, MIM 251170) is typically a disease of infantile onset, characterized by 
psychomotor retardation, ataxia, failure to thrive, cataracts and dysmorphic 
features [45,97]. Patients also suffer from periodic fever attacks, similar to but 
more severe than in HIDS and, in general, they die in early childhood.  
Mevalonate kinase, which phosphorylates mevalonic acid, is a central enzyme in 
the isoprenoid pathway; end-products include cholesterol, dolichol and 
ubiquinone. This pathway is also responsible for isoprenylation, a post-
translational modification of proteins causing them to become membrane-bound. 
How a defect in this metabolic pathway leads to either of the clinical phenotypes is 
obscure. (Random) clinical observation of these patients suggests that the clinical 
presentation of mevalonate kinase deficiency represents a phenotypic continuum 
from mevalonic aciduria to HIDS, instead of two separate phenotypical entities. To 
test this observation, we searched our clinics and database to identify (adult) 
mevalonate kinase deficient patients with neurological signs and symptoms. 

"

The Nijmegen International HIDS registry [46] consists of 81 patients with 
metabolically and/or genetically confirmed mevalonate kinase deficiency. On 
screening this registry, four patients with neurological signs were identified. One 
additional patient with mevalonic aciduria and mevalonate kinase deficiency was 
identified through the neurology clinics. Some of the patients have been described 
earlier [42,46,98].For comparison we also summarize the clinical data from 32 
classical HIDS patients without neurological signs and symptoms in the HIDS 
registry of whom all genetic and metabolic data were available. Patients 1,2, and 4 
were examined by us. Patients 3 and 5 had been examined by others. 
!)&(2=:)()")
("
Genomic DNA was extracted from whole blood or Epstein-Barr immortalized 
lymphoblasts from the patients, and the mevalonate kinase gene was amplified and 
sequenced according to established protocols [2]. For analysis of mevalonate 
kinase enzyme activity, we employed a radiometric assay using extracts of 
cultured lymphoblasts [42]. Proton NMR spectroscopy (500 MHz) was used to 
quantify mevalonic acid in urine at pH 2.5, from samples outside fever attacks. 
Under these conditions mevalonic acid gives a singlet resonance at 1.33 ppm, 
while in some patients also the lactone of mevalonic acid may be observed as a 
1.37 ppm resonance. 
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#1 #2 #3 #4 #5 
hyper-IgD 
syndromec 
n=32 
mevalonic 
aciduriad 
n=11 
Current age (years) 45 44 30a 54 41 31 (11-58) 4 (0,5-12) 
Gender (M / F) M M F M F 16 / 16 5 / 6 
Clinical characteristics 
       
 Periodic fever attacks + + + - + + + 
 Mental retardation + + + ++ ++ - +/++ 
 Language disorder + + ? + ? - ? 
 Cerebellar ataxia + + - + + - +/- (5/10) 
 Ocular symptoms e + + - + + - +/- (6/11) 
 Epilepsy - - + - + - - 
 Age of onset (months) 0 0 6 12 6 3 (0-96) ND 
IgD (IU/mL)f 680 1170 304 20 465 880 (376-5300) ND 
Mevalonate kinase 
mutations 
V377I/ 
W62X 
V377I/ 
W62X 
P167L/ 
G202R 
A334T/ 
H20P 
A334T/ 
W62X 
12 different 
mutations ND 
Mevalonate kinase  
enzyme activity (%)g ND 4.5 1.8 1.1 < 0.5 10.5 (2-32) 1.5 (0-4) 
Mevalonic acid in urine 
(mmol/mol creatinine)h 4 15.4 raised
b
 2730 7200 ND 
10850 
(1700-
56000) 
Table 1. Comparison of patient characteristics. Patient numbering refers to their case number in the International 
Nijmegen HIDS registry. (a) age at death. (b) no quantitative data available. (c) data from all patients in the 
Nijmegen International HIDS registry who fulfilled the following criteria: no neurological symptoms, known 
mutations in the mevalonate kinase gene and known deficient mevalonate kinase enzyme activity. Results 
presented as median (range). (d) data from 11 mevalonic aciduria patients described in Hoffmann et al [45]; 4 of 
them had died before age 4. Results presented as median (range). (e) ocular symptoms include cataracts and 
progressive tapetoretinal degeneration. (f) serum concentration of immunoglobulin D (IgD), normal <100 IU/mL. 
(g) mevalonate kinase enzyme activity, measured in EBV-transformed lymphoblasts, expressed as percentage of 
controls. (h) mevalonic acid concentration in urine, normally undetectable.  ND = not determined. + present, - 
absent, ? unknown. 
 
/
A summary of clinical symptoms and test results is presented in table 1, detailed 
case descriptions are available in the online supplemental data (see appendix). All 
patients were of Dutch descent, and except for patient #1 and #2, who were 
brothers, the family history of the patients was negative. In all five patients, the 
first symptoms appeared within the first year of life. Four of the five patients had 
recurrent fever episodes with characteristic accompanying symptoms such as 
abdominal distress, lymphadenopathy, erythematous skin rash, aphthous ulcera 
and arthralgia. Patient #4 never experienced such fever episodes. This patient had 
a normal IgD concentration. Three patients had mild to moderate mental 
retardation and two had severe mental retardation; all patients except for patient #3 
were institutionalized. The three patients examined by us exhibited a similar 
language disorder: grammatically simple language with a strong predominance of 
Phenotypic continuum in mevalonate kinase deficiency 
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nouns and adjectives, echolalia and palilalia and phonemic paraphasias, and 
omission of the first consonant in words. Four of five patients suffered from 
cerebellar ataxia, more pronounced in gait than in the arms. One patient had left 
temporal epilepsy with complex partial seizures, one other patient had generalized 
tonic-clonic seizures. The ocular symptoms in four of the five patients included 
progressive blindness due to tapetoretinal degeneration and cataracts. Patient #1 
and #2 both suffered from hearing loss, presumably due to frequent ear infections 
and mastoiditis. Generalized muscle hypotonia was observed in patient #4, with 
normal nerve conduction studies. Figure 1 shows severe cerebellar atrophy in 
patient #4. Patient #1 was reported to have suffered a left hemispheric ischemic 
stroke of unknown etiology at age 40, but had recovered with only a very mild 
residual clumsiness. Patient #3 died at age 30 after a brief intercurrent illness, 
diagnosed as staphylococcal pneumonia; autopsy was not performed. The other 4 
patients are still alive. 
%
The patients presented in this paper, who all have mevalonate kinase deficiency, 
illustrate a phenotypic continuum between HIDS and MVA. Four out of five suffer 
from characteristic episodes of fever and inflammation, though intriguingly, one 
patient did not. All have mental retardation with additional neurological signs in a 
varying degree of severity, such as cerebellar ataxia, epilepsy, and a language 
disorder that may or may not be specific for the disease. We were unable to 
determine how this language disorder compares to language deficits in patients 
with mental retardation of other causes. All patients have survived to adulthood; 
one patient died at age 30, due to intercurrent pneumonia.  
This is in sharp contrast to what has been described in the literature on classical 
mevalonic aciduria. One study describes the phenotype of 11 mevalonic aciduria 
patients [45]. The most severely affected had profound developmental delay, 
dysmorphic features, cataracts, hepatosplenomegaly, lymphadenopathy, and 
anemia and died in infancy. Less severely affected patients had psychomotor 
retardation, myopathy, and ataxia. All patients had recurrent crises with fever and 
lymphadenopathy. The authors did not find a relation between the neurological 
phenotype and the remaining enzymatic activity [45]. Another report of 4 young 
patients illustrated that both MVA and HIDS are caused by mevalonate kinase 
Figure 1. T1 weighted sagittal 
midline MRI image, to 
demonstrate severe cerebellar 
atrophy in patient #4. 
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deficiency [99]. Unfortunately, no genotypes were offered by either of these 
reports. Patients surviving to their 6th decade, such as our patient #4, have never 
been described. The patients described here seem to bridge the gap between the 
classical MVA and HIDS phenotypes. Mevalonate kinase deficiency should be 
considered in adult patients with fitting neurological symptoms, with or without 
periodic fever attacks. 
In figure 2, a phenotypic spectrum of MVA/HIDS is proposed. One explanation 
for the varying degree in severity of phenotype might be the specific genotype 
involved. Generally, patients are compound heterozygous for two different 
mutations in the mevalonate kinase gene. These mutations may have a different 
effect on the function of the enzyme, some leading to a minor loss of efficiency 
(e.g. V377I), others causing near complete loss of function (e.g. A334T). The 
resulting sum of the residual enzyme activities and efficiency may account for the 
phenotypical variability (Fig. 2). 
But genotype analysis alone is unable to explain the remarkable variability in 
phenotype. In a study of 3 MVA patients [100] one patient was included with a 
mild phenotype, still alive at 20 years of age with a genotype identical to our 
patient #4. In contrast, one other patient in that report, who was homozygous for 
the I268T mutation, was severely affected and died in the first year of life. We 
have previously described two adult brothers with this genotype who have HIDS 
without any neurological symptoms [42]. Therefore, genetic trans-acting or 
environmental factors have to be considered to explain the phenotypic variability. 
Measurement of urinary mevalonic acid by mass spectrometry or proton NMR 
spectroscopy is the most straightforward step to screen for mevalonate kinase 
deficiency (Fig. 3). Serum IgD is not always elevated in mevalonate kinase 
deficiency, and as illustrated by case #4 normal values do not exclude the 
diagnosis [3].  
Figure 2.  Proposed genotype-phenotype spectrum for mevalonate kinase deficiency. 
 (a) Mevalonate kinase enzyme activity, ranging from 100% (left) to <1% (right). (b) Phenotype 
associated with decreasing enzyme activity, double-headed arrow depicts continuous phenotypic 
spectrum between two extremes (HIDS and mevalonic aciduria). (c) Genotype consists of a combination 
of mild (e.g. V377I), moderate (e.g. H20P, I268T) or severe (e.g. A334T) mutations in mevalonate kinase 
gene. (d) concentration of mevalonic acid detected in urine samples, average estimates, expressed in 
mmol/mol creatinine. 
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Figure 3. Screening for mevalonate kinase deficiency. (a) Screening would be recommended in cases 
with 2 or more of these symptoms, starting from an early age; also cases of recurrent inflammatory 
episodes without other symptoms. It can most directly be done by measuring urinary mevalonic acid 
concentration. When this is elevated, further diagnostic procedures can be performed for confirmation: 
(1) mutation analysis mevalonate kinase gene: relatively easy and available, (2) enzyme activity 
measurement: most direct confirmation but only available in specialist research setting. Data on 
sensitivity or specificity of these tests are lacking. 
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Clinical phenotype
From <2 yrs of age, 2 or more of the followinga:
• recurrent inflammatory episodes
• (progresive) cerebellar ataxia
• mental retardation
• tapetoretinal degeneration, cataracts
Urinary mevalonic acid
Confirmation:
1. mutation analysis mevalonate kinase gene
2. enzyme activity fibroblasts/lymphoblasts
Elevated?
No mevalonate kinase
deficiencyno
yes
Mevalonate kinase 
deficiency
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Patients 1 and 2 are two brothers with a very similar clinical phenotype. Both were 
afflicted since their first month of life with recurrent fever episodes accompanied 
by abdominal distress and an erythematous skin rash, which last a few days and 
occur every 3 to 5 weeks. They were institutionalized at age 8 and 9 respectively 
because of mental retardation, and over the years very slowly deteriorated. In their 
early twenties, tapetoretinal degeneration with cataract was noted in both brothers, 
and also impaired hearing presumably due to frequent ear infections and 
mastoiditis. They had eight siblings, who could not be examined because all 
contact had been severed at an early age. Both lived in an institution where they 
were able to provide adequate self-care.  
The eldest brother (#1) suffered a left hemispheric ischemic stroke of unknown 
etiology at age 40. When examined at age 43, his major symptoms were gait 
problems requiring ambulatory aid, as well as minor articulation and swallowing 
difficulties. At that time the neurological examination showed a small and very 
lean man with a weight of 45 kg; a mid-thoracic kyphosis; mild to moderate 
mental retardation; a language disorder that consisted of telegraphic speech with 
intermittent echolalia and palilalia and phonemic paraphasias; slight dysarthria; 
gait ataxia with minimal arm ataxia; and brisk reflexes. In addition, he suffered 
from a unilateral right arm upper motor neuron paresis. 
Examination of his brother (#2) at age 42 revealed a mildly to moderately retarded 
man, weight 44.5 kg, who produced grammatically simple language, with a 
predominance of nouns and adjectives, echolalia and palilalia, and infrequent 
omission of the first letter of words; a slurred speech; saccadic intrusions in 
vertical smooth pursuit eye movements; mild arm ataxia, but more prominent gait 
ataxia; and brisk tendon reflexes with extensor toe responses but absent Achilles 
tendon reflexes. 

Patient 3 was a Dutch woman referred to us at age 24 because of recurring 
episodes of fever and a high serum concentration of IgD. The fever attacks had 
started when she was 12 months old, and were characterized by abdominal distress 
and arthralgia. Accompanying signs were lymphadenopathy, erythematous skin 
rash, oral and genital aphthous ulcers en sometimes frank arthritis. Such an 
episode would last 5 to 7 days, and recur every 3 to 6 weeks. From 6 months-old 
onwards she had left temporal epilepsy with complex partial seizures. There was a 
behavioral disorder with mild mental retardation. The family history was negative. 
Examination in a fever-free interval showed a young woman of 174 cm length 
with no clear dysmorphic features. Neurologic examination was otherwise 
unremarkable, without signs of cerebellar ataxia. At age 30 she died after a brief 
intercurrent illness, diagnosed as staphylococcal pneumonia. Autopsy was not 
performed. 
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Patient 4 was institutionalized at a very young age because of mental retardation. 
Since his late thirties, his vision deteriorated because of cataract and he became 
wheelchair bound. Episodes of periodic fever were never documented in the 
institution in all the years he lived there. He was first examined by us at age 52. 
This revealed corneal opacities OS, bilateral keratoconus and psoriasis-like skin 
lesion of the abdomen, elbows and knees. Neurological abnormalities included: 
severe mental retardation with adequate cooperation; a peculiar language disorder 
in which he used almost exclusively nouns and adjectives with hardly a verb, and 
with omissions of the first consonant in words; severely decreased visual acuity 
with intact light / dark discrimination; slurred speech; generalized muscle 
hypotonia; mild arm ataxia but severe gait ataxia; brisk tendon reflexes with flexor 
toe responses; and lower leg atrophy with bilateral pes planus valgus. Nerve 
conduction studies were normal. An MRI scan revealed severe cerebellar atrophy 
(figure 1). His serum IgD was not elevated (table 1) 

Patient 5, a 41-year old woman with negative family history, started from an early 
age to suffer from periodic fever attacks with all the characteristic accompanying 
symptoms. These episodes lasted 4 to 5 days and occurred approximately every 6 
weeks in childhood. Development was slightly retarded, and although she walked 
at the age of 12 months it was noticed that she fell very often. At the age of 4 years 
a crisis occurred which was tentatively diagnosed as measles encephalitis. 
Subsequently, she developed severe psychomotor retardation requiring 
institutionalization, epilepsy with generalized tonic-clonic seizures, cerebellar 
ataxia, and progressive blindness due to tapetoretinal degeneration and atrophy of 
the optic nerve.  
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Background: Classical type hyper-immunoglobulin D (IgD) syndrome (HIDS) is 
an hereditary auto-inflammatory disorder, characterised by recurrent episodes of 
fever, lymphadenopathy, abdominal distress and a high serum concentration of 
IgD. It is caused by mevalonate kinase deficiency.  
Objective: to further characterise the acute phase response during fever attacks in 
HIDS in order to improve diagnosis.  
Subjects: 22 mevalonate kinase deficient HIDS patients. 
Methods: Blood samples were drawn during and in between febrile attacks, and 
concentrations of C-reactive protein (CRP), ferritin, procalcitonin, pentraxin 3, 
IgD and cholesterol in several lipoprotein fractions were determined.  
Results: The marked acute phase response at the time of a fever attack in classical 
type HIDS is reflected by a rise in CRP accompanied by a moderate but 
statistically significant rise in procalcitonin and pentraxin 3. In only 2 of 22 
patients, procalcitonin concentration rose above 2 ng/mL during fever attack, 
compatible with the non-infectious nature of these attacks. Ferritin does not reach 
the high concentrations found in Adult-onset Still’s disease. Despite the defect in 
mevalonate kinase, a component of cholesterol metabolism, serum cholesterol did 
not change during attacks. IgD concentration is elevated regardless of disease 
activity, though there is appreciable variation during life. Its role in HIDS remains 
unclear. 
Conclusion: The combination of high CRP concentration plus procalcitonin 
concentration <2 ng/mL in a symptomatic HIDS patient may indicate a febrile 
attack without (bacterial) infection; this observation warrants further investigation 
for its usefulness as a marker in clinical practice. 
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The hyper-immunoglobulinaemia D and periodic fever syndrome (HIDS) is a rare 
disorder which causes life-long recurrent episodes of fever and inflammation [4]. 
Clinically, these episodes may be accompanied by abdominal distress, arthralgia, 
headache, lymphadenopathy, skin rash, and aphthous ulcers [46]. The 
inflammatory attack lasts about 4 to 6 days followed by a spontaneous remission, 
only to recur after a symptom-free period of 4 to 6 weeks. Attacks can be triggered 
by minor trauma, vaccinations, and physical or emotional stress, but often come 
unexpectedly. Laboratory examination at the time of attacks reveals a vigorous 
acute phase response with leukocytosis, raised sedimentation rate, and high serum 
concentrations of C-reactive protein and pro-inflammatory cytokines such as IFNγ, 
TNFα, and IL-6 [50,95]. Almost all patients have an elevated polyclonal 
immunoglobulin D (IgD) and IgA concentration. Previously, we have 
distinguished classical type HIDS and variant type HIDS [40]. While in variant 
type HIDS the nature of the underlying defect is unclear, classical type HIDS is 
caused by mutations in the gene encoding for mevalonate kinase, an enzyme that is 
part of the isoprenoid pathway. The genetic mutations cause a diminished enzyme 
activity of mevalonate kinase, and during a fever attack its substrate, mevalonic 
acid, will accumulate in body fluids and be excreted in the urine. End-products of 
this pathway include cholesterol, dolichol and ubiquinone, and the isoprenoid 
pathway is also essential for the isoprenylation of proteins, a modification 
important for membrane bound proteins. The link between the defective isoprenoid 
metabolism and the inflammatory phenotype of HIDS remains to be resolved.  
The main aim of this study was to further define the acute phase response in the 
inflammatory attacks in classical HIDS patients, actuated by two considerations. In 
the first place, we sought to discriminate between (serious bacterial) infection and 
non-infectious inflammation of a HIDS attack. Such a differentiation is needed in 
clinical practice as the inflammatory episodes in HIDS, with high fever and often 
severe abdominal distress, can pose a serious diagnostic dilemma and frequently 
lead to unnecessary use of antibiotics or even avoidable surgical procedures. This 
prompted us to consider two recently characterised members of the family of acute 
phase proteins as a biological marker: procalcitonin (PCT) and pentraxin 3 (PTX3) 
[101-104]. Secondly, we wanted to test serum concentrations of IgD, ferritin and 
cholesterol in HIDS patients with and without fever, which might be of help in 
differential diagnosis.  
""

We included in this study twenty-two Dutch patients with classical type HIDS, 12 
male and 10 female. All patients suffered from typical recurrent fever episodes, 
shared elevated serum concentrations of IgD and carried mevalonate kinase gene 
mutations. The main patient characteristics are listed in table 1. Sampling of 
plasma and serum was performed at two time points, during fever attack and 
during remission. Our definition of a fever attack for the present study consisted of 
1) raised body temperature (38 °C), 2) typical symptoms and signs of HIDS as 
mentioned earlier and 3) no clinical indications for the presence of infection. 
Remission was defined as the absence of symptoms for at least 1 month. No 
medication was allowed during the study period. Close follow-up of the patients 
did exclude bacterial and/or viral infections during the course of the investigation. 
All patients recovered from the fever episode spontaneously without the use of 
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antibiotics or antiviral medication. The ethical committee of our institution 
approved the study protocol, and all patients gave informed consent. In order to 
delineate the course of IgD during life, we took historical IgD values from patient 
records from 17 classical type HIDS patients, which were available to us through 
the Nijmegen HIDS registry [46]. 
 
Pt 
no. 
Sex Age 
(yrs) 
Onset 
(mnth) 
MVK genotype Fever Lymph-
adenopathy 
Abdominal 
Pain 
Arthralgia Skin 
lesions 
1 F 17 8 V377I/I268T + + + - - 
2 M 18 4 P167L/I268T + + + + + 
3 M 22 0 V377I/I268T + + + + + 
4 M 23 3 V377I/H20P + + + + + 
5 F 26 2 V377I/H20P + + + - + 
6 M 30 3 V377I/H20P + + + + + 
7 M 31 18 P167L/I268T + + + + + 
8 F 34 0 V377I/unknown* + + + + - 
9 F 34 12 P167L/G202R + + + + + 
10 M 37 96 V377I/unknown* + + + + + 
11 F 37 0 V377I/I268T + + + + + 
12 F 38 3 V377I/V377I + + + + + 
13 M 40 24 V377I/deletion + + + + + 
14 M 41 48 V377I/unknown* + + - + + 
15 F 42 12 V377I/deletion + + + + + 
16 M 45 0 V377I/W62X + + + + + 
17 M 46 0 V377I/W62X + + + + + 
18 F 52 ? V377I/G309S + + - - + 
19 F 54 0 V377I/deletion + + - + + 
20 M 54 3 V377I/I268T + + + + + 
21 F 54 12 V377I/I268T + + - - - 
22 M 58 48 V377I/H20P + + - + + 
Table 1. Patient characteristics. 
*In three patients where only one mutation in the MVK gene could be identified, the diagnosis 
classical type HIDS was confirmed by detection of increased urinary mevalonic acid excretion 
during inflammatory attack (patient 8) or decreased mevalonate kinase enzyme activity (patients 10 
and 14). 
0"	"
Determinations of each protein was performed in one assay for all samples. CRP 
concentrations were measured in duplicate by a polyclonal antibody enzyme 
linked immunosorbent assay (ELISA) as previously reported (normal reference 
<2,7 mg/L) [105]. Concentration of procalcitonin was determined by 
chemiluminescent solid phase double antibody immunoluminometric assay 
(LUMItest; BRAHMS Diagnostica GmbH, Berlin, Germany). Two specific 
monoclonal antibodies form a sandwich by binding the two major polypeptide 
chains of procalcitonin (catacalcin and calcitonin); the second antibody carries a 
luminescent tracer. The light emission triggered by oxidation in the presence of 
hydrogen peroxide can be measured by luminometer (detection limit 0,05 ng/mL, 
normal reference <0,5 ng/mL, reference limit used in case of bacterial infection <2 
ng/mL) [106,107].  
Plasma concentration of pentraxin 3 was measured by ELISA, based on the PTX3-
specific monoclonal antibody MNB4 and biotinylated rabbit PTX3-specific 
polyclonal IgG (normal reference <2 ng/mL) [108,109].  
The procedure for the ELISA for measurement of IgD has been published earlier, 
using rabbit anti-human IgD (Dako, Copenhagen, Denmark) as the primary 
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antibody [110]. The lower limit of detection of this ELISA was 1 IU/mL (1.4 
mg/L), normal reference <100 IU/mL.  
Concentrations of cholesterol were measured on the Hitachi 747 analyzer with 
enzymatic, commercially available reagents (Boehringer–Mannheim, Germany) 
(normal reference 4,7-6,5 mmol/L). HDL-cholesterol was measured in the 
supernatant after precipitation with PEG 6000 on the Hitachi 747 analyzer using 
commercially available reagents [111], LDL-cholesterol was calculated by the 
Friedewald formula (normal reference limit <4,7 mmol/L) [112]. 
Ferritin was measured on the Immulite 1 (DPC, Los Angeles, USA) using beads 
coated with monoclonal anti-ferritin and an alkaline phosphatase polyclonal 
conjugate (normal reference limit premenopausal women 80 g/L, men and 
postmenopausal women 280 g/L). 
0)
Statistical analysis was performed using GraphPad Prism version 4 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com. The paired 
nonparametric Wilcoxon signed rank test was used for statistical comparison of 
concentrations during remission and during fever attack. Correlation coefficients 
were calculated with the Spearman correlation test. Data are given as median 
(range) unless otherwise stated. 
 
Figure 1. The acute phase response in the fever attack of HIDS. (a) serum concentration of CRP; 
(b) procalcitonin; (c) pentraxin-3; (d) ferritin; (e) immunoglobulin D; and (f) LDL-cholesterol. 
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During a fever attack, serum concentrations of CRP are invariably and 
significantly elevated, to a median of 210 mg/L (range 67-385 mg/L; p<0.0001, 
Figure 1a). During a period of remission when the patient is without any 
symptoms, CRP concentrations are significantly lower, although often (83% of 
cases) still elevated above normal (12 mg/L (range 1.3-240 mg/L)).  
At the time of fever episodes most patients showed a limited albeit statistically 
significant rise in serum procalcitonin concentration (Figure 1b; median 0.15 vs. 
0.24 µg/L, p=0.0005). A clinically significant increase above the reference limit of 
2 ng/mL used for bacterial infection, was seen in only two patients. Procalcitonin 
concentrations during fever attacks were correlated with CRP concentrations 
(Figure 2a, Spearman r=0.71, p=0.0013). PTX3 concentration (Figure 1c) 
increased during fever in the majority of patients (median 0.45 vs. 1.53 ng/mL, 
p=0.002), with a concentration greater than 2 ng/mL in 8 of 21 patients. However, 
a correlation between CRP and PTX3 was absent, also in the samples taking 
during fever attack (Figure 2b).  
Serum ferritin concentration increased in 61% of the patients during a fever 
episode, up to a maximum of 1398 µg/L (p=0.0002, Figure 1d). There was no 
indication for the presence of hemochromatosis in any of the patients, as ferritin 
values dropped to below 300 µg/L between attacks and the iron saturation as 
determined with transferrin saturation or unsaturated iron-binding capacity was 
below 45% (data not shown). 
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Immunoglobulin D (IgD) serum concentrations were elevated, in most patients to 
at least 5 times the upper level of normal. No difference was found in samples 
taken during remission or during a fever attack (median 639 IU/mL (range 108-
3560 IU/mL) vs. 603 IU/mL (range 92-3090 IU/mL), Figure 1e). There was no 
correlation between IgD and CRP values, either during attacks, or during 
remission (Figure 2c). Intraindividual IgD concentrations determined over a period 
of years show great variation (Figure 3). All HIDS-patients had normal to low-
normal serum cholesterol concentrations during remission; this was true for total 
(mean 3.7 mmol/L ± SD 1.1), LDL- (mean 2.5 mmol/L ± SD 0.9) and HDL-
cholesterol (mean 0.75 mmol/L ± SD 0.3). No changes to any of these 
concentrations occurred during a fever attack (Figure 1f).  
Figure 3.  
Serum IgD concentration in 17 HIDS patients. Each symbol represents a separate patient, some of 
whom have been followed for several years. There is wide intra- and interindividual variation. 
%
These results demonstrate the intense acute phase response during the fever 
episode of classical type HIDS, and provide information on pathophysiological 
mechanisms. The acute phase response in HIDS is best defined by the sharp rise in 
serum concentrations of CRP (Figure 1a). This response is similar to that described 
in patients with familial Mediterranean fever (FMF), although generally the acute 
phase response is more intense and more prolonged than in FMF [113-116]. 
Our main objective was to find a biological marker that discriminates between the 
non-infectious inflammation of a fever attack of HIDS and (bacterial) infection. To 
this end, we examined the acute phase proteins procalcitonin and PTX3. Both 
proteins showed a statistically significant rise during fever attacks, although only 
procalcitonin concentration during fever showed a significant correlation with 
CRP concentration. Specifically, procalcitonin values rose above the threshold of 2 
ng/mL, used as reference limit for bacterial infection, in only in 2 of 22 patients. 
This is similar to the findings in systemic autoimmune disease [102]. This suggests 
that the combination of a high serum CRP and procalcitonin concentration below 2 
ng/mL may be used to distinguish an inflammatory attack of HIDS from an 
intercurrent bacterial infection. The sensitivity and specificity of this combination 
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of markers needs to be determined in future studies. The specific cytokine profile 
in HIDS might account for the limited increase in PTX3 concentration as this acute 
phase protein is induced by interleukin-1 (and not by interleukin-6), while in HIDS 
interleukin-6 is far more upregulated than interleukin-1 [50,103]. 
 
The cause of elevated IgD concentrations in the majority of HIDS patients, which 
prompted the name of this syndrome [1] is still an enigma. In children, the fever 
attacks may precede the rise in serum IgD for several years [117]. Also, some 
HIDS patients, despite having a severe phenotype, never develop high IgD[118], 
while a modest increase in IgD may be found in other hereditary autoinflammatory 
syndromes. On the other hand, isolated IgD has been shown to elicit an 
inflammatory response in isolated mononuclear cells [110]. If the IgD elevation is 
a consequence of the inflammatory phenotype it might be anticipated that its 
concentration varies with the attacks.  In our study, serum IgD concentrations were 
found to be continuously high, irrespective of inflammatory state and/or CRP 
concentration. In addition, we found that serum IgD concentrations vary greatly 
during life (Figure 3), without correlation with clinical symptoms or frequency of 
attacks. These are further arguments to label the high IgD as an epiphenomenon 
rather than central to the pathogenesis. These data also indicate that the timing of 
IgD sampling for diagnostic purposes is irrelevant.  
In our patients, we found relatively low serum LDL- and HDL-cholesterol 
concentrations during remission, but no further decrease with inflammatory 
attacks. This contrasts with the expected decrease of HDL-cholesterol during 
inflammation as has been described for numerous inflammatory disorders [119-
121], and this might be related to the enzyme defect of mevalonate kinase in 
HIDS. 
Despite an elevated ferritin concentration during fever attack in 61% of HIDS 
patients, none of the patients showed the extremely high ferritin concentrations 
(>3000 ng/mL) found in Adult-onset Still’s disease (AOSD [122-124]), an 
inflammatory disorder with unknown aetiology, characterized by spiking fever, 
arthritis, evanescent rash and onset in adulthood [125].    
In conclusion, the fever attack in HIDS is characterized by a strong rise in CRP 
concentration in all patients. Other acute phase proteins, such as pentraxin-3 and 
procalcitonin, showed an increase in some but not all patients. Specifically, this 
study suggests that in classical type HIDS a combination of high CRP 
concentration with procalcitonin below 2 ng/mL can be used as an indication that a 
febrile attack is not due to intercurrent bacterial infection, which can reduce 
unnecessary use of antibiotic therapy. The same may be true for PTX3 when its 
limit is set higher, although this remains more speculative since less is known 
about the right cut-off point. The concentration of IgD, which is high in HIDS, is 
not influenced by the inflammatory episodes. 
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Hyper-immunoglobulinaemia D and periodic fever syndrome (HIDS [Mendelian 
Inheritance in Men, 260920]) is an autosomal recessively inherited disorder 
characterized by recurrent episodes of fever, abdominal distress, arthralgia and 
aphtous ulcers [4]. The constantly elevated immunoglobulin D (IgD) serves as an 
apt marker of the disease, and all patients exhibit a marked acute phase response 
during the fever attacks. It was first described as a separate syndrome in the 
Netherlands [1], but the disease was later identified in patients from other 
European countries such as France [126-129], United Kingdom [130], Germany 
[131,132], Italy [133,134], Turkey [135] and the Czech republic [136] but  also in 
the United States [92] and in Japan [137]. 
Many HIDS patients are found to have mutations in the gene for mevalonate 
kinase [2,3,40], which cause a decreased activity of this enzyme. Mevalonate 
kinase is an essential enzyme in the isoprenoid pathway which eventually results 
in the production of cholesterol, dolichol, and ubiquinone and in protein 
isoprenylation [41]. How the deficient activity of this enzyme causes the clinical 
phenotype is unknown. So far, 18 different mutations have been described, 
distributed throughout almost all coding regions of the gene [41,42]. One 
mutation, which leads to a replacement of valine by isoleucine at codon 377 of the 
protein (V377I), is particularly common, being present in 36 of 45 (80%) 
unrelated HIDS patients [42,138]. Most HIDS patients are compound 
heterozygotes, i.e. they have a combination of two different mutations in the 
mevalonate kinase gene. Usually, patients have a combination of a V377I with an 
I268T mutation (isoleucine → tyrosine at position 286). The clustering of cases in 
The Netherlands and in Western Europe, most notably those with a V377I 
mutation, is remarkable (Figure 1).  
  
Figure 1.  
Geographical distribution of 32 patients 
or families with at least one allele with a 
basepair change 1129G>A in the 
mevalonate kinase gene, leading to 
replacement of valine at codon 377 by 
isoleucine (V377I). Cases, indicated by 
black dot, are clustered especially in the 
Netherlands. Not shown: 1 patient in 
Turkey, 2 patients in the USA. (Figure 
created with “Online map creation”, 
http://www.aquarius.geomar.de/omc). 
 
 
Founder effect in HIDS 
 
 
81 
In an attempt to gain insight in the ancestral origin and to explain the geographical 
distribution of HIDS we chose to perform an extensive haplotype study using five 
closely linked markers surrounding the mevalonate kinase gene in a group of 14 
HIDS families. 
067""
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
Patients for this study were selected on the basis of previous inclusion in the 
Nijmegen International HIDS registry. This registry was set up in 1992 and now 
hosts clinical and laboratory data on 188 HIDS patients (http://hids.net). Briefly, 
all patients had recurrent attacks of fever (≥38.5°C) with an acute phase response 
and a constantly elevated serum IgD (>100 U/mL) measured at 2 occasions with 
at least one month apart, and one or more of the following symptoms during 
attacks: lymphadenopathy; abdominal distress; skin manifestations; arthralgia / 
arthritis; and splenomegaly. 
We identified 16 families with one or more affected siblings with HIDS and 
known mevalonate kinase genotype. Fourteen families were informative enough 
to allow haplotype analysis (Figure 2); they originate from the Netherlands (7 
families), France (2 families), United Kingdom (2 families), Spain (1 family), 
Czech republic (1 family) and Italy (1 family). We also included 4 patients (Dutch 
n=3, United States of America n=1) who were homozygous for the V377I 
mutation. The clinical details and results from genotype analysis of these patients 
and families have been described elsewhere [42,46,139]. Mevalonate kinase 
genotype analysis of the 14 families yielded 11 V377I alleles, 7 I268T alleles, and 
10 alleles with other mevalonate kinase mutations (P167L, H20P, H20N, R215Q, 
two deletions and four unknown). 
  
Figure 2. Pedigrees of 14 HIDS families with one or more affected siblings included in this study. 
The occurrence of the V377I mutation, I268T mutation or an allele with a different mutation in the 
mevalonate kinase gene is indicated. A question mark denotes a family member not available for 
genetic analysis. 
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The control alleles were gathered from unaffected members within the same 
families, to ensure that they would originate from the same population. The study 
was carried out after informed consent from all individuals and formal approval 
was obtained by the Medical Ethical Committee of the University Medical Center 
Nijmegen, The Netherlands.  

2
Genomic DNA was extracted from whole blood or Epstein Barr Virus 
transformed lymphoblastoid cell lines according to standard procedures. The 
following five markers were used for the haplotype analysis: D12S1605, 
D12S1339, D12S1645, D12S234 and D12S1583 (GenBank). Primer sequences 
were obtained from the Genome Database. The markers were amplified using a 
standard PCR method. The marker allele sizes were analyzed with an ABI 
PRISMTM 310 Genetic Analyzer (PE Applied Biosystems). Using BLAST search 
tools, the exact position of the mevalonate kinase gene and markers D12S1339, 
D12S1645 and D12S234 could be determined within two overlapping DNA 
sequences deposited in the Genome Database (AC007623 and AC007570). We 
determined that the HIDS gene is located between markers D12S1645 and 
D12S234.  
>2"?6)
Linkage disequilibrium indicates association between a genetic marker and a 
disease associated mutation, and is a measure for co-segregation of a specific 
haplotype with a mutation in a population. Statistical analysis comparing the 
frequency of the associated numbered marker allele on chromosomes carrying the 
V377I mutation with the frequency on normal chromosomes was based on a chi-
square test for a 2x2 table. Linkage disequilibrium was assessed by the formula δ 
= (PD – PN)/(1-PN), where PD is the frequency of the associated marker allele on 
disease chromosomes and PN the frequency of the same marker allele on normal 
chromosomes [140].   
/
Base-pair sizes of the different existing alleles of the 5 markers examined and 
their frequency in the control alleles are shown in table 1. Figure 3 displays the 11 
definite V377I haplotypes from the 14 families and it is shown that the haplotype 
3-1-4-8 is conserved among persons carrying the V377I mutation. This haplotype 
of at least the two flanking markers was also found on all of the V377I alleles of 
the 4 patients homozygous for this mutation, except in one allele of one Dutch 
patient.Statistical analysis shows a significant linkage disequilibrium for this 
haplotype, as demonstrated in table 2, and the 3-1-4-8 haplotype was not seen at 
all on the V377I-negative control alleles, indicating that it is highly mutation-
associated.  
Seven alleles with the I268T mutation in the mevalonate kinase gene could be 
collected from the 14 families. Allele 6 of marker D12S234 was only found in 
association with the I268T mutation and not in 25 control alleles nor in any of the 
alleles with other mutations in the mevalonate kinase gene. This again suggests a 
founder effect but the small numbers did not allow statistical analysis.  
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Figure 3. The haplotypes of 11 alleles from the HIDS families carrying the V377I mutation, 
analyzed for the indicated markers. Numbers indicate different marker alleles, see table 1 for base-
pair sizes. The common mutation-related haplotype (3-1-4-8) is marked by the shaded area. 
Missing numbers stand for missing data. 
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
The high prevalence of the V377I mutation among HIDS patients from different 
families inferred a founder effect with a common ancestor, and the geographical 
clustering of HIDS seemed to support this assumption. On the other hand, the 
large number of HIDS patients of Dutch origin might just reflect a reporting bias 
due to a locally heightened awareness of the disorder, also because measurement 
of IgD is included as a laboratory test in the diagnostic work-up of patients with 
periodic fever in The Netherlands [6].  
In the present study, we constructed haplotypes surrounding the mevalonate 
kinase gene in HIDS patients from 7 different countries and our results show that 
the majority of V377I alleles studiedshare a single, common ancestral haplotype. 
This indicates that most carriers of the V377I mutation share the same ancestor. 
As most V377I mutation-positive HIDS patients originate from the Netherlands, it 
could be speculated that a founder lived there and that the mutation spread out 
from there, although formal proof is lacking. How frequent is the V377I allele in 
the general population? For the Dutch population of today, it can be estimated that 
there are 30 families with the V377I allele. If we assume Hardy-Weinberg 
equilibrium, the frequency of the V377I allele in the Dutch population would be 
0.3%, or about 1:350.  
Familial Mediterranean Fever ([Mendelian Inheritance in Men 249100]) is another 
autosomal recessive periodic fever syndrome which bears phenotypic similarities 
to HIDS and is caused by mutations in the pyrin gene [4]. Here, a founder effect 
has been established as well [15]. In contrast to HIDS, the carrier frequency of 
mutations in the pyrin gene is much higher and a carrier frequency of up to 1:7 has 
been observed in selected populations [141]. It has been suggested that the high 
frequency of pyrin mutations might be explained by a survival advantage of 
heterozygotes (carriers of one pyrin mutation) [15]. In sera of heterozygous 
carriers of a pyrin mutation, elevated concentrations of acute phase proteins have 
been detected. This finding has given rise to speculations that carriers have a 
Origin
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The Netherlands
The Netherlands
The Netherlands
The Netherlands
United Kingdom
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France
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5 1 V377I 4 8
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5 2 1 V377I 5 8
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primed inflammatory response, which is beneficial to fight infections, and 
consequently compatible with a better survival [13,114]. In addition to this 
putative survival advantage, which would lead to natural selection of this 
mutation, the spread of the mutation might be explained by random genetic drift 
and migration. 
It is remarkable that 17 of 39 (44%) genotypes in unrelated HIDS patients are 
compound heterozygote for the V377I and I268T mutations, which suggests a 
similar origin both with respect to age and region of origin. 
In conclusion, this paper establishes that the most common mutation in HIDS, the 
V377I mutation, originates from a common ancestral haplotype in most cases. 
Current data suggest that a founder of this haplotype and the V377I mutation 
stems from the Netherlands, and that the mutation was spread from there to the 
rest of Europe and to the United States of America. This study underscores the 
importance of establishing the ethnical background of patients in the differential 
diagnosis of periodic fever syndromes. 
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Growing evidence points to a link between isoprenoid metabolism and 
inflammation, although details are still lacking. Apart from the pleiotropic anti-
inflammatory effects of HMG CoA reductase inhibitors, this link is exemplified by 
the inflammatory phenotype of the hyper-IgD and periodic fever syndrome 
(HIDS). This hereditary auto-inflammatory syndrome is caused by deficient 
enzyme activity of mevalonate kinase, one of the central enzymes of the 
isoprenoid pathway. Our aim was to explore the effect of excess mevalonic acid, 
the substrate for mevalonate kinase, on the inflammatory response of peripheral 
blood mononuclear cells (PBMCs) from healthy controls and six mevalonate 
kinase deficient HIDS patients. PBMCs from healthy controls preincubated for 4 
hours with high dose mevalonic acid secreted twice as much interleukin (IL)-6 as 
cells stimulated with LPS alone, while the pro-inflammatory cytokines tumor 
necrosis factor (TNF)- and IL- were increased as well. This increased cytokine 
secretion could be completely suppressed by co-incubation with IL-1 receptor 
antagonist (IL-1ra). Mevalonate kinase-deficient PBMCs secrete more IL-6 and 
IL-1 than control PBMCs, but this difference also disappears upon addition of IL-
1ra. Preincubation with high dose MVA decreases the secretion of IL-1ra by 
PBMCs from controls as well as MK-deficient patients.  
In conclusion, co-incubation of excess MVA with an inflammatory stimulus has a 
pro-inflammatory effect, especially on IL-6 production, mediated by the IL-1 
system. This may be central to the pathogenesis of HIDS. 
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The isoprenoid metabolism is a metabolic pathway with pleiotropic functions 
varying from isoprenylation of proteins to production of cholesterol, coenzyme Q, 
and dolichol [142]. A growing body of evidence points to a previously 
unanticipated role of the isoprenoid metabolism in inflammation. In the first place, 
inhibitors of 3’,5’ hydroxymethylglutaryl coenzyme A (HMG CoA) reductase, the 
major rate-limiting step early in this metabolic pathway, have anti-inflammatory 
properties [143]. These properties include decreased expression of adhesion 
molecules (e.g. intercellular adhesion molecule-1 (ICAM-1) [144]), 
chemoattractant proteins (e.g. monocyte chemotactic protein-1 (MCP-1) [145]), 
pro-inflammatory transcription factors such as nuclear factor-B (NF-B) and pro-
inflammatory enzymes such as cyclooxygenase-2 (COX-2) [146]. In an animal 
model of a central nervous system autoimmune disease, the HMG CoA reductase 
inhibitor atorvastatin induced secretion of the inhibitory cytokines interleukin (IL)-
4, IL-5, IL-10, and transforming growth factor TGF-beta, while at the same time 
suppressing secretion of pro-inflammatory cytokines such as IL-2, IL-12, 
interferon (IFN)- and tumor necrosis factor (TNF)- [147].   
Secondly, this link with inflammation is also apparent from the observation that a 
rare hereditary auto-inflammatory disorder – the hyper-IgD and periodic fever 
syndrome (HIDS) – is caused by a genetic defect of one of the enzymes of 
isoprenoid metabolism, i.e., mevalonate kinase [2,3]. Mevalonate kinase 
deficiency in HIDS results in a phenotype of recurrent episodes of (systemic) 
inflammation and fever. During inflammatory episodes of HIDS, mevalonic acid, 
the substrate for mevalonate kinase, accumulates in body tissues and is excreted in 
urine. HIDS attacks are also accompanied by an impressive release of 
inflammatory cytokines such as IL-1, IL-6, TNF and IFN [50,95]. In a recent 
clinical trial in 6 HIDS patients with mevalonate kinase deficiency, we found that 
simvastatin ameliorates the inflammatory symptoms in HIDS and decreases 
urinary mevalonic acid excretion [148]. A single study explored whether the 
increased interleukin-1 (IL-1) secretion in HIDS was due to an excess 
mevalonic acid or due to a lack metabolites of the isoprenoid pathway and it 
concluded that in their model the latter mechanism appeared to be operative [149].  
However, further details on this link between isoprenoid metabolism and the 
inflammatory system are lacking. In this study, we explored the effect of excess 
amounts of mevalonic acid on the inflammatory response of peripheral blood 
mononuclear cells (PBMCs) from healthy controls and from mevalonate kinase 
(MK) deficient patients. 
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Blood donors were 22 healthy controls ranging in age from 26 to 50 years old (12 
women and 10 men), and 6 mevalonate kinase deficient HIDS patients, aged 
between 33 and 43 years old (2 women and 4 men), with a residual mevalonate 
kinase enzyme activity ranging from 6 to 16%. All patients were symptom-free 
when venous blood was drawn; none of them used any medication at the time. All 
participants gave informed consent and the guidelines of the local ethics 
committee were followed in the conduct of these experiments. 
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Mevalonic acid (MVA) lactone, 3,3-dimethylglutaric acid (DMGA), and E. coli 
055:B5 TCA and phenol-extracted LPS were obtained from Sigma Chemical Co. 
(St. Louis, MO, USA). Human recombinant IL-1ra was a gift of Amgen (Boulder, 
Colorado, USA); IL1 was a gift of Hoffman-La Roche (Nutley, New Jersey, 
USA). Mevalonic acid was prepared by dissolving the mevalonolactone in a 
NaOH solution, for 20 minutes at 50˚C; this solution was neutralized with HCl and 
RPMI buffer. 
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Blood for the isolation of PBMCs was drawn in 10 ml EDTA anti-coagulated 
tubes (Vacutainer System; Becton Dickinson, Rutherford, NJ). PBMCs were 
isolated by density gradient centrifugation over Ficoll-Hypaque (Pharmacia 
Biotech AB, Uppsala, Sweden). The cells from the interphase were aspirated, 
washed three times in sterile PBS, and resuspended in culture medium RPMI 1640 
(Dutch modification; Flow Labs, Irvine, UK) supplemented with L-glutamine (2 
mmol), pyruvate (1 mmol), and gentamicin (50 mg/ml).  
Cells were incubated at 5×105 cells/well in 96-wells polystyrene plates (Greiner, 
Alphen a/d Rijn, The Netherlands), at 37°C and 5% CO2, with or without MVA (1 
or 10 mM) and IL-1ra (10 µg/mL) for 4 hours. After this preincubation, LPS (1 
ng/mL) or IL-1 (10 ng/mL) were added and supernatants were collected after 5 h 
or 24 h of incubation, and stored at -80°C until assay. Viability of cells was 
checked at end of incubation by trypan-blue staining. 
)2
Concentration of IL-6 was determined by a commercially available ELISA kit 
(Pelikine compact; Sanquin, Amsterdam, The Netherlands). For TNF-
concentration, a specific ELISA was used with two avian (duck, chicken) 
antibodies in the pre-analyte and two mammalian (rabbit, goat) antibodies in the 
post-analyte stage [150].  IL-1ß was determined by radioimmunoassay as described 
by us previously [151]. Concentration of IL-1ra was determined with an ELISA 
Development Reagens kit (R&D Systems, Inc.; Minneapolis, MN, USA). 
0)
Statistical analysis was performed using an unpaired or paired (where appropriate) 
two-sided t-test; P < 0.05 was considered significant. The software package used 
for statistical analysis and graphs was GraphPad Prism, version 4.00 (GraphPad 
Software, Inc.). 
/
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The addition of MVA in a concentration of 10 mM to PBMCs of healthy controls 
has no effect on cytokine production or viability (data not shown). However, when 
cells are preincubated with 10 mM MVA for 4 hours, and subsequently exposed to 
a low dose of LPS (1 ng/mL) for 6 hours, twice as much IL-6 is produced as when 
cells are exposed to LPS alone, without MVA (figure 1a). The same twofold 
increase in IL-6 response is seen when cells preincubated with 10 mM MVA are 
Pro-inflammatory effect of excess mevalonic acid 
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exposed to a 1000-fold concentration of LPS (1 µg/mL; data not shown). 
Preincubation with MVA is necessary: when MVA and LPS are added at the same 
time, the pro-inflammatory effect of MVA disappears (data not shown). 
Preincubation with saponificated DMGA, a fatty acid with similar chemical 
characteristics as MVA, does not have any effect on the LPS response either (data 
not shown). These last two findings support the theory that MVA has a specific 
effect, and does not work through direct destabilization of LPS micelles.  
Figure 1 (a) Ratio of IL-6 secretion on stimulation with low dose LPS (1 ng/mL) after 
preincubation with mevalonic acid (MVA), interleukin-1-receptor antagonist (IL-1ra) or both, 
relative to IL-6 secretion on LPS stimulation alone. IL-1ra completely blocks the pro-inflammatory 
effect of preincubation with MVA. (b) Increased secretion of IL-6, TNF and IL-1 on stimulation 
with low dose LPS after pre-incubation with MVA. The effect is most pronounced for IL-6. (c) 
Stimulating effect of pre-incubation with MVA on IL-6 secretion is similar for stimulation with 
either low dose LPS or IL-1. (d) Pre-incubation with MVA decreases IL-1ra secretion by LPS 
stimulation, but even more on stimulation with IL-1. * = p<0.05 for effect of pre-incubation; ** = 
p<0.05 when compared to pre-incubation with MVA alone; ***=p<0.05 when comparing stimulus 
LPS with IL-1. 
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The effect of excess MVA on cells exposed to LPS can be completely inhibited by 
addition of IL-1 receptor antagonist (IL-1ra) (figure 1a). This suggests a role of IL-
1 in the pro-inflammatory effect of excess MVA. On the other hand, our data 
suggest also that the effect is not completely mediated by IL-1 as the response of 
IL-1 after incubation with LPS is much more subtle than that seen for IL-6 or 
TNF- (figure 1b). We next investigated whether increased IL-1 receptor 
expression might be involved, by stimulating with IL-1 instead of LPS. This 
shows a similar pro-inflammatory effect of MVA preincubation (figure 1c). At the 
same time, secretion of IL-1ra is lower after preincubation with MVA, most 
notably when stimulated with IL-1 (figure 1d). 

(2"&A
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"#
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PBMCs from MK-deficient HIDS patients were used to compare the response to 
that of PBMCs from healthy controls. Incubation with only 10 mM MVA (without 
LPS) resulted in increased secretion of IL-6 in the MK-deficient PBMCs, while 
this was clearly not the case in PBMCs from healthy controls (figure 2); a similar 
pattern was seen for IL-1 secretion. 
The following experiments with low dose LPS were performed with an incubation 
time of 24 hours, which resulted in an even more pronounced effect of 
preincubation with MVA in healthy controls than with the incubation time of 6 
hours, as measured in terms of secretion of IL-6 (figure 3a) or IL-1 (figure 3b). 
However, the effect is still greater on IL-6 (5 times increased secretion after 
preincubation with MVA) than on IL-1 (3.2 times increased secretion).  
MK-deficient PBMCs produce slightly more IL-6 after stimulation with low dose 
LPS (figure 3a). Preincubation with MVA also increases IL-6 secretion in MK-
deficient PBMCs, but the effect is smaller and IL-6 secretion by PBMCs on LPS 
after preincubation with MVA is similar to that of healthy controls (figure 3a).  
 
Figure 2. Incubation of PBMCs from healthy controls with 10 mM MVA alone does not lead to IL-
6 secretion, while MK-deficient PBMCs from HIDS patients do secrete more IL-6 on incubation 
with MVA compared to medium alone. 
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In accordance with the experiments with healthy PBMCs, we observed that the 
increased IL-6 secretion of MK-deficient PBMCs on low dose LPS could be 
inhibited by addition of IL-1ra (figure 3a). The effect of MVA can also be 
completely reversed by co-incubation with IL-1ra. IL-1 secretion on stimulation 
with low dose LPS with or without MVA mirrors the response of IL-6 (figure 3b). 
MK-deficient PBMCs secrete more IL-1ra when exposed to LPS than control 
PBMCs; in both MK-deficient and control PBMCs IL-1ra secretion is diminished 
after preincubation with MVA (figure 3c). Stimulation with IL-1 results in a 
different picture: MK-deficient PBMCs secrete less IL-6 on stimulation with IL-1 
when compared with control PBMCs, with or without preincubation with MVA 
(figure 3d). 
Figure 3. MK-deficient PBMCs (n=6) secrete more IL-6 (a) and IL-1 (b) than control PBMCs 
after stimulation with LPS. Upon pre-incubation with MVA, IL-6 secretion in both groups is 
increased to the same concentration. Co-incubation with IL-1ra inhibits the extra IL-6 secretion 
seen in MK-deficient PBMCs on LPS stimulation as well as inhibiting the pro-inflammatory effect 
of pre-incubation with MVA. (c) MK-deficient PBMCs also secreted more IL-1ra on LPS 
stimulation, but pre-incubation with MVA decreases IL-1ra secretion in both. (d) Upon stimulation 
with IL-1, MK-deficient PBMCs secrete less IL-6 than controls, with or without pre-incubation 
with MVA. 
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This study shows that an excess amount of mevalonic acid has a pro-inflammatory 
effect, most pronounced with regard to IL-6 secretion. The effect is apparently 
mediated through IL-1, as the production of IL-6 can be completely blocked by 
addition of IL-1ra. The effect we observed is dose-dependent, and is only seen 
after preincubation with MVA before adding an inflammatory stimulus (LPS or 
IL-1 alike). This suggests that MVA primes the cells to become more sensitive to 
a subsequent pro-inflammatory stimulus. The decreased secretion of IL-1ra after 
MVA preincubation may contribute to this effect. 
PBMCs (lymphocytes and monocytes) from HIDS patients are deficient in 
mevalonate kinase enzyme activity due to the underlying germ-line genetic defect. 
To compensate for this, the activity of HMG-CoA reductase, the enzyme 
preceding MK in the isoprenoid pathway, is upregulated [43]. Together this will 
lead to elevated intracellular MVA concentrations, and this is thought to 
subsequently restore the flux through the mevalonate pathway and help to maintain 
near normal levels of isoprenylated end-products in these patients [43]. This effect 
is mirrored by mevalonic acid excretion in urine, which increases to detectable 
levels during attacks, but decreases to much lower values during remission. On the 
other hand, this compensatory increase of MVA concentration may at the same 
time, in an autocrine fashion, prime cells to respond excessively to inflammatory 
stimuli (figure 3a, 3b). This might then result in the fever attack which is central to 
the HIDS phenotype.  
Our results also show that MK-deficient cells secrete more IL-1ra than controls. 
This is in line with earlier experiments using a whole blood culturing system [50] 
and this autocrine inhibitory loop may explain why MK-deficient cells respond 
less to an IL-1 stimulus, probably through a compensatory effect (figure 3d). 
Preincubation with MVA causes a decrease of secretion of the anti-inflammatory 
cytokine IL-1ra in both MK-deficient cells and controls, which may contribute to 
the pro-inflammatory effect of MVA.  
Treatment of HIDS patients with simvastatin, which reduces urinary MVA 
excretion, leads to improvement of symptoms with fewer days of illness and 
inflammation [148]. This also fits with the growing body of evidence for anti-
inflammatory and immuno-modulatory effects of statins [143]. Frenkel et al. in 
their experiments with mononuclear cells from controls and HIDS patients did not 
detect a pro-inflammatory effect of preincubation with MVA [149]. This may have 
been due either to the relatively low concentration of MVA used (1 mM, compared 
to 10mM in our study), or to the inflammatory stimulus used: anti-CD2-CD28 
antibody, a specific T-cell stimulus, which was previously used in one of the few 
models demonstrating a pro-inflammatory effect of statins [152].  
The central role of IL-1 in HIDS as demonstrated in these experiments emphasizes 
the link with other hereditary autoinflammatory syndromes. Defective regulation 
of IL-1 by proteins from the pyrin family has been shown to be one of the central 
pathogenic mechanisms in familial Mediterranean fever and the cryopyrin-
associated periodic syndromes [153-156]. These results also suggest that treatment 
of HIDS patients with a recombinant IL-1ra (Anakinra) may decrease the 
inflammatory symptoms. In fact, our first results with this drug underscore this 
(Bodar et al, unpublished observation). 
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In conclusion, co-incubation of excess MVA with an inflammatory stimulus has a 
pro-inflammatory effect, especially on IL-6 secretion, probably mediated by the 
IL-1 system. This may be central to the pathogenesis of HIDS. 
 
!2<"
We are grateful to Marcel van Deuren, Department of General Internal Medicine, 
University Medical Center St. Radboud, Nijmegen, the Netherlands, for his advice 
and discussion. We thank Evelien Bodar, Department of General Internal 
Medicine, University Medical Center St. Radboud, Nijmegen, the Netherlands, for 
her help with obtaining samples and isolating PBMCs. Anna Simon is a recipient 
of a Dutch organization for Scientific Research Fellowship for Clinical 
Investigators (NWO nr. 920-03-116).  
 7 
 
 Chapter 8 
Limited efficacy of 
Thalidomide in the treatment 
of febrile attacks of the 
Hyper-IgD and periodic fever 
syndrome 
A Randomized, Double-Blind, Placebo-
Controlled Trial 
 
Joost P.H. Drenth, Alieke G. Vonk, Anna Simon, Richard Powell1, Jos W.M. 
van der Meer 
 
1Queen’s Medical Center, Clinical Immunology Unit, Nottingham, 
United Kingdom.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Journal of Pharmacology and Experimental Therapeutics 2001; 298:1221-26 
© American Society for Pharmacology and Experimental Therapeutics 
Chapter 8 
 
98 
!6
Hyper-IgD and periodic fever syndrome (HIDS) is an autosomal recessive disorder 
featured by recurrent febrile attacks. Previous unpublished experience (J. van der 
Meer and R. Powell) suggested that thalidomide may prevent febrile attacks. Six 
HIDS patients (5 male and 1 female) who had at least one febrile attack every 
6 weeks, entered a randomized, double-blind, placebo-controlled crossover trial to 
explore the efficacy of a daily 200-mg thalidomide dose in the treatment of 
recurrent febrile attacks of HIDS. The patients received either thalidomide, 200-
mg daily, or placebo for 16 weeks, followed by a 4-week washout period and 
another 16-week treatment (crossover) with either thalidomide or placebo. Patients 
completed a weekly diary card noting attacks and side effects. During the study, C-
reactive protein (CRP), serum amyloid A (SAA), interleukin (IL)-6, tumor 
necrosis factor (TNF)-, IL-1 receptor antagonist, soluble TNF receptor p55 and 
p75, and lipopolysaccharide-stimulated IL-1 and TNF- production were 
measured at six different points, whereas urine neopterin levels were measured 
weekly. During the active treatment with thalidomide, there were 10 attacks 
compared with 13 attacks with placebo. Thalidomide resulted in a nonsignificant 
decrease of CRP and SAA, but the concentrations of other inflammatory 
mediators, including urine neopterin, remained unchanged. One patient developed 
sensory polyneuropathy, but this resolved when thalidomide administration was 
stopped. The effect of thalidomide in HIDS is limited to a decrease in acute phase 
protein synthesis without an effect on the attack rate.  
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In 1984, van der Meer and colleagues described six patients with periodic fever 
and a constantly elevated serum polyclonal IgD and called the syndrome 
hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) [1]. HIDS is an 
autosomal recessive disorder, and to date more than 150 familial and isolated cases 
are known [46]. It should be distinguished from other periodic fever syndromes, 
such as the autosomal recessive familial Mediterranean fever and autosomal 
dominant tumor necrosis factor receptor-associated periodic fever syndrome 
(http://hids.net; [157]). HIDS patients have a long history of recurrent attacks of 
fever, frequently preceded by chills and accompanied by headache, bilateral 
cervical lymphadenopathy, and occasionally by oral and vaginal aphthous ulcers, 
abdominal pain, and diarrhea. Laboratory analyses invariably reveal an acute 
phase response during attacks and a constantly elevated serum level of polyclonal 
IgD [46]. Symptoms commence at an early age and persist throughout life, and the 
febrile attacks occur every 4 to 8 weeks, lasting 3 to 7 days. Patients are 
asymptomatic between attacks, although the acute phase response may persist. 
Symptomatic episodes are associated with increased concentrations of 
inflammatory cytokines, such as TNF-, interleukin (IL)-6, and interferon (IFN)-, 
and of the anti-inflammatory compounds IL-1ra and soluble TNF receptor p55 and 
p75 [50]. HIDS is caused by missense mutations in the mevalonate kinase gene, 
which leads to reduced enzyme activity of mevalonate kinase and results in small 
amounts of mevalonic acid in the urine [2,3,42]. Despite the progress in 
understanding the pathogenesis of the disorder, treatment remains largely 
supportive. Although initial reports suggested benefits from colchicine, subsequent 
experience with the drug failed to substantiate this [1,133]. Similarly, isolated case 
reports have mentioned success with various dosages of steroids, immunoglobulin 
infusions, and cyclosporine, but application in a larger group did not confirm this.  
 
Thalidomide, infamous for its severe teratogenicity, is able to inhibit TNF- 
production by human mononuclear cells and to normalize elevated plasma TNF- 
concentrations [158,159]. In addition, thalidomide inhibits IFN- synthesis and 
constrains leukocyte chemotaxis [160]. The drug has been shown to have a 
consistent benefit in a wide variety of inflammatory disorders, such as erythema 
nodosum leprosum [161,162] and Behçet's syndrome [163]. A large randomized 
trial showed that thalidomide is very effective for treating oral and genital ulcers 
and follicular lesions of Behçet syndrome [164]. Preliminary data obtained in two 
HIDS patients showed that thalidomide resulted in a dramatic relief of symptoms 
(J. van der Meer and R. Powell, unpublished observations). Therefore, we initiated 
a 36-week randomized, double-blind, placebo-controlled trial to assess the effect 
of a daily 200-mg thalidomide dose on the frequency, intensity, and duration of 
attacks in HIDS patients.  
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Patients were selected from the Nijmegen HIDS registry. This database carries the 
pertinent clinical and laboratory data of patients with HIDS. Because all patients 
were required to visit the University Medical Center St. Radboud regularly 
throughout this trial, we recruited only Dutch patients. The patients were informed 
about the trial by a nation-wide patient meeting in Nijmegen, August 1999. Only 
male HIDS patients and women who had had a surgical sterilization procedure 
were invited to take part in the study. Additionally, female patients were required 
to either use condoms or refrain from sexual intercourse during the study. Only 
patients over 18 years old and having frequent febrile attacks (more than one 
attack every 6 weeks) were eligible for the study. All patients who enrolled in this 
study were screened for mutations in the mevalonate kinase gene. The numbering 
of the patients in this study refers to the original patient number in the Nijmegen 
HIDS registry [46]. Given the average attack frequency in our patients (at least one 
every 6 weeks), we defined effective thalidomide treatment as treatment that was 
able to decrease the number of attacks by 50%. Our study was designed to have an 
80% power of detection and a decrease of 45% in the frequency of attacks.  
*%
The trial was a 36-week randomized, placebo-controlled crossover trial evaluating 
the efficacy of thalidomide taken at a dosage of 200 mg daily in the treatment of 
HIDS patients suffering from recurrent febrile attacks. The study consisted of two 
periods of 16-week treatments with thalidomide or placebo separated by a 4-week 
washout. The trial was conducted at the outpatient clinic of the Division of 
General Internal Medicine of the University Medical Center St. Radboud in 
Nijmegen, The Netherlands. Permission of the local Medical Ethical Committee 
had been obtained. A clinical pharmacist who was not directly involved in the trial 
prepared a simple, computer-generated, random-number list. The code was kept at 
the Department of Clinical Pharmacy and was opened only after all data had been 
entered into a computer for analysis. Before study entry, the prospective 
candidates were informed about the design, purpose, and duration of the study and 
received oral and written information concerning adverse effects of thalidomide. 
Patients gave written informed consent before enrolling in the trial. Subjects were 
screened at the beginning of the trial, and baseline demographic and relevant 
clinical information was obtained. They all had normal results on clinical 
neurological evaluations. Physical examinations and laboratory measurements 
were performed at baseline and at weeks 8, 16, 20, 28, 36.  
%
At baseline and at the 20-week visit, the patients received two bottles containing 
either 100-mg thalidomide tablets (Grünenthal GmbH, Aachen, Germany) or 
placebo tablets identical in appearance to the thalidomide tablets. Patients were 
instructed to take two tablets each evening. At week 16 and week 36, unused 
tablets were collected and counted to determine compliance. Patients were allowed 
to use antipyretic drugs, such as acetaminophen or nonsteroidal anti-inflammatory 
drugs, throughout the study period. One patient (patient 4) used a fixed low-dose 
steroid (prednisone 10 mg/day) throughout the study period.  
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Attacks 
The primary outcome measure was defined as the number of attacks. To register 
the number and severity of attack, all patients were asked to complete a weekly 
diary card to register the presence or absence of symptoms and the severity using a 
visual analog scale. The following characteristics were listed: lymphadenopathy, 
abdominal pain, nausea, diarrhea, vomiting, arthralgia, skin lesions, aphthous 
ulcers, and headache. The patients could indicate the severity of the symptoms on 
a scale ranging from 0 to 7. Attacks were defined as fever (>38.5°C) together with 
one or a combination of the following symptoms: abdominal distress (pain, 
vomiting, diarrhea), joint involvement (arthralgia, arthritis), skin lesions, and/or 
lymphadenopathy. Each week this symptom card was mailed to the principal 
investigator by the patient.  
Acute Phase Response and Cytokine Measurements 
Serum IgD was measured at the onset of the trial using an enzyme-linked 
immunosorbent assay (ELISA), as described elsewhere [110]. Blood samples were 
drawn six times throughout the whole study period: at baseline and at weeks 8, 16, 
20, 28, and 36, and the serum/plasma concentrations of the following 
inflammatory mediators were measured. C-reactive protein (CRP) and serum 
amyloid A (SAA) were measured using sensitive ELISAs [105]. Measurements of 
serum TNF-, IL-1ra, and IL-1 were performed using fluid phase 
radioimmunoassays, whereas IL-6 was measured with an ELISA [151]. The 
concentrations of sTNFr p55 and sTNFr p75 were measured in serum using an 
ELISA developed by Hoffman-La Roche (Basle, Switzerland) [50]. Cytokine 
production was measured using a whole blood culture system developed in our 
laboratory's assay [50]. Briefly, two 2-ml tubes containing 24 µl of EDTA-K3 
(10,000 kallikrein-inactivating units per milliliter; Bayer, Leverkusen, Germany) 
were drawn. One tube was incubated immediately, and the other tube was 
incubated after addition of 25 µl of lipopolysaccharide (Escherichia coli serotype 
055:B5; Sigma, St. Louis, MO; final concentration 10 µg/ml of blood). After 24 h 
of incubation at 37°C, both tubes were centrifuged at 2250g for 10 min and then at 
15,000g for 5 min to obtain platelet-poor plasma. Aliquots were stored at 70°C 
until assay.  
Neopterin Measurement 
Previous data indicated that the excretion of neopterin in urine conveniently 
correlated with the febrile attacks. We therefore asked the patients to collect 
weekly urine samples, which were stored at 20°C until assay. Neopterin was 
determined by reversed-phase high-performance liquid chromatography [165]. 
Briefly, urine samples were centrifuged to remove debris, diluted in a 1 to 10 ratio 
with water containing dimethylpterine as an internal standard, and injected directly 
onto a Techsphere 5 ODS column (HPLC Technology, Ltd., Welwyn Garden City, 
Hertfordshire, UK). A binary gradient elution was used with an initial mobile 
phase of 2% methanol in 15 mM phosphate buffer, pH 6.4, increasing to 25% 
methanol after 12 min, and creatinine was detected separately using a kinetic 
alkaline picrate (Jaffe) method. The ratio of neopterin to creatinine was calculated 
to compensate for variations of urine density. The median urine neopterin value for 
a group of 65 healthy controls was 149 µmol/mol creatinine (range 62-273).  
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RNA was extracted from Epstein-Barr immortalized cell lines, and cDNA was 
produced using standard techniques. The complete coding region of the 
mevalonate kinase gene was amplified by polymerase chain reactions, and we 
determined the nucleotide sequences of the amplified fragments by standard 
semiautomated methods on an ABI PRISM 377 (PerkinElmer Life Science, 
Boston, MA) [2].  

&0" &&
Because thalidomide can cause peripheral neuropathy, a careful neurological 
examination was performed at each visit. Patients who developed any sign of 
neuropathy were excluded from continuation of the trial. The patients mailed a 
weekly diary card, which contained a list of potential side effects. In total, they 
could choose from a list of 16 precoded side effects.  
0!)
Continuous variables were compared by using the Wilcoxon rank-sum test. 
Probability (P) values were calculated on the basis of two-tailed t tests. A P value 
of less than 0.05 was considered to be the lowest level of significancy.  
/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Six patients (5 male and 1 female) enrolled in the study between August and 
September 1999. The demographic data are depicted in Table 1. The mean age at 
the start of the study was 32.5 (standard deviation 13.7) years and all patients had 
had their first attacks before the end of their first year of life. Patients reported an 
attack frequency once every 2 to 9 weeks. The length of the febrile episodes varied 
between 2 to 7 days in these HIDS patients. All patients had elevated serum IgD 
concentrations, which ranged from 154 to 4224 IU/ml.  

!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Four patients carried the V377I missense mutation (valine replacing isoleucine at 
codon 377 of the mevalonate kinase protein). This mutation is considered to be the 
prototype mutation in HIDS. One patient was homozygous for this mutation, and 
three were compound heterozygote, most commonly in combination with I268T 
(isoleucine replacing a threonine at codon 268). In patient 26, we were unable to 
detect a mutation on one of the chromosomes.  
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No. in 
HIDS 
registry 
Sex Age (years) 
Age at 
onset 
(months) 
Average  
length of 
attack (days) 
Average  
attack/ 
weeks 
Maximal 
IgD 
(IU/ml) 
Mutations in 
MVK gene 
4 M 51 0 3-4 1/4 991 V377I/I268T 
26 M 20 3 2-3 1/3-4 4224 V377I/? 
27 M 28 18 2-3 1/2 1731 P167L/I268T 
31 M 19 0 7 1/4 656 V377I/I268T 
89 F 35 3 4 1/2-3 376 V377I/V377I 
102 M 48 12 4-5 1/6-9 154 I268T/I268T 
 
Table 1. Clinical characteristics of the patients. The average attack frequency was reported by the 
patient at time of the diagnosis. 
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All patients were able to complete the trial. However, one patient (patient 102) 
receiving thalidomide discontinued treatment after 9 weeks because he developed 
numbness and paraesthesias of the extremities. Four days after discontinuation of 
the trial medication, the signs of sensorial neuropathy had disappeared, and a 
physical examination performed at the end of the trial 6 weeks later showed 
normal discriminative and vibration sensations and physiological muscle stretch 
reflexes. The data from this patient were analyzed on an intention-to-treat analysis. 
Compliance rates for thalidomide or placebo use, as calculated from the returned 
pill counts, were similar in both groups (95% versus 96%). Three patients used 
antibiotics at some point during the trial because of suspected upper airway 
infections. During thalidomide treatment, patients 31 and 89 were treated with a 
combination of amoxicillin/clavulanic acid, and patient 34 was treated with 
erythromycin.  
In the complete study period, including the washout period, the six patients 
registered a total of 30 attacks (one attack every 7.2 weeks). During active 
treatment with thalidomide, there were 10 attacks compared with 13 attacks with 
placebo (Table 2). The number of symptomatic days was similar with thalidomide 
(65 days) or placebo (87 days). The length of attacks was similar during both 
treatment blocks (thalidomide 6.3 days versus placebo 6.2 days). With 
thalidomide, the number of symptoms was 2.9 per attack compared with 3.5 with 
placebo. The severity of the separate symptoms during the febrile episodes, as 
indicated on a scale from 0 to 7, was 3.8 (standard deviation 2.2) with thalidomide 
and 4.2 (standard deviation 2.8) with placebo.  
No. in 
HIDS 
Registry 
Placebo Washout Thalidomide 
4 1 0 0 
26 3 3 2 
27 3 2 1 
31 1 0 3 
89 4 1 3 
102 1 1 1 
Total 13 7 10 
 8 
Table 2. The distribution of the 
number of attacks in the six 
individual HIDS patients during the 
crossover trial among placebo and 
thalidomide (200 mg/day). 
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Thalidomide treatment resulted in a moderate decrease of CRP and SAA when 
compared with placebo. At start of the active treatment, mean CRP concentration 
was 40.1 mg/l, and this decreased to 12.2 mg/l at the end of the trial. A similar 
effect was seen on SAA concentrations, which decreased from 30.8 mg/l to 3.9 
mg/l (Fig. 1, upper panel). These differences were not significant. Thalidomide 
treatment did not affect plasma IL-1RA or IL-6 concentrations. With placebo, both 
these parameters rose during the last 6 weeks of the trial (Fig. 1, lower panel). 
Likewise, active treatment did not influence the sTNFr concentrations in plasma 
when compared with placebo.  
 #8("
Figure 2 shows the LPS-stimulated production of the various cytokines tested. The 
production of IL-1 in patients with HIDS during thalidomide treatment was 
similar to that of placebo. Given the specific TNF- inhibiting property of 
thalidomide, we anticipated a decrease of the TNF- production. However, we 
failed to note an effect of the drug on the ex vivo LPS-stimulated production of 
TNF-.  
-	
Patients collected 92 weekly urine samples in the placebo period and 88 urine 
samples with thalidomide treatment. Figure 3 shows box and whisker plots of the 
values throughout the trial. With placebo the median value was 270.5 µmol/mol 
creatinine, which did not differ from those obtained during thalidomide (281 
µmol/mol creatinine) or during the washout period (264.5 µmol/mol creatinine). In 
all 204 samples submitted, 51% had values above the upper limit of those found in 
healthy individuals (273 µmol/mol creatinine). Febrile attacks clearly influenced 
neopterin levels, and higher values were seen during periods with disease activity. 
During the 30 attacks, the average neopterin value was 657 µmol/mol creatinine, 
clearly higher than with remission (mean values 329 µmol/mol creatinine). There 
was no significant difference between thalidomide and placebo with respect to the 
neopterin excretion during attacks (data not shown). Most notably, we detected 
very high values (>1000 µmol/mol creatinine) in 5 of 167 samples of patients who 
reported to have a remission. One patient had a value of 2598 µmol/mol creatinine 
but denied any clinical disease activity before or at the point of sampling.  
0" &&
Three patients did not note any side effects. The other three patients recorded a 
total of 165 symptoms, as indicated by their diaries. During thalidomide, 115 
symptoms were recorded compared with 50 during placebo. As depicted in Table 
3, patients most commonly complained about a dry mouth and fatigue. As 
previously mentioned, one patient reported symptoms of polyneuropathy 
necessitating termination of thalidomide treatment. No patient developed 
neuropathy after the trial (Table 3).  
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Figure 2. The effect of thalidomide treatment (closed bullets) or placebo (open bullets) on the E. 
coli lipopolysaccharide stimulated ex vivo production of TNF- (left pannel) and IL-1 (right 
panel) as assessed in a whole-blood culturing system. The values at the x-axis refer to time of 
sampling during the trial and indicate baseline (0), 8 weeks (8), and 16 weeks (16). Note the 
absence of any effect of thalidomide treatment on ex vivo TNF- production.  
Figure 1. The effect of treatment with thalidomide (closed shapes) or placebo (open shapes) on 
CRP (left upper panel), SAA (right upper panel), IL-1RA (lower left panel), IL-6 (right lower 
panel). Data are given as mean ± S.E.M. The values at the x-axis refer to time of sampling during 
the trial and indicate baseline (0), 8 weeks (8), and 16 weeks (16). Note that there is a trend of 
lower CRP, SAA, IL-1RA, and IL-6 values after 16 weeks of thalidomide treatment as compared 
with the same time point during placebo. 
 
Figure 3. Box and Whisker plots of 
urine neopterin excretion. Samples were 
collected weekly, and data reflect the 
results from treatment with placebo (n = 
92 weeks), washout (n = 24 weeks), and 
thalidomide (n = 88 weeks). 
 Thalidomide did not influence the 
neopterin excretion in HIDS patients.  
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Placebo Thalidomide  
Event 
 
 
No. of 
weeks 
No. of 
patients 
No. of 
weeks 
No. of 
patients 
Fatigue 14 1 28 3 
Numbness 3 1 16 2 
Paresthesias 5 2 15 2 
Dry mouth 9 1 28 3 
Drowsiness  
 
0 10 2 
Sleepiness  
 
0 5 3 
 
Table 3. Comparative incidence of adverse events among patients treated with thalidomide and 
placebo during the 36 weeks of the randomised trial. Values are given as number of weeks as 
indicated on diary card returned by the patients and by the number of patients who experienced the 
adverse at any time during the trial.  
%
In this article, we describe the results from the first randomized placebo-controlled 
therapeutic trial in HIDS. Given the propensity of the HIDS symptoms to wax and 
wane over time, we developed a thorough randomized trial to assess the 
therapeutic efficacy of thalidomide. The assessment period of 36 weeks was long 
enough because all patients had repetitive attacks at either phase of the trial. 
Intervention with thalidomide did result in a minor, nonsignificant decrease of 
febrile attacks in HIDS patients, and four of six patients had fewer attacks with 
thalidomide. However, this effect is clinically insignificant. One reason for 
disappointing results might be that the dosage of thalidomide was too low. On the 
other hand, if increasing the dosage would lead to a greater benefit, this would 
probably come at the cost of a higher incidence of unwanted side effects. In light 
of the results of this randomized trial and given the small balance between efficacy 
and side effects, thalidomide is not the drug of choice in the treatment of HIDS 
attacks. However, we need to consider other (biochemical) effects of treatment.  
Biochemically, treatment with thalidomide was associated with a small decrease of 
serum CRP, SAA, and IL-1ra. Decrease of acute phase proteins such as SAA may 
be a desired goal in the treatment of a periodic fever syndrome. SAA is thought to 
be the precursor of AA-type amyloidosis, a much feared complication of periodic 
fever syndromes. For example, in familial Mediterranean fever colchicine 
treatment, results not only in a decrease of the frequency of attacks but also a 
decrease in the incidence of amyloidosis [22]. In our patients, high CRP and SAA 
values were detected throughout the study period. In all samples collected during 
the complete study period, the average CRP value was 32.7 mg/l (S.D., 44.3), and 
that of SAA was 15.9 mg/l (S.D., 57.7). However, despite important elevated SAA 
levels, amyloidosis has not yet been observed as a complication of HIDS, and a 
clear pathogenetic interpretation is lacking here. We noted important elevations of 
urine neopterin during the whole trial regardless of treatment. Neopterin is 
considered a nonspecific marker of T-cell activation, and it is released from 
macrophages and monocytes following interferon- stimulation. Elevated urine 
neopterin levels have been found in a variety of disorders, such as systemic lupus 
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erythematosus [166], familial Mediterranean fever [167], and tuberculosis [168]. 
Previously, we showed that urine neopterin levels accurately reflect disease 
activity, and this study confirmed this notion [95]. Our patients had active disease 
as assessed by the neopterin excretion because 51% of the samples had values 
above the upper limit of normal [165]. Again, thalidomide did not influence urine 
neopterin levels, which parallels the observed lack of clinical efficacy. The 
intensity of the attacks, as reflected by the height of the excretion of neopterin, was 
not affected by thalidomide when compared with placebo.  
We did not find an effect of thalidomide treatment on either plasma TNF- 
concentration or on the LPS-stimulated ex vivo production of TNF-. This was 
surprising considering the in vitro ability of thalidomide to decrease the production 
of TNF- in human monocytes by inhibition of the transcription of TNF- mRNA. 
It is possible, however, that the dosage given to our patients is too low to 
reproduce the aforementioned (in vitro) effects. On the other hand, our results 
correspond with other clinical trials, which also showed that thalidomide is not an 
effective systemic TNF- inhibitor [169]. We could speculate that this lack of 
TNF- inhibition explains the limited efficacy of the drug, as observed in our 
study. On the other hand, thalidomide was able to heal aphthous ulcerations in the 
esophagus of patients infected with human immunodeficiency virus despite 
absence of an effect on plasma TNF- level [170]. This suggests that the inhibitory 
effect of thalidomide on TNF- is apparent only on tissue level. Extrapolated to 
HIDS, this might indicate that TNF- is not as important in the pathogenesis of 
HIDS as suggested earlier, and that other factors may be operative.  
In our trial, thalidomide treatment was associated with certain toxicity. We gave 
thalidomide at bedtime to minimize somnolence and dizziness. Although this 
might increase the acceptability of the drug, we saw that fatigue, drowsiness, and 
sleepiness were more frequent with thalidomide as opposed to placebo. Likewise, 
numbness and paraesthesias were more frequently observed with thalidomide. One 
patient developed polyneuropathy after 9 weeks of treatment, but this was 
completely reversible. The occurrence of neurotoxicity appears to be, in part, 
disease specific, and the severity of neurotoxicity has not been consistently 
correlated with the total dose of the drug. In general, the neurotoxicity is reversible 
if the symptoms are recognized early; however, prolonged and irreversible 
polyneuropathy can occur [171]. The two HIDS patients who had a good clinical 
response to thalidomide both developed polyneuropathy, and this was irreversible 
in one patient (J. van der Meer and R. Powell, unpublished observations). The 
rather limited efficacy of thalidomide in decreasing the number of febrile attacks 
and the potential risk of (ir)reversible neurotoxicity precludes its prolonged use in 
HIDS. The use of thalidomide is further limited to adult males or sterilized 
females. This is a problem because, given the autosomal recessive inheritance 
pattern of HIDS, half of the patients are female. Most female patients are in their 
reproductive years; the average age of the patients carrying HIDS mutations in the 
Nijmegen HIDS registry is 30.2 ± 17.7 years.  
Given the rather limited effect of thalidomide, we think that a search for new 
potential therapeutic avenues is warranted. Given the molecular defect of HIDS, it 
is tempting to speculate that inhibition of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase, the enzyme that precedes mevalonate kinase in the cholesterol 
synthesis, might be fruitful. Currently, we are performing a drug trial aimed to 
study the effect of high-dose simvastatin in the treatment of HIDS attacks.  
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Hyper-IgD and periodic fever syndrome, a hereditary autoinflammatory syndrome, 
is characterized by lifelong recurrent episodes of fever and inflammation. No 
effective treatment is known. It is caused by a defect of mevalonate kinase, an 
enzyme following HMG-CoA-reductase in the isoprenoid pathway. We wanted to 
test the hypothesis that inhibition of HMG-CoA reductase would ameliorate the 
inflammatory attacks. Six patients with hyper-IgD syndrome and proven 
mevalonate kinase deficiency were followed for two treatment periods with either 
simvastatin 80 mg/day or placebo for 24 weeks, separated by a 4-week washout 
period in a double-blind fashion. Simvastatin resulted in a drop in urinary 
mevalonic acid concentration in all patients and decreased the number of febrile 
days in five out of six patients. No side effects were observed. These data offer 
preliminary evidence for the hypothesis that simvastatin may improve 
inflammatory attacks in the hyper-IgD syndrome. This highlights the anti-
inflammatory properties of HMG-CoA reductase inhibition. 
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The hyper-IgD and periodic fever syndrome (HIDS; Mendelian Inheritance in Men 
(MIM) #260920) is a rare hereditary autoinflammatory syndrome caused by 
mutations in the mevalonate kinase gene [2,3]. Patients with HIDS suffer from 
periodic fever episodes that usually start from the first year of life and are 
characterized by high fever, lymphadenopathy, abdominal distress, myalgias and 
skin lesions [4]. These inflammatory episodes generally last four to six days, and 
recur every four to six weeks.  
Mevalonate kinase is one of the central enzymes in isoprenoid metabolism, which 
has numerous end products such as cholesterol, ubiquinone, and dolichol and is 
also essential for isoprenylation of proteins (figure 1). Mevalonic acid, or 
mevalonate, is the product of the enzyme 3’-hydroxy-3’-methylglutaryl-coenzyme 
A (HMG-CoA) reductase [142]. The mutations in the mevalonate kinase gene lead 
to a deficient mevalonate kinase enzyme activity and accumulation of its substrate 
mevalonic acid, most notably during fever attacks. However, it is not exactly clear 
how this results in the inflammatory phenotype of HIDS. 
 
 
Figure 1. Schematic representation of the isoprenoid metabolism with its end-products. Indicated is 
the metabolic defect in HIDS and the point of inhibition by simvastatin. 
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Treatment options available for HIDS do not reflect our current understanding of 
pathophysiology of the disease. So far, therapeutic experiments have sought to 
curtail the inflammatory response in HIDS and have met with mixed results. For 
example, thalidomide (200 mg) given as an inhibitor of TNF response, failed to 
elicit a beneficial effect in a controlled clinical trial [52]. Uncontrolled evidence 
suggests that a small proportion of patients benefit from prednisolone, and recently 
open-labelled use of etanercept reduced the frequency and severity of symptoms in 
two HIDS patients [172]. Although etanercept has shown a beneficial effect, 
potential side effects such as the increased risk on infections and severe 
neurological damage [173,174] may preclude its prolonged use. Moreover, it is not 
known whether the beneficial initial response is followed by sustained 
improvement over a longer period of time. However, in our opinion non-controlled 
clinical observations are not the most optimal setting in HIDS, because of the 
highly variable nature of frequency and severity of the fever attacks. This calls for 
a more rigorous approach.  
The discovery of mevalonate kinase as the gene implicated in HIDS led us to 
hypothesize that HIDS patients might benefit from the use of a HMG-CoA 
reductase inhibitor such as simvastatin. In theory, this would restore the balance in 
the isoprenoid metabolism and reduce the mevalonic acid overload. Despite these 
theoretical considerations, preliminary data from a single study in 2 children with 
classical mevalonic aciduria, the severe form of mevalonate kinase deficiency, are 
not encouraging [45]. Short term treatment with low dose lovastatin (initially 5 
mg, later 10 mg) precipitated a severe crisis in both, prompting discontinuation of 
the statin. Therefore, we first explored whether statins could be tolerated by HIDS 
patients (who have a mild mevalonate kinase deficiency).  In a 4-week pilot study 
with high dose atorvastatin (80 mg/day) in three HIDS patients we observed no 
precipitation of inflammatory attacks, and more importantly, no side effects. These 
results encouraged us to investigate our hypothesis in a randomized double-blind 
crossover study of six HIDS patients. 
""
We selected patients from the Nijmegen HIDS registry [46] when they fulfilled the 
entry criteria for the study, i.e. 1) mevalonate kinase gene mutations on both 
alleles, 2) age over 16 years and 3) frequent attacks (more than 1 per 6 weeks). 
The study was approved by the local Medical Ethical Committee and all 
participants gave written informed consent.  
The follow-up period of 52 weeks consisted of two treatment periods of 24 weeks 
with a 4-week washout period in between. Patients were randomized to receive 
simvastatin 80 mg/day in the first or second treatment period, with placebo tablets 
in the other period. A clinical pharmacist not directly involved in the study 
prepared a simple, computer-generated, random-number list for randomization. 
The code was held at the Department of Clinical Pharmacy, UMC St. Radboud, 
Nijmegen, and was only opened after all data had been entered into a computer for 
analysis. Concomitant medications were allowed throughout the study and 
recorded. 
The primary outcome measure was defined as the number of febrile days. 
Secondary outcome parameters were number of fever attacks, urinary 
concentration of mevalonic acid and serum lipid concentrations. Attacks were 
defined as fever (>38.5°C) together with one or more of the following symptoms: 
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abdominal distress (pain, vomiting, or diarrhoea), joint involvement (arthralgia, 
arthritis), skin lesions, lymphadenopathy. Patients used weekly diary cards to 
register number, duration and severity of attacks on a visual analogue scale and to 
record possible side-effects of study medication. At each clinic visit (week 0, 12, 
24, 28, 40 and 52) blood was drawn to determine concentration of plasma Alanine 
Transferase (ALT) and Creatine Kinase (CK) and serum lipids using an automated 
enzymatic assay. Patients collected weekly urine samples on which mevalonic acid 
concentration was measured by isotope-dilution gas-chromatography/mass 
spectrometry as described before [175] albeit slightly modified.  
GraphPad Prism (version 4.00 for Windows, GraphPad Software, San Diego, 
California, USA) was used for statistical analysis of data. Where appropriate, we 
used the two-tailed paired t-test or two-tailed Mann-Whitney test. Data are given 
as mean ± standard deviation, unless stated otherwise. A p value <0.05 was 
considered as the threshold for statistical significance. 
 
Table 1 – patient characteristics 
 
Patient 
no. 
Mutations in 
mevalonate 
kinase 
Mevalonate 
kinase enzyme 
activity (%) 
Maximal 
serum IgD 
(U/mL) 
1 V377I/H20P 8.5 450 
2 V377I/I268T 7.2 900 
3 V377I/H20P 11.3 4224 
4 V377I/del92bp 10.5 809 
5 V377I/V377I 5.7 376 
6 V377I/H20P ND 1140 
ND = not done 
/
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At the start of the study, the Nijmegen HIDS registry contained data on 58 HIDS 
patients with proven mevalonate kinase deficiency. Patients were excluded 
because of age (<16 yrs) (n=25), infrequent attacks (n=8), refusal to participate 
(n=12) or miscellaneous reasons (n=7, this includes lost to clinical follow-up, 
residence abroad or homelessness at start of study). Four patients (two men and 
two women) were enrolled in December 2000, two other male patients started in 
March and September 2001, with an average age of 34 years (range 17-56 years). 
Patient characteristics are summarized in table 1. Three patients were randomly 
assigned to start with placebo in the first six-month period, to go on with 
simvastatin in the last six months; the other three patients were treated in the 
reverse order. All six patients completed the follow-up. 
Medication used concomitantly with the study medication consisted primarily of 
acetaminophen, in equal amounts in the two periods. Patient no. 1 was on a 
continuous dose of colchicine 1.5 mg throughout the year of follow-up. Patient no. 
6 had been on oral prednisolone for the year previous to the study because of 
severe joint involvement; within 6 weeks of the start of the simvastatin treatment 
period (in her case the first period) prednisolone had been tapered and stopped 
without complications. 
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Table 2. Overview of  results 
Febrile attacks, length and severity scorec Pt 
no. 
Starta Orderb Subjective 
preference First period Wash-out Second period 
1 Dec S-P Equal 4 d;  
vas 2 
4 d; 
vas 5 
3 d;  
vas 1   
5 d;  
vas 3 
4 d; 
vas 3 
3 d;  
vas 2 
3 d; 
vas 1 
4 d;  
vas 4 
3 d;  
vas 2  
2 Sept S-P Placebo 4 d; 
vas 7 
5 d;  
vas 9 
4 d;  
vas 6 
5 d; 
vas 4    
3 d;  
vas 3 
6 d; 
vas 7    
3 Dec P-S Simvastatin 7 d; 
vas 8 
8 d;  
vas 8 
9 d;  
vas 9 
8 d;  
vas 10  
7 d; 
vas 8  
7 d;  
vas 5 
14 d; 
vas 9    
4 Mar P-S Simvastatin 12 d; 
vas 6 
6 d;  
vas 4 
6 d;  
vas 7     
1 d; 
vas 8 
7 d;  
vas 9    
5 Dec P-S Simvastatin 8 d; 
vas 4 
7 d;  
vas 9 
7 d; 
vas 3 
8 d; 
vas 9 
4 d;  
vas 1   
9 d; 
vas 7 
6 d;  
vas 8    
6 Dec S-P Simvastatin 4 d; 
vas 1 
4 d;  
vas 3 
5 d;  
vas 1 
4 d;  
vas 1 
10 d; 
vas 1   
9 d;  
vas 2 
3 d;  
vas 1 
6 d;  
vas 1 
10 d; 
vas 1 
6 d; 
vas 3 
aMonth of start in study protocol (Dec = December, Sept = September, Mar = March).  
bOrder of treatment: S-P = simvastatin-placebo, P-S = placebo-simvastatin 
cIndividual fever episodes per patient; indicated are duration in days (d) and severity as measured 
by the patient on a visual analogue scale (vas) from 0-10 points, with 10 as most severe. 

In the complete study period of 52 weeks, the patients registered a total of 44 fever 
attacks (on average, one every 7 weeks per patient) and 262 days of illness (table 
2). During the placebo period, a total of 146 febrile days were reported versus 100 
days in the simvastatin treatment period – this amounts to an average of 24.3 ± 
11.0  vs. 16.7 ± 6.9 days per patient per 6 months (decrease of 7.6 days or 31%; 
p=0.12, 95% confidence interval –3 to 18.36, figure 2). The effect seemed to be 
more pronounced in the patients who used simvastatin in the second period than in 
those who started with simvastatin. This might indicate a carry-over effect, but  the 
small number of patients precludes a definitive conclusion.  
The number of fever attacks was low (total 23 vs. 18 for placebo vs. simvastatin; 
table 2). For the whole group, a mean number of 3.8 ±1.2 was observed in the 
placebo period, versus 3.0 ±1.3 in the simvastatin period (p=0.29). No consistent 
effect of drug treatment was observed on either severity or duration of attacks 
(table 2). Four patients had a subjective preference for simvastatin, one patient 
considered the periods equal, and one patient preferred the placebo period 
although classifying the past year as a “light one” (both of these in the simvastatin-
placebo order group, table 2). 
Figure 2. Primary outcome measure: number of days 
of illness in each six months period. A) Mean number 
of days of illness and standard error of the mean for 
the total group of patients during placebo and 
simvastatin. B) Individual results for the 6 patients. 
Indicated are the two groups, starting either with 
placebo (black symbol) or with simvastatin (white 
symbol). This seems to demonstrate an interaction 
between treatment order and treatment effect: 
patients who started with placebo have a larger 
reduction in days of illness during simvastatin.  
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At baseline, the HIDS patients had normal to low-normal serum concentrations of 
LDL-cholesterol (mean 2.6 mmol/l ±1.0). As expected, simvastatin significantly 
reduced serum total cholesterol (mean 4.8 ±1.2 vs. 3.0 ±0.5 mmol/l at end of 
treatment, 38% reduction, p=0.016) and LDL-cholesterol (mean 3.3 ±0.9 vs.1.5 
±0.7 mmol/l at end of treatment, 55% reduction, p=0.0052; figure 3), with no 
difference between the two treatment-order groups (data not shown).  
B)(".
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The six patients collected 133 urine samples in the placebo period and 135 samples 
in the simvastatin period (total 20 missing samples). The MVA concentration 
mirrored the clinical symptoms, with high peaks up to 14.6 mg/g creatinine during 
a fever attack (normal values 0.4 ± 0.18 mg/g creatinine), although discrepancies 
between MVA concentration and clinical symptoms can be observed (figure 4). 
The mevalonic acid concentration in the placebo period was significantly higher 
than in the simvastatin treatment period, whether looking at median absolute 
concentrations (4.9 vs. 1.9 mg/g creatinine, p<0.001, 61% reduction, figure 5), or 
at median area-under-the-curve (115.5 vs. 59.9 mg/g creatinine*wk, p=0.004). 
This pattern was consistent for all six patients. 
0"&&
Side-effects were not reported by five out of six patients. Patient no. 1, who 
remained on a steady dose of 1.5 mg colchicine throughout the study period, 
reported symptoms of flatulence during the whole year, specifically nightmares 
with simvastatin and increased tiredness and myalgias whilst on placebo. Neither 
treatment affected CK or ALT concentrations. 
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Figure 3. Serum LDL-cholesterol 
concentration, mean of 6 patients at 
beginning and end of treatment 
period (* p<0.0052). 
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Figure 4. Urinary mevalonic acid (MVA) concentration in weekly collected urine samples in the six 
individual patients, in the placebo period (white symbols), 4-week washout period (crossed symbol 
and dotted line) and simvastatin period (black symbols). Also indicated are the fever episodes of 
each patient (black horizontal bars). Patient no. 3 omitted to collect urine samples during the 
washout period, patient no. 5 admitted to non-compliance at the end of the study period. 
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Figure 5. Box-and-whisker plots of urinary mevalonic acid (MVA) concentration in the six 
individual patients in the placebo period vs. the simvastatin period, arranged from lowest (patient 
no. 5) to highest (patient no. 3) known mevalonate kinase enzyme activity (mevalonate kinase 
activity in patient 6 not determined). The dotted line represents the normal concentration detected 
in healthy controls (0.4 ±0.18 mg/g creatinine). 
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This study is the first to investigate a pharmacological intervention specifically 
designed to target the metabolic defect in HIDS. The cohort of patients included in 
this study is small, which is largely related of the rarity of the disorder (6 patients 
represent almost 10 percent of the worldwide known patient population at the start 
of study). We observed a positive clinical effect in five of the six patients, with a 
decrease in the number of febrile days, although the difference did not reach 
statistical significance.   
HIDS has been linked to mutations in the mevalonate kinase gene and decreased 
mevalonate kinase enzyme activity since 1999 [2,3], but despite intensive research 
efforts the actual pathogenesis has yet to be determined. It has been suggested that 
the primary defect lies in the decreased flux through the isoprenoid metabolism 
leading to shortage of end-products, which is compensated by increased mevalonic 
acid [43,149]. Alternatively, high mevalonic acid concentrations may in itself be 
toxic and result in the inflammatory attacks. Mayatepek et al. reported a close 
correlation between the concentration of the proinflammatory mediator leukotriene 
E4 with the urinary level of mevalonic acid [176].  Although the suggested 
beneficial effect observed in the current study would not refute the former 
hypothesis, the results are more in line with the latter hypothesis, even more so 
since clinical improvement is mirrored by lower mevalonic acid excretion. 
However, it is possible that inhibition of HMG-CoA reductase results in a new 
equilibrium in the isoprenoid metabolism through feedback mechanisms or other 
selection methods. This could favour the production of certain end-products over 
others, thereby correcting a putative shortage. Such an effect is reminiscent of the 
situation in Smith-Lemli-Opitz syndrome, a rare hereditary disorder characterized 
by pathologically low concentrations of cholesterol. It is caused by a deficiency of 
7-dehydrocholesterol reductase, the last step in the Kandutsch-Russell cholesterol 
biosynthetic pathway. Inhibition of HMG-CoA reductase by statins in this 
syndrome results in a paradoxical increase of cholesterol [177], most likely 
through augmentation of residual enzyme activity. 
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The possible benefit of simvastatin appears to go beyond the period the drug was 
actually used. In particular, we observed a possible carryover effect in clinical 
outcome parameters in patients first treated with simvastatin and then by placebo. 
How does this relate to the biological action of simvastatin? The high dose of 
simvastatin resulted in the expected decrease of cholesterol (figure 3) from the 
normal serum cholesterol values at the start of this study. Interestingly, the 
possible carryover effect was not mirrored by the cholesterol concentration, asat 
the end of the wash-out period cholesterol concentrations had normalized while the 
clinical effect still persisted..  
The mechanism for the observed carryover effect is not clear. It is possible that 
prolonged treatment with simvastatin results in a depletion of accumulated 
mevalonic acid restoring the balance within the isoprenoid pathway. However, this 
hypothesis does not seem to be corroborated by the rapid increase of mevalonic 
acid excretion observed in our patients after discontinuation of simvastatin. 
Alternatively, the simvastatin treatment has restored depleted concentrations of 
one or more isoprenoid end-products, such as isoprenylated proteins, which may 
persist for a prolonged period.   
We did not observe side effects in our patients, which differs appreciably with 
results obtained in children with severe mevalonate kinase deficiency where statins 
allegedly induced attacks [45]. Several factors might be responsible for this 
discrepancy. In the first place, we observed  that although simvastatin had a 
beneficial effect, it did not result in a complete absence of inflammatory crises. 
Possibly the attacks seen by Hoffmann et al. were part of the ‘normal’ phenotype 
of the disease and not caused by the statin. A longer treatment of the 2 children in 
Hoffmann’s study might have resolved this issue. Secondly, both the children 
described by Hoffmann used supplements that exert an influence on the isoprenoid 
metabolism, including cholesterol, ubiquinone and vitamin E. The resulting effect 
of this combination treatment on the isoprenoid metabolism is hard to predict, but 
may be disadvantageous. A third possible explanation is the higher residual 
mevalonate kinase enzyme activity in HIDS compared to classical mevalonic 
aciduria (5.7-11.3% vs. 0-1.5%) [45]. Therefore, the results of this study can not be 
extrapolated to patients with classical mevalonic aciduria.  
In conclusion, we describe preliminary evidence for a possibly effective treatment 
for the hyper-IgD and periodic fever syndrome (HIDS) in a randomized double-
blind follow-up study of six patients. Although our trial is small, randomised trials 
are clearly to be preferred over observational studies and, in our opinion, 
controlled studies provide the only way that any unbiased measurements of 
effectiveness can be made. In any case, we hope to set the stage for a larger trial 
and additional clinical experience with HMG-CoA reductase inhibitors in HIDS in 
more patients over a longer period of time is desirable to prove its standing in 
clinical practice.  This study again highlights the relation between inflammation 
and the isoprenoid metabolism, and offers additional evidence for the anti-
inflammatory activity of HMG-CoA reductase inhibitors [143,178]. 
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Hereditary autoinflammatory syndromes are characterized by recurrent episodes of 
fever and inflammation. Six subtypes have been described, caused by mutations in 
4 different genes. Apart from a common phenotype of lifelong recurrent 
inflammatory attacks, all of them have distinct features and specific therapeutic 
options, which emphasizes the need for a specific diagnosis in each case. The aim 
of this study was to examine whether genetic screening would allow classification 
of previously unclassified patients. We also examined whether individual patients 
suffering from an autoinflammatory syndrome carry additional mutations in one of 
the other autoinflammatory genes. We included 60 patients with an unclassified 
autoinflammatory syndrome, 87 patients diagnosed with either hyper-IgD 
syndrome (HIDS), familial Mediterranean fever (FMF) or TNF-receptor associated 
periodic syndrome (TRAPS), and 50 healthy controls. DNA samples were 
screened for the most prevalent mutations in the MEFV, TNFRSF1A, MVK and 
CIAS1 genes. This yields only one possible diagnosis of FMF in the 60 previously 
unclassified patients. Two low-penetrance mutations were found in equal numbers 
in the groups of patients and controls. Thus, screening of known genes involved in 
these disorders does not yield additional relevant information. Differential 
diagnosis of hereditary autoinflammatory syndromes can be made by thorough 
clinical examination followed by targeted genetic analysis of one or two most 
likely syndromes. High prevalence, low penetrant mutations from 
autoinflammatory genes do not occur more frequently in hereditary 
autoinflammatory patients compared to the general population. 
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Periodic fever syndromes are characterized by recurrent episodes of fever and 
inflammation [4]. Currently, they are designated by the term (hereditary) 
autoinflammatory syndromes, because fever may be absent, while periodic 
inflammation (triggered by an often unknown stimulus and without signs of 
autoimmunity) is a key feature. Six distinct hereditary autoinflammatory 
syndromes have been genetically characterized (table 1). Apart from lifelong 
recurrent inflammatory attacks, these syndromes have distinctive features, such as 
age of onset, duration of attacks, accompanying symptoms, prognosis and ethnic 
origin. The differential diagnosis remains a challenge. A correct diagnosis enables 
specific therapeutic interventions, and options have expanded considerably 
[154,179,180]. 
The advent of genetic testing for the autoinflammatory syndromes has had a 
number of consequences: (i) the clinical phenotypes and ethnic distribution of each 
of these syndromes turned out to be much more variable than anticipated; (ii) quite 
some patients presenting with a clear phenotype cannot be classified by genetic 
testing; (iii) patients with a combination of mutations from two autoinflammatory 
genes have been reported [181,182], which raises the question whether this might 
be more common. 
For this study, we asked whether more rigorous and non-restricted genetic 
screening would allow classification of patients with undiagnosed periodic fever. 
Further, we aimed to examine whether the combination of gene mutations of 
various autoinflammatory syndromes in a single patient occurs more often than 
expected.  
 
Table 1. Hereditary autoinflammatory syndromes.  
Syndrome Inheritance pattern Gene Protein 
Most frequent 
mutations 
Familial Mediterranean Fever 
(FMF) 
Autosomal 
recessive MEFV Pyrin (marenostrin) 
M694V, V726A, 
M694I, M680I, 
E148Q† 
Hyper-IgD and periodic fever 
syndrome (HIDS) 
Autosomal 
recessive MVK Mevalonate kinase V377I 
TNF-receptor associated 
periodic syndrome (TRAPS) 
Autosomal 
dominant TNFRSF1A 
TNF-receptor type I 
(p55) 
R92Q†, P46L†; 
various mutations in 
exon 2-4 
Cryopyrin-associated periodic 
syndrome (CAPS)* 
Autosomal 
dominant CIAS1 Cryopyrin 
Various mutations 
exon 3 
*This includes Muckle-Wells syndrome (MWS), Familial Cold Autoinflammatory Syndrome 
(FCAS) and Chronic Infantile Neurological Cutaneous and Articular syndrome (CINCA; also 
known as Neonatal Onset Multisystemic Inflammatory Disease (NOMID)).  
†These mutations are alternatively described as low-penetrance mutations, disease-modifying 
factors or even polymorphisms instead of disease-causing mutations. 
Not included in this table or study: Blau syndrome, caused by mutations in the NOD2/CARD15 
gene, and Pyogenic Sterile Arthritis, Pyoderma gangrenosum and Acne (PAPA) syndrome, caused 
by mutations in CD2BP1-gene. 
"
"
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For this study we included all patients with suspected autoinflammatory syndrome 
referred to our clinic (as a tertiary referral center in the Netherlands and through 
the International HIDS registry (hids.net)) between January 1992 and December 
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2003. Control DNA samples from 50 healthy Dutch were donated by the 
Department of DNA Diagnostics, UMC Nijmegen. We discerned two groups of 
patients: those without a classifying diagnosis (unclassified) and those with a 
confirmed diagnosis (diagnosed).  
Unclassified patients   
Clinical workup in these patients had failed to establish a specific diagnosis. 
Inclusion criteria were: [1] recurring episodes with fever and documented acute 
phase response for more than two years; [2] no genetic diagnosis, despite one or 
two specific genetic tests of most likely syndrome; [3] DNA sample or nucleated 
cells available. We were able to collect 60 patients. Clinical information was 
collected with a standardized questionnaire (24 patients) or by our clinical 
observation (36 patients). A positive family history was present in 9 patients. 
Fifty-five patients were of North-West European Caucasian origin, including 36 
Dutch patients; others came from Italy [2], Greece [1], Slovakia [1] and Japan [1]. 
Twenty-nine of these patients were designated as variant type HIDS [40], defined 
as a clinical phenotype compatible with HIDS, elevated serum immunoglobulin D 
(IgD) and no mevalonate kinase gene mutations.  
Diagnosed patients 
This group encompassed 87 patients, whom we previously diagnosed using 
clinical workup (history taking, physical examination) and specific genetic 
analysis. It includes 64 classical type HIDS patients from 49 families in the 
International HIDS registry, 15 Dutch patients with TRAPS from 7 families and 8 
unrelated patients with FMF.  
 
Table 2. 
Restriction enzyme analysis 
Gene Mutation Enzyme Primers 
TNFRSF1A R92Q Nci-I 5’-GCTGCTCCAAATGCCGAAAG-3’ 5’-GGTTTTCACTCCAATAATGCCG-3’ 
 P46L Nci-I 5’-CTTGTGTTCTCACCCGCAG-3’ 5’-CTTTCGGCATTTGGAGCAGC-3’ 
MVK V377I BsmA-I 5’-TGTAAAACGACGGCCAGTGTCTCGAAGTGGAGGCCACGAAGCAG-3’ 5’-CCAGCACAGAGTCGAACTGCAG-3’ 
MEFV M694V Hph-I 5’-GAATGGCTACTGGGTGGAGAT-3’ 5’-GGCTGTCACATTGTAAAAGGAG-3’ 
 V726A Alu-I 5’-GAATGGCTACTGGGTGGAGAT-3’ 5’-GGCTGTCACATTGTAAAAGGAG-3’ 
 M694I BspH-I 5’-GGCTGTCACATTGTAAAAGGAG-3’ 5’-GCTACTGGGTGGTGATAATCAT-3’ 
 M680I Hinf-I 5’-GAGGTTGGAGACAAGACAGCATGG-3’ 5’-TCGGGGGAACGCTGGACGCCTGGTACTCATTTTCCT-3’ 
 E148Q Bst-NI 5’-GCCTGAAGACTCCAGACCACCCCG-3’ 5’-AGGCCCTCCGAGGCCTTCTCTCTG-3’ 
DNA sequencing 
TNFRSF1A Exon 2,3,4 5’-GATCTGCTACCCCTAAGC-3’ 
5’-CCCACACACCACTCAAGACC-3’ 
   
5’-GTGTTCTCACCCGCAGCCTA-3’ 
5’-GGAAGTGCCACCGCATGGG-3’ 
CIAS1 Exon 3  5'-GCATCTCAGGTGGATGTGTG-3’  
5'-CTGCCAGTCAGTGCAGAGCGG-3’ 
   
5'-GACCTGATCATGAGCTGCTGC-3’ 
5'-TGGTTCCAGATTCCATCTGC-3’ 
   
5'-CATGTGGAGATCCTGGGTTT-3’ 
5'-CCAGAAGGACTGTCACGTCTCG-3’ 
   
5'-TCTACAGCTTCATCCACATG-3’ 
5'-GGGCTGTGGCAACAGTATTTGG-3’ 
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DNA was isolated from blood lymphocytes by standard procedures. Polymerase 
chain reaction (PCR) amplification of specific segments of the MVK, MEFV, and 
TNFRSF1A gene was performed for restriction fragment length polymorphism 
(RFLP) analysis (table 2). We amplified exon 2, 3 and 4 of TNFRSF1A gene and 
exon 3 of CIAS1 gene for DNA sequencing (table 2). Primers were either designed 
by us or adapted from available literature with minor modifications [12,183-185]. 
For the RFLP analysis, PCR products were digested by restriction enzymes (table 
2) at appropriate temperatures and incubation times. Digested samples were run on 
a 2-3% agarose gel (Biozym) and stained with ethidium bromide. Using purified 
PCR products, sequencing was performed according to standard procedures on 
both DNA strands using the same forward and reverse primers as those in the PCR 
step. 
/
Table 3 lists the results of the elaborate genetic screening. 
 
  
Autoinflammatory 
syndrome nos 
(of which variant 
type HIDS) 
Healthy 
controls 
Classical 
type 
HIDS 
TRAPS FMF 
Gene Mutation n=60 (29) n=50 n=64 n=15 n=8 
MVK V377I 0 (0) 0 NA (52)† 0 0 
MEFV M694V 1 (1) 0 0 0 NA 
 V726A 0 (0) 0 1 0 NA 
 M694I 0 (0) 0 0 0 NA 
 M680I 0 (0) 0 0 0 NA 
 E148Q 1 (1) 2 2 1 NA 
TNFRSF1A P46L 0 (0) 0 0 NA 0 
 R92Q 1 (0) 1 1 NA 0 
 Sequencing 
exon 2,3,4 0 (0)* ND ND NA ND 
CIAS1 Sequencing 
exon 3 0 (0) ND ND ND ND 
Table 3. Autoinflammatory syndrome nos = patient with autoinflammatory syndrome not 
otherwise specified; NA= not applicable; ND = not determined. *except for the R92Q mutation 
as detected by restriction enzyme analysis. †the V377I mutation was previously found in 52 of 
the 64 classical type HIDS patients. 
B&"	
In 60 unclassified patients, we identified 3 patients who carried one mutation for 
one of the genes mentioned in table 1. No patients were found with a V377I 
mutation in the MVK gene, and neither did DNA sequencing of exon 3 of the 
CIAS1 gene and exon 2, 3 and 4 of the TNFRSF1A gene yield any additional 
mutations. 
A 13-year-old Slovakian girl appeared to carry one M694V MEFV gene mutation. 
This patient had her first fever episode at age 5; these episodes lasted ~3 days and 
were accompanied by abdominal pain and lymphadenopathy. In the last few years, 
she has been free of symptoms. Maximal IgD concentration: 134 U/mL (normal 
reference value <100 U/mL). Her family has no Jewish or Mediterranean origin, 
and colchicine had not been tried. As the phenotype resembled HIDS, she had 
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been analyzed for HIDS, but comprehensive sequencing of MVK was negative. 
She did not carry any of the other FMF mutations tested.  
Secondly, we detected a R92Q TNFRSF1A gene mutation in a 10-year-old 
Swedish boy, presenting with fever episodes, lasting about 7 days, since the age of 
4 months. He also had headache, diarrhea, abdominal pain and lymphadenopathy. 
Laboratory examination shows high concentration of C-reactive protein during 
fever, and a continuously high IgD (680 U/mL). His older sister and his father 
have similar symptoms and laboratory values, but did not carry this mutation. 
Elaborate sequencing of the TNFRSF1A gene yields no other abnormalities. 
Lastly, we detected a E148Q mutation in MEFV gene in a 12-year-old Japanese 
boy, whose case history was published earlier [186]. This boy has recurrent 
episodes of fever, cervical lymphadenopathy, headache and occasional abdominal 
pain, with a continuously raised serum IgD (maximal 371 U/mL). Comprehensive 
DNA analysis of the MVK gene failed to detect mutations. 
%"	
In the group in whom we had previously made a clinical and genetic diagnosis of 
HIDS, TRAPS, or FMF, we detected 5 patients with mutations in other 
autoinflammatory genes.  
An Armenian refugee girl, aged 7, living in the Netherlands, had been diagnosed 
as classical HIDS because of monthly episodes of fever, arthralgia, abdominal 
pain, oral ulcers and erythematous rash, which last 4-6 days and had started in her 
first year of life. She did not respond to colchicine. Her IgD serum concentration 
was 700 U/mL and MVK gene analysis demonstrated homozygosity for the V377I 
mutation, confirmed by sequencing of her parents. Now, she was found to be a 
carrier of a V726A mutation in MEFV gene. No other MEFV mutations were 
found. 
An E148Q mutation in the MEFV gene was detected in DNA samples from two 
brothers of Dutch Caucasian origin, with classical HIDS (MVK genotype 
P167L/I268T). A man of Dutch origin, previously diagnosed with TRAPS (D93E 
mutation in TNFRSF1A gene) was identified as carrier of E148Q mutation in the 
MEFV gene. None of the latter three are of Mediterranean or Jewish descent. A 
Dutch woman with classical HIDS (MVK genotype V377I/I268T) was found to be 
a carrier of a R92Q mutation in the TNFRSF1A gene. 
%-!	
We detected one R92Q TNFRSF1A gene mutation and two E148Q MEFV gene 
mutations in 50 control DNA samples. 
%
Systematic genetic screening of patients with unclassified periodic fever, who had 
previously undergone one or two specific genetic tests, yields no mutations in 
57/60 patients. Our screen netted only one possible diagnosis of FMF. Before this 
study, we had considered HIDS in this patient, but in hindsight FMF was more 
likely given her clinical phenotype.  
Another patient carried an E148Q mutation in the MEFV gene, and one a R92Q 
mutation in the TNFRSF1A gene. The latter are regarded as low-penetrance 
mutations, disease-modifying factors or even polymorphisms instead of disease-
causing mutations, because of the high prevalence in control populations 
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(frequency 1.2-6.4%) [58,187,188]. We confirm this in our study, as 4% and 2 % 
respectively of our relatively small group of 50 healthy Dutch controls carries 
these mutations. It is therefore questionable whether these patients should be 
diagnosed with either FMF or TRAPS.  
These results demonstrate that clinical examination combined with directed 
genetic testing for one or two of the most likely syndromes forms the basis for 
diagnosis of the autoinflammatory syndromes included in this study. While it is 
true that clinical phenotype of the autoinflammatory syndromes may overlap and 
that therefore clinical diagnostic criteria, such as those of Tel-Hashomer for FMF 
[29], are not useful for differential diagnosis within this group of disorders, in the 
large majority of patients clinical examination will point towards one or two 
specific syndromes. DNA analysis can be focused on syndromes with highest 
clinical suspicion. As we have shown, screening of all known genes involved in 
these disorders is unlikely to yield additional relevant information.  
This notion is confirmed by the clinical workup of the 87 previously diagnosed 
patients. We made a positive diagnosis in 84/87 using a single genetic test, while 
in only 3 cases an additional genetic test was necessary to establish a positive 
diagnosis. 
This study also reemphasizes that a substantial proportion of patients with a 
definite autoinflammatory syndrome does not fall into any known genetic 
category. Most are sporadic cases, although there are patients with affected family 
members. The cause of disease in these patients remains elusive. 
The second part of this study focused on the prevalence of combinations of 
mutations in more than one autoinflammatory gene. Although we found the low 
penetrance gene mutations R92Q in TNFRSF1A and E148Q in MEFV in patients 
with a different autoinflammatory disorder, their prevalence was not different from 
that in controls. Thus, the combination of disease-causing mutation(s) with a 
mutation in another autoinflammatory gene in a single patient only reflects the 
high prevalence of these latter low-penetrance mutations (or polymorphisms) in 
the general population [181,182]. The same holds true for the V726A MEFV 
mutation found in the Armenian girl with HIDS: carrier frequency in healthy 
Armenians for exon 10 mutations in this gene is 16%, of which about one fifth is 
the V726A mutation [14].   
In conclusion, for diagnosis of an autoinflammatory syndrome we recommend a 
thorough clinical examination, including detailed medical history, use of 
medication, family history, ethnic origin and physical examination during an 
attack. An acute phase response (raised C-reactive protein or leukocytosis) should 
be present during the inflammatory episode. With current clinical knowledge of 
autoinflammatory syndromes, this information will yield a working diagnosis of 
one or two possible syndromes [4]. Subsequently, confirmation of this working 
diagnosis can be sought by directed genetic tests. Screening for mutations in all 
possible genes is not recommended, because this is not likely to yield extra 
information. Development of a set of validated discerning clinical criteria for 
differential diagnosis of the hereditary autoinflammatory syndromes is more likely 
to be helpful. 
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Two Dutch patients suffering from recurrent fever attacks who went undiagnosed 
for more than 40 years are described. Their diagnosis of periodic fever was made 
when molecular analysis revealed novel mutations in the tumor-necrosis factor 
(TNF)-receptor (TNFRSF1A) gene, establishing the diagnosis of TNF-receptor 
associated periodic syndrome (TRAPS). TRAPS is an autosomal dominant 
disorder, characterized by recurring episodes of fever, arthralgia and skin lesions. 
It is caused by mutations in the 55kDa TNFRSF1A gene. This finding has 
facilitated the treatment for TRAPS as blocking of TNF signaling seems to 
alleviate the symptoms. The use of a short course of recombinant p75-TNFR:Fc 
fusion protein (etanercept) induced prolonged remission in one patient described 
here. 
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Prolonged or recurrent fevers are one of the greatest challenges to the diagnostic 
skills of the clinician. In a prospective study of 167 immunocompetent patients 
with fever of unknown origin, no diagnosis could be made in 50 patients [6]. In 
those with recurrent fever, the chance of reaching a diagnosis was even lower [6]. 
Until recently, the different forms of periodic fever were diagnosed using clinical 
criteria because knowledge on the pathogenesis was absent. Consequently, 
treatment was limited to supportive measures. The recent discovery of the genetic 
background of a number of familiar periodic fever syndromes [2,3,7,15,90] has 
greatly simplified diagnostic procedures in patients with recurrent febrile attacks 
[89].  
Tumor necrosis factor (TNF)-receptor associated periodic syndrome (TRAPS, 
OMIM [142680]) is an autosomal dominant disorder characterized by recurrent 
febrile attacks accompanied by abdominal distress, arthralgia or arthritis, myalgia, 
migrating erythematous skin lesions and conjunctivitis. Mutations of the 55kD 
TNF-receptor gene (TNFRSF1A) on chromosome 12 have been established as the 
cause of this syndrome and due to this finding effective therapy could be 
developed. In the cases presented here we demonstrate the role of genetics in 
diagnosis and treatment of TRAPS. In both cases, the positive family history was 
an important clue leading to genetic screening and diagnosis. 
 
/	&

A 62-year old woman of Dutch origin contacted us after reading a local newspaper 
article on periodic fever. She recognized the patient history described in that article 
as similar to her own. Six years previously, she had been examined at our center 
for fever of unknown origin, participating in a prospective multicenter study [6], 
but no diagnosis could be made at that time. For over 40 years, she has suffered 
twice a year from fever attacks characterized by a spiking fever up to 40°C, 
accompanied by general malaise, chills, fatigue, myalgia and abdominal pain. The 
b
a
Figure 1. Family trees of case 1 (a) and 
2 (b); cases indicated by arrow. Line 
through a symbol = deceased. = 
affected,  = unaffected,  = carrier 
of mutation without clinical symptoms. 
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attacks resolved spontaneously only after 4 to 6 weeks, but could be aborted earlier 
when non-steroid anti-inflammatory drugs were started early. The further medical 
history revealed two uncomplicated pregnancies, an appendectomy and two 
gynecological operations including hysterectomy because of the fever. A brother, 
sister and a daughter had similar attacks (figure 1a). With the exception of fever, 
physical examination during an attack was normal. Laboratory examination 
showed a raised erythrocyte sedimentation rate (93 mm/hr), leukocytosis 
(22.7*109/l) and a normal serum IgD concentration (41 U/ml). Numerous cultures 
of blood, urine, feces, sputum and bone marrow had remained negative. Additional 
diagnostic interventions, including computer tomographic (CT) scanning of 
abdomen, an 111Indium-IgG scan for detection of focal inflammation and 
endoscopic cholangiography revealed no abnormalities. We considered the 
diagnosis TRAPS because of the low frequency and long duration of the febrile 
attacks and the autosomal dominant inheritance pattern in the family. DNA 
analysis revealed a novel missense mutation in the TNFRSF1A gene, which leads 
to a replacement of tyrosine at position 38 of the TNFRSF1A protein for a cysteine 
(Y38C). This mutation was subsequently detected in three other family members. 
One of her brothers and a half-brother and half-sister, aged between 39 and 63 
years, were without symptoms despite having the disease associated genotype.  

A 62-year old woman of Dutch origin was referred because of recurrent episodes 
of fever from the age of six. Attacks were characterized by fever (> 40°C), 
accompanied by conjunctivitis, erythematous skin lesions, myalgia /arthralgia 
especially of hands and legs, and abdominal pain. In general, these episodes lasted 
2 to 3 weeks, and recurred several times a year. Treatment with prednisone (up to 
20 mg/day) during an attack only slightly ameliorated the symptoms. The medical 
history further revealed appendectomy, hysterectomy and diagnostic laparotomy, 
all because of unexplained fever and abdominal pain. Her father, brother, daughter 
and niece had similar, albeit milder, attacks with fever. In the 2 years before 
admission, the severity, frequency, and duration of the fever attacks increased, 
despite increasing steroid dosages. When prednisone was tapered in order to 
exclude an underlying infection, the febrile attacks did not abate but persisted. At 
admission she appeared ill, febrile (40°C), had severe abdominal distress, skin 
lesions and arthralgia. There was an important acute phase response as mirrored by 
the elevated erythrocyte sedimentation rate (100 mm/hr), C-reactive protein (219 
mg/L) and leukocyte count (34.2*109/L). Elaborate investigations, including CT 
scanning of thorax and abdomen, an 111Indium-IgG scan and microscopic 
examination and cultures of bone marrow failed to yield a diagnosis. Although IgD 
was elevated (269 IU/mL; normal <100 IU/mL), the clinical picture was not 
considered compatible with another periodic fever syndrome: hyper-IgD and 
periodic fever syndrome [46].  Because of the long duration of the attacks and the 
apparent autosomal dominant inheritance pattern of the disease in the family, 
TRAPS was suspected.  Sequencing of the TNFRSF1A gene of the patient revealed 
a novel missense mutation resulting in a cysteine to phenylalanine substitution at 
codon 29 of the protein (C29F). 
Given the central role of TNF signaling in the pathogenesis of TRAPS, and the 
persistence and severity of the attack in patient 2, we explored the efficacy of 
treatment with recombinant p75TNFR:Fc fusion protein (Etanercept, Enbrel®) 
[189]. On three successive days, a subcutaneous injection of Etanercept (25 mg) 
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was given. As shown in Figure 2, within two days the body temperature 
dramatically declined and the symptoms of myalgia, arthralgia and malaise rapidly 
improved, while the inflammatory parameters returned to baseline. Two weeks 
after treatment, the patient was discharged. She remained in clinical remission for 
six months without any therapy. After that time she returned with fever, myalgia, 
abdominal pain and skin lesions. Laboratory examination again showed increased 
inflammatory parameters. Because of the relative mildness of the attack, and the 
limited availability of the drug in our country, she was treated with a single dose of 
Etanercept (25 mg s.c.). This again resulted in a disappearance of fever and 
symptoms, and decline in inflammatory parameters. However, this time the 
remission lasted only two weeks. Subsequently, she received four successive 
injections of Etanercept of the same dose (25 mg s.c.) which now induced a long-
lasting remission. 
%
Long before the elucidation of the molecular pathophysiology of fever a number of 
families with autosomal dominant inherited periodic fever were reported in the 
literature [53,56,59,190-192]. Although there were some similarities in 
presentation different names were coined, including Familial Hibernian Fever, 
Familial Periodic Fever and Autosomal Dominant Recurrent Fever. A genome-
wide linkage in an Australian family with familial periodic fever indicated linkage 
with chromosome 12 and this finding was confirmed in an Irish/Scottish family 
with familial Hibernian fever suggesting that these families were suffering from 
the same disease [55,193]. Subsequent investigations demonstrated that affected 
Figure 2. Effect of treatment with etanercept in case 2. The upper panel depicts body temperature, the 
thick straight lines indicate the time when the patient had accompanying symptoms as described in the 
text. Time of subcutaneous injection with 25 mg etanercept is indicated by a cross. In the lower panel, 
the dotted line shows the serum concentration of C-reactive protein (CRP) in mg/L during this period. 
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patients from these families all had mutations in gene encoding for the 55 kD TNF 
receptor protein (TNFRSF1A). In order to group these families it was proposed to 
refer to this syndrome as TRAPS [7].  
Up to now, 14 different missense mutations in the TNFRSF1A gene, located on 
chromosome 12, have been described in different families with TRAPS. The novel 
missense mutations reported here (C29F and Y38C) affect cysteine residues within 
the extracellular domain of TNFRSF1A involved in disulphide bonding, similar to 
most of the previously described mutations [7,63,189]. Most TRAPS mutations 
have a penetrance of around 75%, as is seen in case 1. Genetic analysis of the 
TNFRSF1A gene should be performed in a patient with recurrent episodes of fever 
of unknown origin that last at least one week and a positive family history in an 
autosomal dominant inheritance pattern. 
TNF is an important pro-inflammatory cytokine, and cellular signaling is mediated 
by the TNFRSF1A receptor. Upon activation the TNFRSF1A is clipped off from 
the cell surface and released into the circulation. Consequently, TNF signaling is 
interrupted and soluble TNFRSF1A can bind to and inactivate circulating TNF, 
thereby exhibiting anti-inflammatory effects. It is postulated that TRAPS 
mutations impair TNFRSF1A shedding and reduce the pool of the circulating 
protein. Indeed, when measured during remissions serum TNFRSF1A 
concentrations are low relative to normal controls [7]. It is suggested that the 
impaired shedding results in continuous pro-inflammatory TNF signaling. 
Treatment of patients with TNF inhibitors, therefore, provides a rational 
therapeutic approach.   
Etanercept is a recombinant fusion protein that consists of the other soluble TNF-
receptor (p75) linked to the Fc portion of human IgG1 and it has profound anti-
inflammatory actions by blocking TNF. Etanercept is used as a disease modifying 
agent in rheumatoid arthritis, where the drug is given twice weekly. Using this 
scheme, continuous administration of etanercept was reported to be beneficial in 
improving clinical and laboratory parameters in a small number of TRAPS patients 
[189].  As demonstrated in our patient it does not seem necessary to subject 
TRAPS patients to twice weekly etanercept injections. The repeated response 
strongly suggests that a short course is sufficient to induce prolonged remission of 
TRAPS attacks. This should be investigated in a formal clinical trial. 
In the case of TRAPS, the spin off of genetic research has clearly improved the 
quality of life of patients by giving the opportunity for a clear diagnosis avoiding 
various unnecessary medical interventions and offering the possibility of genetic 
counseling. Elucidation of the molecular background of this syndrome has 
furthermore afforded the development of novel therapeutic strategies.   
!2<"
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Establishing a diagnosis in patients with recurrent episodes of fever is often very 
difficult [5,6]. The episodes of fever and signs of inflammation may lead to a 
considerable morbidity and to notable frustration in patients and doctors as 
extensive diagnostic attempts often fail to reveal the cause. However, after ruling 
out infectious causes for the febrile attacks one should consider syndromal causes 
of periodic fever. Currently, at least three separate periodic fever syndromes have 
been recognized: hyper-IgD and periodic fever syndrome (HIDS, MIM260920), 
the tumor necrosis factor (TNF)-receptor associated periodic syndrome (TRAPS, 
MIM142680), and the best known and most prevalent syndrome familial 
Mediterranean fever (FMF, MIM249100).  The identification of causative genes 
for each of them [2,3,7,15,90] has greatly advanced diagnostic possibilities and has 
implications for treatment as well.  
We wish to present the following observation as an example of a typical familiar 
case of periodic fever and amyloidosis. With the use of molecular tools we were 
able to make a definitive diagnosis of TRAPS. 
	
A 61-year old woman of Dutch-Indonesian ancestry was referred because of 
recurrent episodes of high fever and proteinuria. She had her first attack of fever as 
a 9-year-old child in Indonesia. At that time no elaborate diagnostic procedures 
were performed and the recurrent fever was attributed to attacks of malaria. She 
moved to the Netherlands at the age of 21 years and shortly thereafter she was 
admitted to a hospital because of a 3-week long attack of fever which subsided 
spontaneously. No pertinent diagnosis could be made. From that time onwards the 
fever episodes occurred approximately twice a year and generally lasted up to 3 
weeks. 
A 
C 
B 
Figure  1. a. Family tree, index patient indicated by arrow. Line through a symbol = deceased. filled 
symbol = affected, open symbol = unaffected, dotted symbol = carrier of mutation without clinical 
symptoms. b. DNA sequence electrospherogram of C70Y mutation (TGC  TAC, indicated by arrow)  
in the gene for the type 1 TNF-receptor which is found in the affected members of this family. c. DNA 
sequence of healthy individual with normal pattern (TGC) at position 70. 
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Table 4. Clinical features and laboratory results of affected family members 
Age (yrs)  Attacks   Symptoms and signs   Laboratory results 
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II:1* 61 9 21 † Yes No No No No NA 2.7 0.9 10.5 22.0 
III:4 45 8 14 1x/yr Yes Yes Yes Yes Yes NA 15 2.5 0.81 3.23 
IV:1 20 5 14 1x/yr Yes Yes No Yes Yes No 8 3.2 0.66 3.28 
IV:2 18 0 14 1x/yr Yes Yes Yes Yes Yes Yes 28 5.9 1.00 3.80 
IV:3 15 2 21 1-2x/yr No Yes Yes Yes Yes No 105 11 0.69 3.15 
* proband and main subject of this clinical observation. † varying frequency during life, now no attacks 
anymore, see text for details. Individual = generation and number from family tree (fig. 1). CRP= C-
Reactive Protein (normal <2.7 mg/l) measured in serum; SAA = serum amyloid A protein (normal 
<4.2mg/l) measured in serum; sTNFR = soluble TNF-receptor concentrations in plasma, p55 = type 1 
(normal <1,50 ng/ml), p75 = type 2 (normal <2,51 ng/ml).  All laboratory measurements were done 
from samples taken in the attack-free interval.  
 
Usually, a short course of steroids was administered because the impression 
existed that this ameliorated the attacks. Apart from fever, generalized myalgia and 
fatigue during the attacks she had no specific symptoms. During each of her three 
(uncomplicated) pregnancies she was free from symptoms, but after each delivery 
she experienced a severe febrile bout. Attacks could further be provoked by 
emotional and physical stress. She gave a positive family history. Her sister, who 
died at age 47 due to breast carcinoma, had experienced similar febrile attacks 
during life. Three of her sister's six children and three of her sister’s five grandsons 
were also affected (fig. 1).  
Symptoms and pertinent laboratory results of our patient and four affected 
relatives are summarized in Table 1. There are not enough data available to 
determine definitely which of the parents of our patient transmitted the disease to 
their offspring. It is also unclear whether the disease originated from the Dutch or 
Indonesian side of the family. Our patient noticed an increase in the frequency of 
the fever attacks after reaching menopause to about 4 to 5 times each year.  
In the following years she developed renal failure, despite colchicine treatment. 
Both rectal and renal biopsies showed evidence of type AA amyloidosis. Since 
1997 she has been dependent on intermittent hemodialysis. Most remarkably, the 
decrease of renal function coincided with a cessation of fever episodes, and since 
1996 she is free from attacks (fig. 2). The autosomal dominant inheritance, the 
long duration of attacks, and the (partial) response to steroids reminded us of 
TRAPS. After sequencing the TNFRSF1A gene, which codes for the p55 TNF-
receptor, the incriminated molecule in TRAPS [183], we discovered a novel 
missense mutation in our patient. This replaces cystine by tyrosine at position 70 
of the amino acid sequence of the protein (C70Y, fig. 1). The C70Y mutation has 
been found in 10 of 17 tested family members, two of whom remain asymptomatic 
up to this day, which suggests a penetrance of 80%. With the exception of our 
patient (II:1), the affected family members had low concentrations of soluble 
TNFRSF1A in their blood (table 1) as measured by ELISA (La Roche) [50]. 
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The acronym TRAPS was recently suggested by McDermott et al. [7] to be used 
for a group of autosomal dominantly inherited periodic fever syndromes 
previously known by several names (e.g. Familial Hibernian Fever, Familial 
Periodic Fever). Patients experience recurrent attacks of fever accompanied by 
abdominal pain, myalgia, skin lesions and conjunctivitis. Nephropathic reactive 
amyloidosis of the AA type has been reported in four patients up till now [59,194]. 
The attacks occur in varying frequency and generally last two to three weeks. 
Laboratory examination reveals acute phase response. The autosomal dominant 
inheritance pattern is one of the main characteristics which distinguishes TRAPS 
from the two other main periodic fever syndromes, familial Mediterranean fever 
and Hyper-immunoglobulinemia D and periodic fever syndrome, both being 
autosomal recessive. 
The gene responsible for TRAPS is located on the short arm of chromosome 12 
[55,193] and encodes for the type I receptor of TNF (TNFRSF1A) [7]. The 
TNFRSF1A protein is a cell membrane coupled receptor expressed on a large 
variety of cells. TNF has many effects, including induction of cytokine secretion, 
increased expression of adhesion molecules on leukocytes and endothelial cells, 
activation of leukocytes, fever and cachexia. Activation of the receptor also leads 
to a specific negative feedback mechanism called shedding: the receptor is cleaved 
by a protease, by which the extracellular part of the receptor is released in a 
soluble form into the extracellular space, where it can act as a competitive 
inhibitor of TNFRSF1A. Mutations in this gene lead to a structural change in the 
extracellular part of the receptor and it has been suggested that this impairs 
shedding of the receptor [7]. Following this hypothesis, the auto-inflammatory 
phenotype of TRAPS results from an impaired downregulation of membrane-
bound TNFRSF1A, and decreased formation of soluble TNFRSF1A [7]. As a 
consequence, a trivial trigger leads to an uncontrolled inflammatory response.  
Until recently, no adequate treatment for TRAPS was available and attacks were 
treated symptomatically by oral steroids and colchicine with varying results. After 
the discovery of the molecular defect, the administration of recombinant soluble 
TNF receptors became a logical therapeutic step. Indeed, in selected patients it 
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Figure 2. Calculated creatinine clearance as a measure of renal function in relation to occurrence and 
cessation of fever attacks. The last fever attack occurred November 1995. 
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seems beneficial with a decrease in frequency of attacks [189]. We did not treat 
our patient with recombinant soluble TNF receptors because she did not have any 
further attacks or evidence of acute phase response. As soluble TNF receptors are 
cleared from the body by the kidneys, we expected high concentrations in our 
patient because of coexisting renal failure. This was confirmed: plasma 
concentrations of soluble TNF receptor were clearly elevated (table 1). As shown 
in Fig. 2 the cessation of fever episodes in our patient coincided with the 
deterioration of her renal function. A relation between these two observations 
could be explained by the rise in concentration of soluble TNFRSF1A, which 
could protect her from further attacks of fever. 
!2<"
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Interleukin-1 (IL-1) is one of the central pro-inflammatory cytokines, and in vitro 
studies have implicated IL-1 as important pathogenic factor in several 
autoinflammatory syndromes [70,149,156]. Hawkins et al. reported good results 
with the recombinant IL-1 receptor antagonist (IL-1ra) anakinra [195] in two 
patients with Muckle-Wells syndrome, one of the autoinflammatory syndromes 
[196]. This prompted us to try anakinra in a patient with severe, treatment-resistant 
tumor necrosis factor (TNF)-receptor associated periodic syndrome (TRAPS; 
Mendelian Inheritance in Men Database no. 142680). 
 
The patient is a 19-year old Dutch woman, diagnosed with TRAPS, confirmed by 
a C43Y-mutation in the TNF-receptor type 1 (TNFRSF1A) gene. From the age of 
1, she suffers from episodes of fever, general malaise, abdominal pain, myalgia 
and painful erythematous skin lesions, accompanied by vigorous acute phase 
response. Numerous therapies were tried, including non-steroidal anti-
inflammatory drugs (NSAIDs), methotrexate,  and cyclosporin, with disappointing 
results; the only reasonably effective drug was prednisone, at least 30 mg daily. 
After the diagnosis TRAPS was made she started with the TNF-inhibitor 
etanercept [179]. This improved symptoms temporarily, but the acute phase 
response persisted and prednisone could not be tapered. A brief trial of sirolimus, 
an inhibitor of T-cell activation [197], had to be stopped because of severe allergic 
reaction. The last year, inflammatory symptoms had become unremitting and 
occurred daily.  Between July 2002 and November 2003 (total: 22 measurements), 
median CRP concentration was 117.5 mg/l (interquartile range 70.5-157.5) and 
leukocytes 20.9x109/l (interquartile range 14.95-23.6). The patient consented to 
use of anakinra, given subcutaneously at a dose of 100 mg daily. This resulted in 
remarkable improvement of symptoms and an unprecedented decrease of CRP-
concentration and leukocyte count within days (figure 1). Prednisone could rapidly 
be tapered to 10 mg daily. After 1 month the patient was symptom-free and feeling 
well for the first time in many years. She did suffer pain and redness at the 
anakinra injection site (figure 2). 
 
TRAPS is an hereditary autoinflammatory syndrome, characterized by recurrent 
episodes of fever and inflammation, caused by TNFRSF1A gene mutations. Its 
clinical features can vary greatly between patients, from a recurrent mild localized 
myalgia to the incapacitating  severe symptoms as described in our patient [54]. In 
mild cases, the occasional use of NSAIDs is usually sufficient for symptom-
management. After discovery of the genetic etiology, anti-TNF treatment in the 
form of etanercept has been introduced and found to be successful in many cases 
[54,64,179]. However, not all patients benefit and initial response may wear off 
with prolonged therapy, necessitating alternative therapies. In one severe case 
unresponsive to etanercept, Drewe et al. [197] describe a beneficial response to 
sirolimus. This could not be used in our patient because of an allergic reaction. 
Anakinra is a recombinant form of IL-1ra, an endogenous inhibitor of IL-1 
signaling, used in the treatment of rheumatoid arthritis [195]. It is usually well 
tolerated; the most common side effect is an injection-site reaction with pain, 
erythema and local inflammation [198]. This beneficial response to anakinra 
argues for a central role of IL-1 in the pathogenesis of TRAPS [70,149,156,196]. It 
is generally assumed that in TRAPS the inflammatory effects of TNFα and 
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lymphotoxin (LT) are not countered adequately, because of a lack of soluble TNF-
receptor, the major inhibitor of TNF. In that respect it is hard to understand that the 
TNF-receptor construct, etanercept, had hardly any therapeutic effect in our 
patient. Perhaps even more difficult to explain is the effectiveness of  IL-1ra, since 
IL-1β and IL-1α are responsible for only a small part of the biological effects of 
TNFα and LT. Further research is required here, while also long-term efficacy 
needs yet to be determined. 
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Figure 2. Erythematous and painful 
injection site reaction associated 
with subcutaneous use of anakinra 
on the upper leg of the patient. Such 
reactions clear up after a few days, 
and are less severe when anakinra is 
used in the abdominal region. 
Figure 1. Concentration of C-reactive protein 
(CRP) and leukocytes in a patient with TRAPS, 
from February 2003 to January 2004. 
Treatment used is shown in the bottom half of 
the figure, in dosage of mg per day (except for 
etanercept, which is dosage per week). Shortly 
after start of anakinra (gray area of graphs), the 
concentration of CRP and leukocytes dropped 
to the normal range. 
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Familial Mediterranean fever is a hereditary syndrome characterised by recurrent 
episodes of fever and serositis, resulting in pain in the abdomen, chest, joints and 
muscles. It is primarily diagnosed in people of Jewish, Arabic, Turkish or 
Armenian ancestry and is caused by mutations in the gene encoding for pyrin. 
Abdominal FMF attacks resemble the clinical presentation of ‘acute abdomen’, 
with severe abdominal pain and rigidity, but in FMF symptoms always resolve 
spontaneously. It is important to distinguish these regular pain episodes from small 
bowel obstruction due to adhesions to prevent life-threatening bowel strangulation. 
In most cases, colchicine will prevent new painful attacks. This seminar also 
discusses other causes of abdominal pain in FMF patients.  
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A 24-year old man of Turkish origin, living in the Netherlands, was referred to our 
University hospital because of unexplained abdominal pain. Since the age of 19, 
he suffers from episodes of severe abdominal pain, occurring about once every 
month. He abstains from eating or drinking during attacks because this increases 
the pain. Accompanying symptoms are often (though not always) high fever, mild 
diarrhoea, and sometimes chest pain. The pain resolves spontaneously within 2 or 
3 days. Family history is negative, but his parents are cousins. On presentation to 
the emergency ward of a district hospital, which occurred regularly, physical 
examination was usually compatible with ‘acute abdomen’. Laboratory evaluation 
during such an episode showed evidence of inflammation with increased serum 
concentration of C-reactive protein, but otherwise no abnormalities. Twice, 
laparotomy was performed because of suspected appendicitis or gastric 
perforation, which yielded a normal appendix, while biopsies showed microscopic 
evidence of haemorrhagic peritonitis. The patient met the clinical criteria for FMF 
and was started on colchicine 1 mg daily, with favourable effect. There was no 
evidence of amyloidosis. DNA analysis revealed that he was homozygous for a 
Met694Val mutation in the MEFV gene.  
 
$"'
"&(.'
'1
This is a typical story for a patient with Familial Mediterranean Fever (FMF). 
FMF is a hereditary autoinflammatory disorder characterised by lifelong recurrent 
episodes of fever and serositis, resulting in pain in the abdomen, chest, joints and 
muscles (table 1) [4,36]. In the majority of patients, these inflammatory attacks 
start before the age of 20 [24]. The onset of a typical FMF attack is acute, and the 
symptoms persist for only a short time (6 to 96 hours) before they resolve 
spontaneously. It is an autosomal recessive disease, which is most prevalent in 
people from the Mediterranean basin, including Sephardic Jews, Arabs, Turks and 
Armenians. Prevalence is estimated to be as high as 1 in 700 in Israel and 1 in 
1400 in Turkey. There is often a delay of 5 to 10 years from the onset of symptoms 
before the correct diagnosis is made; major factors contributing to this delay were 
found to be patient´s neglect of symptoms and physician´s unawareness of FMF 
[199]. Even in a region where FMF can be encountered frequently, at least 11 
FMF patients could be detected in a group of 59 children who had been given the 
diagnosis functional abdominal pain per exclusionem [200]. The major long-term 
complication, which occurs in up to 40% of untreated patients with FMF, is AA 
type amyloidosis resulting in renal insufficiency. 
 
Clinical feature Frequency 
n=1558 
Fever 100% 
Peritonitis 94% 
Arthritis 54% 
Pleuritis 39% 
Rash 30% 
Table 1. Frequency of clinical features of FMF among 1558 patients, which include Jews (n=515), 
Turks (n=601), Arabs (n=227) and Armenians (n=215) (adapted from Ben Chetrit et al. [36]) 
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FMF is caused by mutations in the MEFV gene, which encodes for the protein 
pyrin (or marenostrin) [15,90]. About 40 different mutations have been described 
until now, although just four or five mutations account for the majority of FMF 
cases. The function of pyrin was unknown at the time of discovery, but it has since 
been identified as a cytoplasmic protein and member of a family of proteins that 
all contain a domain first described in pyrin, the so-called pyrin domain. These 
proteins are involved in regulation of inflammation, apoptosis and/or cytokine 
secretion. Pyrin is thought to indirectly regulate caspase-1 function, and therefore 
influence interleukin-1 processing and apoptosis. Thus, FMF is caused by a 
disordered regulation of inflammation, resulting in excessive inflammatory attacks 
after ‘trivial’ stimuli. 
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Abdominal pain is the most frequent symptom encountered in FMF; 95% of 
patients report this as the main symptom during at least some of their fever 
episodes, while 50% cite such an ‘abdominal attack’ as the first symptom of their 
disease [201]. Presentation of a typical abdominal attack will resemble that of 
‘acute abdomen’. Onset is sudden and acute, leading to rapid development of 
symptoms within 1-2 hours. The abdominal pain is usually diffuse throughout the 
entire abdomen, although in some cases it may be localized; it may be very severe 
in intensity. Patients prefer to lie still, as pain is aggravated on movement. This 
may be accompanied by any bowel activity, ranging from constipation (most 
often) to diarrhoea. Findings on physical examination will be compatible with 
‘acute abdomen’ as well: distension of the abdomen, rigidity, direct and rebound 
tenderness, and reduced peristaltic sounds [201]. The intensity of symptoms and 
signs of an inflammatory attack in FMF will decrease spontaneously after 12-24 
hours, and usually, the attack resolves over the following 48 hours [201]. Thus, 
after about three days the patient will be symptom-free again. The duration of 
remission is variable between patients and within patients and may last for weeks 
or months, or even longer [202]. So-called incomplete abdominal attacks may 
occur. These differ from ‘typical’ abdominal attacks in one or two features, which 
may include absence of fever, minimal change in acute phase parameters, absence 
of ’true’ peritonitis and/or localisation of the abdominal pain to a single specific 
abdominal area. It may be difficult to differentiate an ‘incomplete’ abdominal 
attack from other causes of abdominal pain, mainly because of its atypical 
presentation [24,29]. 
 
Table 2. CT findings in 14 patients with FMF during acute abdominal attack (adapted 
from Zissin et al. [203]). 
No. of 
patients CT findings 
12 Engorged mesenteric vessels and/or thickened mesenteric folds 
6 Mesenteric and/or retroperitoneal lymphadenopathy 
6 Ascites 
4 Ascites with focal peritonitis 
3 Splenomegaly 
2 Dilated small bowel loops 
1 Mural thickening of the ascending colon 
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Laboratory examination during an FMF attack will reveal a vigorous acute phase 
response, including leukocytosis with a left shift, increased erythrocyte 
sedimentation rate and increased concentrations of C-reactive protein, fibrinogen 
and serum amyloid A protein [113]. Plain abdominal radiography may show 
dilatation of small bowel with air-fluid levels; in a study by Aharoni et al. this was 
seen in 11 of 34 plain abdominal films made in symptomatic FMF patients [204]. 
On computed tomography (CT) scanning, the most common finding during an 
abdominal attack in FMF is non-specific mesenteric pathology, which may include 
engorged mesenteric vessels, thickened mesenteric folds and mesenteric and/or 
retroperitoneal lymphadenopathy [203]. Minimal ascites, with or without focal 
peritonitis, splenomegaly and dilated small bowel loops may also be present on CT 
scanning (table 2). No role for MRI in FMF has been defined yet.  
On laparoscopy or laparotomy during an acute attack, it is possible to observe 
signs of peritonitis, including oedematous and hyperaemic peritoneal folds or 
greater omentum. Microscopic examination of omentum biopsies will reveal a 
sterile non-specific inflammation, which may be purulent or haemorrhagic and 
accompanied by signs of chronic recurrent peritonitis, such as peritoneal inclusion 
cysts [201,205]. A sterile peritoneal exudate containing fibrin and 
polymorphonuclear cells is usually present in the peritoneal cavity [23]. Fibrous 
adhesions may ensue (see below). 
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FMF is a clinical diagnosis, and for diagnostic purposes, a set of clinical criteria 
was designed by Livneh et al. [29] (table 3). However, this was validated in Israel 
in a population with a very high prevalence of FMF, and it is unknown whether 
they work as well in other populations [4]. The criteria include a beneficial 
response to colchicine. Additionally, DNA testing of the MEFV gene may be used 
as a confirmatory test. 
 
 
Major criteria: Typical attacks with peritonitis (generalized) 
 Typical attacks with pleuritis (unilateral) or pericarditis 
 Typical attacks with monarthritis (hip, knee, ankle) 
 Typical attacks with fever alone 
 Incomplete abdominal attack 
Minor criteria: Incomplete attacks involving chest pain 
 Incomplete attacks involving monarthritis 
 Exertional leg pain 
 Favorable response to colchicine 
 
Table 3. Diagnostic criteria for diagnosis of FMF (Tel-Hashomer) (adapted from Livneh et al. 
[29]). Requirements for diagnosis of FMF are 1 major criteria or 2 minor criteria. Typical attacks 
are defined as recurrent (3 of the same type), febrile (38°C) and short (between 12 hours and 3 
days). Incomplete attacks are defined as painful and recurrent attacks not fulfilling all the criteria 
for a typical attack. 
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The inflammatory peritoneal exudate and recurrent peritonitis in FMF may lead to 
intraperitoneal adhesions. Adhesive small bowel obstruction is not uncommon in 
FMF patients, especially after previous (often unnecessary) abdominal surgical 
procedures. In a study of 355 children with FMF with a mean follow-up of 8 years, 
Ciftci et al. identified 11 patients with adhesive small bowel obstruction, where 
adhesiolysis or resection of strangulated ileum or jejunum was necessary [206].  
It can be very difficult to differentiate between small bowel obstruction  (a 
potentially life-threatening complication) [201] and a severely painful, but 
otherwise harmless abdominal attack in FMF, which will resolve spontaneously. In 
the first case, surgical intervention must not be delayed, while in the second case 
this course of action might lead to further complications. The same is true for the 
differential diagnosis of acute appendicitis. In women, it can be difficult to 
differentiate an FMF attack restricted to the pelvic region from pelvic 
inflammatory disease [207]. Such pelvic attacks are often precipitated by 
menstruation or pelvic instrumentation [201]. 
The clinical course of the abdominal pain will often enable differentiation. In a 
typical FMF attack, signs and symptoms will peak within a few hours, remain 
stable for 12-24 hours and then gradually subside within an additional 6-12 hours, 
to resolve completely within 24-72 hours [201]. In the case of small bowel 
obstruction leading to strangulation, or appendicitis, there will be a continuous 
progressive deterioration of the clinical picture. Most FMF patients are intimately 
familiar with the ‘normal’ pattern of symptoms during a typical abdominal attack, 
and close observation is warranted when the patient reports abdominal complaints 
which are experienced differently [201]. In a small retrospective study of 
abdominal CT scanning in 17 known FMF patients with abdominal symptoms, 
Zissin et al. were able to correctly identify two patients with appendicitis and one 
patient with complicated small bowel obstruction, while in the remaining 14 
patients CT findings were compatible with mild peritonitis and acute surgical 
intervention could be correctly avoided (table 2) [203]. Thus, the use of abdominal 
CT may be a promising tool for differential diagnosis in complicated cases.  
Laleman et al. report the use of fluoro-deoxy-glucose positron-emission 
tomography (FDG-PET) in a patient with suspected FMF and abdominal pain 
[208]. FDG-PET demonstrated diffuse peritoneal uptake, fitting with diffuse 
peritoneal inflammation, but without local obstruction, appendicitis or other bowel 
diseases, such as Crohn’s disease. The authors suggest that the use of FDG-PET 
during an FMF attack may be helpful for establishing the differential diagnosis, 
but its use is precluded by limited availability. Further research into its clinical 
applicability is warranted. 
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Colchicine prophylaxis  
First-line treatment of FMF is colchicine. Its clinical efficacy as prophylaxis in 
FMF was established thirty years ago in three small randomized controlled double-
blind trials [33,34,209]. All three had a crossover design and recorded number of 
fever attacks as primary outcome measure. Zemer et al. [33] included 22 patients 
(18 of whom were men) of Sephardic Jewish origin and 13 patients were included 
in the final analysis. The treatment consisted of twice daily 0.5 mg colchicine or 
placebo for two months each, in random order. The patients had a total number of 
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67.5 attacks during two months of placebo versus 17.5 during colchicine (atypical 
attacks were counted as half; p<0.01). Eleven of 13 patients had fewer attacks on 
colchicine [33]. Dinarello et al. [34] used an alternative crossover design with 
alternating 28-day cycles of colchicine and placebo in random order in each of 
their 11 adult patients. Initial colchicine dose was three times daily 0.6 mg, but this 
dose would be reduced when gastrointestinal side-effects occurred, which in effect 
happened in all patients. In the final analysis, the most used dosage of colchicine 
was twice daily 0.6 mg. The study was terminated after 11 months when an 
interim analysis showed good results. The number of attacks for the total group of 
11 patients was 38 in the placebo versus 7 in the colchicine courses (p<0.001). 
Four of 6 patients who completed the trial benefited significantly from colchicine 
(defined in this study as a difference of at least 5 between total number of attacks 
on placebo versus colchicine) [34]. Goldstein and Schwabe [209] performed a 
study with two 90-day periods of colchicine 0.6 mg thrice daily versus placebo. 
Ten of fifteen patients completed this study; 7 of these were of Armenian origin, 
and 8 were male. On placebo therapy the patients reported a total of 59 attacks 
versus 5 attacks in the colchicine period. In 7 of the 10 patients, no attacks 
occurred while on colchicine. No mention is made of any side-effects or dose 
reduction of colchicine, despite the relatively high treatment dose of 1.8 mg daily 
[209].  
Numerous clinical observational studies have corroborated the results of the initial 
trials. The accumulated experience tells us that  colchicine provides significant 
improvement in up to 90% of patients, while in 60% of patients it will prevent 
attacks altogether [22]. Optimal dosage should be determined in each individual 
patient, to gain a maximal effect with minimal side-effects (see below). General 
recommendation is to start colchicine in a dose of 1 mg daily (either 0.5 mg twice 
daily or 1 mg once a day [24]), and increase this slowly until remission is 
achieved, to a maximum of 2.5 mg/day.  
Colchicine, fertility and children  
Colchicine may affect male fertility by inducing oligospermia or azoospermia, but 
this is relatively rare [210]. Male FMF patients wanting to create progeniture 
should not be deterred from continuous use of colchicine. Colchicine does not 
seem to affect female fertility, frequency of miscarriage or teratogenicity [35,211], 
despite contrary results from in vitro studies. In fact, female fertility and outcome 
of pregnancy have improved in FMF patients using colchicine, due to a decreased 
incidence of peritoneal adhesions and of acute attacks which cause miscarriage 
and/or early delivery [210]. In Israel, pregnant female FMF patients on colchicine 
are offered amniocentesis with karyotyping [210]. However, there is no robust 
evidence that suggests that colchicine use throughout pregnancy carries a 
substantial teratogenic or mutagenic risk when used at recommended 
doses.Colchicine is detected in breast milk of women using the drug, but the dose 
ingested by the infant is less than one tenth of the therapeutic dose (per kg) in 
adults [212], and clinical follow-up of children whose mother continued on 
colchicine while breast-feeding is favourable [210]. Thus, breast feeding is not 
contraindicated during colchicine use. In children, long-term colchicine use has 
been shown to be safe and without a negative effect on growth; rather, the 
cessation of FMF attacks and return to health will improve growth and 
development [210].  
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Alternatives to daily oral colchicine  
Although oral colchicine remains the mainstay of treatment, alternatives to daily 
colchicine to suppress the periodic inflammatory attacks in colchicine-resistant 
patients are actively sought. Before the discovery of the benefit of colchicine, 
numerous other therapies were reported to be effective (e.g. estrogen therapy [213] 
or low-fat diet [214]) but none of these have withstood the test of time or thorough 
controlled investigation.  
It would be desirable to have a drug available that is able to abort inflammatory 
attacks at the very onset of symptoms. Wright et al. [215] report this effect of 
intermittent use of colchine – starting at the earliest suspicion of an attack with a 
course of six tablets of 0.6 mg on the first day of (preliminary) symptoms, and two 
tablets on each of the two following days, distributed evenly over time. In a 
double-blind controlled study, they compared this with placebo in a total of 9 
patients, and found that 21 of 28 attacks were aborted by colchicine  (an aborted 
attack was defined by symptoms lasting less than 8 hours and absence of fever), 
while only 3 of 31 attacks were aborted when treated with placebo [215]. The only 
side-effect reported was diarrhoea. 
Tunca et al. [216] published a pilot study on the use of interferon (IFN) alpha as an 
adjunct to daily colchicine at the onset of a fever attack, after they observed a 
cessation of attacks in a colchicine-resistant FMF patients during 6 months of IFN 
alpha treatment for his chronic hepatitis B [217]. In an open-labelled, uncontrolled 
study, 7 FMF patients on daily colchicine who still experienced fever attacks used 
IFN alpha (3 million IU s.c.) at the earliest onset of a total of 18 attacks, which led 
to rapid resolution of symptoms, in a median of 3 hours time [216]. A formal 
double-blind trial by the same investigators failed to confirm the initial positive 
results [218]. Calguneri et al. [219]  reported use of IFN alpha for 6 months in 7 
colchicine-resistant patients, in a dose of 4.5 million IU s.c. three times a week. 
None of the patients experienced any attack during this period, in contrast to the 
mean number of 26 attacks per year before start of IFN alpha.  
Lidar et al. [220] have tried the addition of weekly intravenous colchicine at a dose 
of 1 mg to oral colchicine in an open-labelled study of 3 months in 13 patients 
with frequent FMF attacks despite high dose of oral colchicine. They found a 
significant reduction in number (mean 4.2 to 1.9 attacks per person) and severity 
of attacks, particularly abdominal and pleural attacks, without side effects. 
However, daily use of colchicine is still recommended in all FMF patients because 
this is the only treatment that has been proved beneficial against development of 
amyloidosis, as follows below. 
Colchicine and amyloidosis  
Compliance to colchicine treatment should be strongly emphasized, even in the 
face of apparent unresponsiveness, as it has been shown to prevent the occurrence 
of the major long-term complication of FMF: amyloidosis. This was nicely 
demonstrated by Zemer et al. [221] in a follow-up study of 960 FMF patients 
during 4 to 11 years after they were recommended to start colchicine (1 to 2 mg 
daily). All patients were free of proteinuria at the onset of the follow-up. Persistent 
proteinuria, taken as a sign of amyloidosis, developed in only 4 of 906 patients 
who adhered to the prophylactic schedule while it occurred in 16 of 54 who 
admitted non-compliance [221]. This latter percentage exactly corresponded to the 
incidence of amyloidosis in a historic control group without treatment. Colchicine 
also seemed to stop further deterioration of renal function in 73 of another group 
of 86 FMF patients with proteinuria at the onset of the study. In 24 FMF patients 
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who had already developed nephritic syndrome or uremia, colchicine did not cause 
improvement, suggesting that amyloidosis had developed to far to be resolved in 
these patients [221]. This same group demonstrated in a subsequent study of 68 
FMF patients with amyloidosis in a follow-up of 5 or more years that the 
therapeutic dosage of colchicine for amyloidosis in FMF is >1.5 mg/day, and that 
this is only effective in this first stages of amyloidosis before overt deterioration of 
renal function [222]. 
Since the introduction of colchicine, the incidence of amyloidosis in FMF has 
dropped dramatically. Amyloidosis was previously observed in 30-50% of FMF 
patients and in areas with a high prevalence of FMF, where colchicine is not 
routinely available, such as Armenia, amyloidosis is still common.  
Management of abdominal attack  
During an abdominal attack, conservative management is the mainstay. Colchicine 
is ineffective for the full-blown acute FMF attack. Diclofenac (75 mg administered 
intramuscularly) may be used for pain relief [24]. Other agents (e.g. reserpine, 
steroids) have only limited efficacy. Many patients become familiar with their 
disorder and deal with the inflammatory attacks at home, without consulting a 
doctor, once they know the diagnosis and its consequences.  
When a FMF patient presents with an atypical course of an abdominal attack, close 
observation is warranted to exclude complications, such as adhesive small bowel 
obstruction and strangulation (see above). Elective laparoscopic appendectomy has 
been suggested in FMF patients to prevent unnecessary emergency surgery [223], 
but this has not been recommended by others, because any surgical procedure may 
provoke an attack and add to the formation of adhesions [24]. 
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Crampy abdominal pain, diarrhoea and nausea due to hyperperistalsis are frequent 
side effects of colchicine [224,225]; these adverse effects are most pronounced 
with maximum therapeutic doses. Gastrointestinal intolerance is used in clinical 
practice as a parameter of dose titration and may serve as a warning to protect 
patients from toxic doses.  
Colchicine intoxication is a rare, but serious and potentially lethal complication. In 
general, the severity of the reaction correlates with the dose administered and a 
high case-fatality rate is associated with an oral dose above 40 mg in adults, but 
there is considerable individual variability and lethal toxicity has been described 
with doses as low as 7 mg orally [224]. Risk factors for colchicine intoxication 
[224] are intravenous use, use of loading doses, use in elderly patients, prior 
maintenance colchicine use, excretory organ failure (renal or hepatic dysfunction) 
and drug interactions (especially cimetidine and other cytochrome P-450 inhibitors 
and cyclosporine [201]). 
Clinical presentation of intoxication starts with a gastrointestinal phase 
characterized by diffuse abdominal pain, nausea, vomiting and severe 
(haemorrhagic) diarrhoea, which may develop into paralytic ileus. This is 
accompanied by volume depletion and hypotension [224,225]. From 24 to 72 
hours after ingestion, multiorgan failure may develop, including bone marrow 
depression, renal failure, adult respiratory distress syndrome, heart failure and 
disseminated intravascular coagulation [224]. If the patient survives this second 
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phase, recovery will set in thereafter, typically accompanied by alopecia. The hair 
loss is usually reversible, but permanent alopecia has been described [224]. 
Management of colchicine intoxication is mainly supportive and symptomatic. 
Because of the rapid distribution of colchicine and its high binding affinity, 
haemodialysis and plasma exchange are ineffective [224]. There is no specific 
antidote available; immunotherapy with anticolchicine antibodies is still in 
development. 
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As mentioned above, type AA systemic amyloidosis is a serious complication of 
FMF. This type of amyloid fibrils may be deposited in many organs, including the 
kidneys, adrenals, intestines, spleen, liver, stomach, thyroid gland, heart and lungs 
[201]. Clinically, the kidneys are the most significant organs involved, as 
amyloidosis will eventually impair renal function and lead to kidney failure.  
Microscopic evidence for amyloid depositions in the gastrointestinal tract can be 
found early in the course of FMF. Nevertheless, amyloidosis of the intestines will 
only result in clinical symptoms in a minority of patients and often only after many 
years of asymptomatic amyloid deposition, when the entire wall of the small 
intestine is affected [226]. These symptoms may include constipation or intractable 
diarrhoea and severe malabsorption, especially in the case of bacterial overgrowth 
and bile acid deconjugation due to decreased mobility of the small intestine [201]. 
However, it may be difficult to differentiate amyloidosis-induced diarrhoea from 
colchicine-induced diarrhoea [201]. 
Another possible manifestation of amyloidosis in the intestinal tract is ischemic 
enterocolitis [227,228], which may result in fibrosis, mucosal ulceration or colonic 
obstruction or perforation. Clinical, radiological and histopathological features of 
amyloid-associated ischemic enterocolitis may mimic those of Crohn’s disease, 
except for the absence of transmural lymphoid aggregates and granulomas 
[228,229]. Spontaneous rupture of an amyloid spleen, resulting in acute abdomen, 
as is sometimes described in AL type amyloidosis [230], is rarely seen in AA type 
amyloidosis [231], and has never been described in FMF. 
In recent years, the incidence of clinical manifestations of extra-renal amyloidosis 
is increasing and associated with longer survival in patients with renal amyloidosis 
due to hemodialysis and renal transplantation [201], although the overall incidence 
of amyloidosis has declined due to the use of colchicine. It is not yet known 
whether colchicine also has a beneficial effect on gastrointestinal amyloidosis, as 
is seen in renal amyloidosis. Often, the dose of colchicine optimal for anti-
amyloidogenic effect (2 mg per day) cannot be tolerated by patients with 
gastrointestinal amyloidosis, which aggravates the diarrhoea. 
Diagnosis of amyloidosis requires tissue biopsy, preferentially of the involved 
organ (usually rectal biopsy or renal biopsy); an alternative to obtain tissue is fine-
needle aspiration of abdominal fat pad, although one small study suggests that this 
might not be very sensitive in FMF [232]  The tissue sample is then stained with 
Congo Red to detect amyloid deposits. Further classification of the type of 
amyloid can be done by immunohistochemistry with specific antibodies [233].   
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Several inflammatory diseases have been found in association with FMF, some of 
which may be accompanied by abdominal pain. Such associations may complicate 
clinical interpretation of the symptoms and may thwarth diagnosis.  
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An increased prevalence of inflammatory bowel disease in FMF was reported in 
two studies. Cattan et al. [234] described 3 patients with concomitant FMF and 
either Crohn’s disease or ulcerative colitis in a group of 300 FMF patients from 
173 families of non-Ashkenazi Jewish descent; eight other persons in these 
families studied had inflammatory bowel disease without FMF. Crohn’s disease 
was diagnosed in 7 of nearly 5000 FMF-patients from the FMF-registry in Tel 
Hashomer, Israel [235]. While Cattan et al. [234] found that the patients with 
inflammatory bowel disease in the FMF families were more severely affected, 
Fidder et al. [235] report similar severity on comparison with a Crohn’s disease 
control group, although the prevalence of amyloidosis was increased. This 
association of Crohn’s disease with FMF is interesting in the light of the recent 
findings of NOD2 gene mutations as a susceptibility factor in Crohn’s disease. The 
NOD2 (or CARD15) protein belongs to a family of proteins involved in 
inflammation and apoptosis and is (indirectly) related to the pyrin domain family. 
The defects underlying Crohn’s disease and FMF are thus thought to be located in 
closely related areas of inflammation and might have a modifying effect on each 
other.  It remains to be seen whether FMF patients with concomitant inflammatory 
bowel disease do have specific NOD2 gene mutations. However, questions might 
be raised about the diagnosis of inflammatory bowel disease in some FMF 
patients, in the light of the similarity between ischemic enterocolitis due to 
amyloidosis and Crohn’s disease [228] and based on the fact that not all FMF-
cases were confirmed by demonstration of transmural granulomas and lymphoid 
aggregates in biopsies [234,235], while proteinuria due to amyloidosis was more 
prevalent in this group. 
A number of types of vasculitis, which may be accompanied by abdominal 
symptoms, have been associated with FMF as well [201,236], although it could be 
questioned in some cases, whether vasculitis is a manifestation of FMF, rather than 
an associated disorder.  
Behçet’s disease (found in 16 of 4000 FMF patients [237]) is an episodic 
inflammatory disorder of unknown pathogenesis, with a broad clinical picture that 
may include oral and genital aphthous ulcers, pustulosis, erythema nodosum, 
arthritis, central nervous system involvement and pathergy (hyperreactive skin 
lesion evoked by a needle prick) [238]. Abdominal pain and diarrhea are common 
as well; this type of abdominal pain is usually more prolonged than the short 
abdominal attacks seen in FMF. A second type of vasculitis, reported more 
frequently in FMF patients, is Henoch-Schönlein´s purpura (4-7% of FMF patients 
[23,239,239]) often in a severe form; gastrointestinal symptoms in Henoch-
Schönlein´s purpura may include colicky abdominal pain, nausea, vomiting, 
diarrhoea or constipation and frequently stools with blood or mucus are observed 
[201]. Thirdly, the systemic necrotizing vasculitis, polyarteritis nodosa (PAN), is 
found in 1% of FMF patients [239,240] and may lead to abdominal symptoms 
ranging from vague non-specific pain to bowel infarction and perforation due to 
ischemia [201]. 
Three case reports have been published on patients who developed peritoneal 
mesothelioma after years of abdominal FMF attacks [241-243]. The development 
of malignancy was suggested to be linked to the chronic recurrent peritonitis, but 
questioned by others [201]. 
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FMF is part of an expanding group of hereditary disorders known as familial 
autoinflammatory syndromes, which are commonly characterized by recurrent 
episodes of fever and inflammation [4]. Abdominal pain and other signs of 
abdominal distress are also frequently seen in the TNF-receptor associated 
periodic syndrome (TRAPS) [54] and the hyper-IgD and periodic fever syndrome 
(HIDS) [46].  
In HIDS, the clinical presentation of abdominal pain is usually less dramatic, and 
often the pain is more crampy than fitting with full-blown serositis. Other frequent 
symptoms and signs are (cervical) lymphadenopathy, headache, myalgia, 
arthralgia and a erythematous skin rash [46]. The fever episodes generally last 
somewhat longer than in FMF, usually 4 to 6 days, and they start within the first 
year of life [4]. Characteristically, a continuously high concentration of 
immunoglobulin D (IgD) and IgA is detected in serum. Inheritance pattern of 
HIDS is autosomal recessive. HIDS is caused by mutations in the gene encoding 
for mevalonate kinase, an enzyme in the isoprenoid pathway [2,3]. 
TRAPS is usually distinguished by inflammatory episodes of longer duration; 
attacks of 14 to 21 days are often seen, although episodes of a few days may occur 
[58,60]. Apart from abdominal distress, the high spiking fever during such 
episodes may be accompanied by myalgia, arthralgia, migratory erythematous skin 
lesions and ocular involvement, including conjunctivitis and periorbital edema [4]. 
The genetic mutations in TRAPS are found in the gene encoding the type 1 TNF-
receptor [7].; it is autosomal dominantly inherited  
Unnecessary laparotomies, intraperitoneal adhesions and small bowel obstruction 
are complications of both HIDS and TRAPS, as seen in FMF. Abdominal pain is 
more rarely reported in the clinical spectrum of cryopyrin-associated periodic 
syndromes, which are characterized by joint or skin manifestations, among other 
features [66,70,73].  
0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Familial Mediterranean fever is a hereditary syndrome characterized by recurrent 
episodes of fever and serositis, resulting in pain in the abdomen, chest, joints and 
muscles. It is primarily found in people of Jewish, Arabic, Turkish and Armenian 
ancestry. Causative mutations are located in the MEFV gene, which encodes for 
the protein pyrin. 
Abdominal FMF attacks present clinically as an ‘acute abdomen’ with severe 
abdominal pain and rigidity, which resolve spontaneously within 3-4 days. It is 
important to distinguish these attacks from small bowel obstruction due to 
adhesions, a serious complication of FMF. In the case of a FMF attack, surgery 
will be of no help and will only increase the risk of adhesions, while in adhesive 
small bowel obstruction surgical intervention should not be delayed in order to 
prevent life-threatening bowel strangulation. Distinction can be made on close 
observation of the clinical course, while abdominal imaging by CT may be helpful. 
FMF is effectively treated by use of oral colchicine in more than 90% of patients. 
However, abdominal pain and diarrhoea are frequently observed side-effects of 
colchicine use, and may also represent the first phase of colchicine intoxication. 
Abdominal pain in FMF patients may also be caused by one of the associated 
types of vasculitis, such as Behçet’s disease or Henoch Schönlein´s purpura. 
Abdominal pain in FMF 
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Recurrent episodes of fever and abdominal pain are also seen in other 
autoinflammatory syndromes, especially TNF-receptor associated periodic 
syndrome and hyper-IgD syndrome. 
 
Practice points 
• Abdominal attacks in FMF are characterized by signs of ‘acute abdomen’, but will 
resolve spontaneously within 3-4 days. 
• FMF is a hereditary syndrome characterized by lifelong recurrent episodes of 
fever and serositis (mainly peritonitis).  
• FMF is especially prevalent in people from the Mediterranean, including 
Sephardic Jews, Arabs, Turks, and Armenians. 
• Diagnosis of FMF is based on a set of clinical criteria, and may be confirmed by 
DNA analysis of the MEFV gene. 
• Treatment of FMF consists of colchicine. 
• The recurrent peritonitis may lead to peritoneal adhesions and small bowel 
obstruction 
• It is important to differentiate between small bowel obstruction and the abdominal 
FMF attack. 
• The first phase of potentially life-threatening colchicine intoxication is 
characterized by diffuse abdominal pain, nausea, vomiting and (haemorrhagic) 
diarrhoea. 
 
 
 
Research agenda 
• The exact function of pyrin, the mutated protein in FMF, needs to be determined. 
• Detailed controlled studies are necessary to define the best method of pain relief 
in FMF. 
• The precise mechanism of action of colchicine needs to be determined. 
• Further development of a diagnostic tool to distinguish an abdominal FMF attack 
from other causes of ‘acute abdomen’ is warranted. 
• Other therapies to prevent and combat inflammatory attacks and to prevent 
amyloidosis should be sought for. 
 14 
 
 Epilogue 
General summary 
Epilogue 
 
166 
The subject of this thesis is a group of rare hereditary disorders, collectively called 
auto-inflammatory syndromes, with a specific focus on the hyper-IgD and periodic 
fever syndrome (HIDS). The autoinflammatory disorders are characterized by 
lifelong recurrent episodes with fever, usually accompanied by other inflammatory 
symptoms such as abdominal pain, diarrhoea, rash or arthralgia. The inflammatory 
episodes are separated by symptom-free intervals. 
 
In chapter 1 we describe the clinical characteristics of these syndromes in detail. 
Diagnosis of an autoinflammatory syndrome needs to be considered in a patient 
with a history of years of inflammatory attacks with symptom-free intervals in 
between. The inheritance pattern along with specific hallmarks will usually point 
to the right diagnosis.  
 
The discovery of the causative genes has had an enormous impact in the field of 
periodic fevers. Earlier investigations had shown that mutations in mevalonate 
kinase (MVK) gene cause HIDS. Chapter 2 reports our investigations into the 
genotype in a series of HIDS patients and offers a much broader view as we 
detected 11 different missense mutations, one deletion and the absence of 
expression of one allele. The large majority of the patients were compound 
heterozygotes for two mutations. Of these, V377I is the most common mutation, 
followed by I268T. On the basis of this study, we propose that the diagnostic 
screen of the MVK gene in HIDS should be first directed on V377I and I268T 
mutations. 
 
In the study described in chapter 3, we wanted to ascertain the role of MVK 
mutations and usefulness of molecular diagnosis in HIDS in a cross-sectional 
study of 54 patients. Mutation analysis revealed mutations in the MVK gene in 41 
patients (subsequently designated as “classic type HIDS”), while in 13 of the 54 
patients no mutation could be detected even though they did exhibit the clinical 
phenotype of HIDS and completely fulfilled the clinical criteria (“variant type 
HIDS”). Classic type HIDS patients had lower mevalonate kinase enzyme 
activities, higher IgD concentrations, and more additional symptoms with attacks. 
We propose to diagnose HIDS using clinical criteria; these patients can then be 
divided into classic type and variant type HIDS patients by genetic analysis. The 
classic type HIDS patients are a relatively homogeneous group with a predictable 
inheritance pattern and clinical presentation, which facilitates the counselling of 
the individual patient. The group of variant type HIDS patients is more 
heterogeneous and may represent several different as-yet-undefined disorders. 
 
Both mevalonic aciduria, characterized by psychomotor retardation, cerebellar 
ataxia, recurrent fever attacks and death in early childhood, and HIDS, with 
recurrent fever attacks without neurological symptoms, are caused by a functional 
deficiency of mevalonate kinase (MK). In a systematic review of known MK 
deficient patients (chapter 4), we identified 5 adults with phenotypical overlap 
between these two syndromes, which argues for a continuous spectrum of disease. 
One explanation for the varying degree in severity might be the genotype involved, 
but this cannot be the whole answer. Genetic trans-acting or environmental factors 
will have to be considered to explain the phenotypic variability. 
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The aim of the study in chapter 5 was to further define the acute phase response in 
the inflammatory attacks in classical HIDS patients, primarily to try to 
discriminate between (serious bacterial) infection and non-infectious inflammation 
of a HIDS attack. One of the proteins of interest was procalcitonin, which reaches 
high serum concentrations during infection. In only 2 of 22 HIDS patients, 
procalcitonin concentration rose above 2 ng/mL during fever attack, compatible 
with the non-infectious nature of these attacks. Thus the combination of high CRP 
concentration plus procalcitonin concentration <2 ng/mL in a symptomatic HIDS 
patient may indicate a febrile attack without (bacterial) infection; although this 
observation warrants further investigation for its usefulness as a marker in clinical 
practice.  
 
In chapter 6, we asked ourselves the question why classic type HIDS families, 
especially those carrying a V377I mutation in the MVK gene, are mainly from the 
Netherlands. Through an extensive haplotype study, we established that this V377I 
mutation, originates from a common ancestral haplotype. Data suggest that a 
founder of this haplotype came from the Netherlands, and that the mutation was 
spread from there to the rest of the world.  
 
Chapter 7 examines the effect of an excessive amount of mevalonic acid, the 
substrate for mevalonate kinase, on isolated peripheral blood mononuclear cells. 
This study shows that an excess amount of mevalonic acid exhibits a pro-
inflammatory effect, most pronounced in terms of IL-6 secretion. The effect is 
primarily mediated via IL-1 as it can be completely blocked by addition of IL-1ra. 
This may be central to the pathogenesis of HIDS.  
 
The next two chapters describe two clinical trials in HIDS. 
In chapter 8, six classic type HIDS patients who had at least one febrile attack 
every 6 weeks, entered a randomized, double-blind, placebo-controlled crossover 
trial to explore the efficacy of a daily 200-mg thalidomide dose in the treatment of 
recurrent febrile attacks. The effect of thalidomide, a drug known to inhibit 
production of several cytokines, in HIDS was limited to a slight decrease in acute 
phase protein concentration without an effect on the attack rate. Next, we explore 
the effect of simvastatin, an inhibitor of HMG-CoA reductase, one enzyme step 
prior to MK in chapter 9. Six classic type HIDS patients were enrolled a double-
blind clinical trial consisting of  two treatment periods with either simvastatin 80 
mg daily or placebo for 24 weeks, separated by a 4-week washout period. 
Simvastatin resulted in a drop in urinary mevalonic acid concentration in all 
patients and decreased the number of febrile days in five out of six patients. No 
side effects were observed. These data suggest that simvastatin improves 
inflammatory attacks in the hyper-IgD syndrome. This also highlights the anti-
inflammatory properties of HMG-CoA reductase inhibition. 
 
Apart from a common phenotype of lifelong recurrent inflammatory attacks, all of 
the hereditary autoinflammatory syndromes have distinct features and specific 
therapeutic options, increasing the need for a specific diagnosis in each case. In 
chapter 10, we examined whether genetic screening would allow classification of 
previously unclassified patients. This yields only one possible diagnosis of FMF in 
the 60 previously unclassified patients. Thus, screening of known genes involved 
in these disorders does not result in significant additional  information. Differential 
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diagnosis of hereditary autoinflammatory syndromes is possible with thorough 
clinical examination followed by targeted genetic analysis of one or two most 
likely syndromes.  
 
In the next three chapters, we take a closer look at TRAPS.  
In chapter 11, we describe two Dutch TRAPS patients suffering from recurrent 
fever attacks who went undiagnosed for more than 40 years. The use of a short 
course of etanercept, a recombinant p75-TNFR:Fc fusion protein, at the time of 
attack consistently induced prolonged remission in one of these patients. This 
suggests that it is not necessary to subject TRAPS patients to continuous twice 
weekly etanercept injections, but that a short course at time of attack is sufficient. 
Another TRAPS patient is described in chapter 12. This patient developed the 
most dreaded complication of TRAPS, systemic amyloidosis, leading to renal 
failure. She experienced a cessation of inflammatory attacks, which coincided with 
the deterioration of her renal function. We demonstrated elevated plasma 
concentrations of soluble TNF receptor, which is cleared from the body by the 
kidneys. It is our impression that this increased soluble TNF receptor 
concentration protects her from further attacks of fever. 
Chapter 13 reports the beneficial response of a young patient with a severe, 
treatment-resistant form of TRAPS to the recombinant IL-1ra protein Anakinra. It 
is generally assumed that in TRAPS the inflammatory effects of TNFα and 
lymphotoxin (LT) are not countered adequately, because of a lack of soluble TNF-
receptor, the major inhibitor of TNF. In that light it is difficult to explain the 
effectiveness of IL-1ra, since IL-1 is responsible for only a small part of the 
biological effects of TNFα and LT.  Further research is required to elucidate the 
enigmatic role of IL-1 even in TRAPS. 
 
Lastly, we turn to FMF in chapter 14. Abdominal FMF attacks present clinically 
as an ‘acute abdomen’ with severe abdominal pain and rigidity, which resolve 
spontaneously within 3-4 days. It is important to distinguish these attacks from 
small bowel obstruction due to adhesions, a potentially life-threatening 
complication of FMF. Distinction can be made by close observation of the clinical 
course, while abdominal imaging by CT may be helpful. 
'		(
The results described in chapter 7, on the role of mevalonic acid and IL-1 in HIDS, 
have left a number of questions unanswered concerning the pathogenesis of this 
disorder. Current evidence points to toxicity of MVA rather than shortage of an 
isoprenoid end-product. How does mevalonic acid exert its pro-inflammatory 
effect – through its influence on the isoprenoid pathway, or through some more 
direct effect? How can the pathogenesis of HIDS be linked to that of the other 
hereditary autoinflammatory syndromes – in other words, where does the 
inflammasome, thought to be central in the pathogenesis of FMF and cryopyrin-
associated periodic syndromes, fit in? Another field which is likely to yield 
interesting results for this group of disorders is (regulation of) apoptosis.  
Unravelling of the pathogenesis of HIDS will continue to provide suggestions for 
possible new treatment options. Simvastatin is successful in reducing the number 
of days of illness in HIDS, as reported in chapter 9, though it is not a complete 
cure. It will especially be of interest to find a treatment which can be offered at 
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time of attack to curtail the inflammatory symptoms, and which could if necessary 
be used in addition to continuous prophylactic treatment with simvastatin. Taking 
into account the beneficial report on the TNF-inhibitor etanercept in two young 
HIDS patients [172], this will be a promising option to investigate. The results of 
chapter 7 suggest that it will be worthwhile to investigate the effect of IL-1ra 
(Anakinra) in HIDS. 
The discovery of causative genes, treatment options and research into 
pathogenesis, as also described in this thesis, has been made possible only because 
of the accurate phenotypical characterisation of patients with periodic fever. 
Careful analysis and proper clustering of these patients is indispensable in order to 
allow the elucidation of the genetic background as well as the evaluation of 
possible treatment options. This is greatly stimulated by development of central 
periodic fever registries, such as the International HIDS registry in Nijmegen (see 
website hids.net), which also afford the opportunity to appreciate previously 
unrecognised symptoms. Even yet, despite recent research, many periodic fever 
patients do not fall in one of the above-mentioned disease categories. This 
represents a great challenge. It is to be expected that in the future other periodic 
fever syndromes and corresponding genes will be discovered.  
Up till now, the International HIDS registry mainly contains data gathered at the 
time patients are included in the database, which allows us to do cross-sectional 
studies. It is our plan to try and extend this in the near future with follow-up data, 
to enable us to study natural course and prognosis of HIDS. Such information has 
not been obtained in any systematic way so far. One of the interesting aspects of 
the prognosis of HIDS is the virtual absence of systemic amyloidosis as a 
complication of this chronic recurrent inflammatory disorder; research in this field 
is likely to yield valuable information on the pathogenesis of systemic amyloidosis 
in general. 
Even after twenty years, the role of IgD in HIDS remains obscure (see also chapter 
5), and IgD is still the orphan among the immunoglobulins. Not all patients that 
have MVK gene mutations and a diminished MK activity will have a high serum 
IgD, while IgD concentration may be (moderately) high in other disorders. This 
had led some  researchers to suggest that the name HIDS (Hyper-IgD and periodic 
fever syndrome) is not appropriate anymore to describe this hereditary 
autoinflammatory disorder, because it puts too much emphasis on IgD. While this 
may be true, we have to point out that this name is well anchored in the medical 
literature and enjoys wide recognition. Given the fact that the exact pathogenesis 
of HIDS is still unknown, we feel that suggestions for a change of name are rather 
premature at this time. 
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Het onderwerp van dit proefschrift is een groep zeldzame erfelijke aandoeningen 
die autoinflammatoire syndromen genoemd worden, met speciale aandacht voor 
het hyper-IgD en periodieke koorts syndroom (HIDS). De autoinflammatoire 
syndromen worden gekenmerkt door levenslang terugkerende episoden met koorts, 
meestal vergezeld van andere symptomen van ontsteking zoals buikpijn, diarrhee, 
huiduitslag of arthralgie. Deze perioden met ontsteking worden afgewisseld door 
een symptoom-vrij interval. 
 
In hoofdstuk 1 beschrijven we de klinische kenmerken van deze syndromen. De 
diagnose van een autoinflammatoir syndroom dient te worden overwogen bij een 
patiënt met een voorgeschiedenis van jarenlange ontstekingsaanvallen afgewisseld 
met perioden zonder symptomen. Het overervingspatroon in combinatie met een 
aantal specifieke kenmerken geeft meestal voldoende aanwijzingen om tot de 
juiste diagnose te komen. 
 
De ontdekking van de betrokken genen heeft een enorme invloed gehad op het 
onderzoek naar periodieke koorts. Eerder onderzoek had uitgewezen dat HIDS 
wordt veroorzaakt door mutaties in het mevalonaat kinase (MVK) gen. Hoofdstuk 
2 vermeldt de resultaten van ons onderzoek naar het genotype in een groep HIDS 
patiënten. De meerderheid van de patiënten was samengesteld heterozygoot voor 
twee mutaties. V377I is de meest voorkomende mutatie, gevolgd door I268T. Op 
basis van dit onderzoek raden wij aan bij een diagnostisch onderzoek van het MVK 
gen in HIDS eerst te kijken naar V377I en I268T mutaties. 
 
Het onderzoek beschreven in hoofdstuk 3 had als doel de rol vast te stellen van 
MVK mutaties en het nut van DNA-diagnostiek in HIDS. In een groep van 54 
patiënten werden mutaties in het MVK gen gevonden bij 41 patiënten (hierna 
aangeduid als “klassieke type HIDS”), terwijl in de 13 andere patiënten geen 
mutaties gevonden werden hoewel ze voldeden aan de klinische criteria voor 
HIDS (“variant type HIDS”). Klassieke type HIDS patiënten hadden minder 
mevalonaat kinase enzymactiviteit, hogere concentraties van IgD, en meer 
bijkomende symptomen tijdens een koortsaanval. Het is ons voorstel om de 
diagnose HIDS te stellen op basis van klinische criteria; deze patiënten kunnen dan 
onderverdeeld worden in klassieke type en variant type HIDS door genetisch 
onderzoek. De klassieke type HIDS patiënten vormen een relatief homogene groep 
met een bekend overervingspatroon en klinische presentatie – dit kan helpen in de 
begeleiding van de individuele patiënt. De groep van variant type HIDS patiënten 
is veel diverser en het is goed mogelijk dat deze groep bestaat uit patiënten die in 
feite leiden aan andere tot op heden nog-niet-beschreven autoinflammatoire 
aandoeningen. 
 
Zowel klassieke mevalonacidurie, gekenmerkt door psychomotore retardatie, 
cerebellaire ataxie, periodieke koortsaanvallen en overlijden op jonge leeftijd, als 
HIDS, met periodieke koortsaanvallen zonder neurologische symptomen, wordt 
veroorzaakt door een functionele deficiëntie van mevalonaat kinase (MK). Na 
systematissche evaluatie van bekende MK-deficiënte patiënten (hoofdstuk 4) 
konden we 5 volwassen patiënten identificeren met een overlappend fenotype van 
deze twee syndromen. Dit pleit voor een continu spectrum van ziekte. De variatie 
in ernst zou deels veroorzaakt kunnen worden door het specifieke onderliggende 
genotype, maar dit kan niet alles verklaren. Om deze fenotypische variabiliteit 
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volledig te verklaren zal gekeken moeten worden naar “genetic trans-acting” en/of 
naar omgevingsfactoren. 
 
Het doel van het onderzoek in hoofdstuk 5 was het nader beschrijven van de acute 
fase respons tijdens de ontstekingsaanvallen in klassieke type HIDS patiënten, met 
name om te proberen het onderscheid te maken tussen (ernstige bacteriële) infectie 
en de niet-infectieuze ontsteking van een HIDS-aanval. Hierbij hebben we onder 
andere gekeken naar het eiwit procalcitonine, dat tijdens infectie een hoge serum 
concentratie bereikt. In slechts 2 van 22 HIDS patiënten kwam de procalcitonine 
concentratie boven de 2 ng/mL tijdens een koortsaanval, wat past bij het niet-
infectieuze karakter van deze aanvallen. De combinatie van een hoge CRP-
concentratie met een procalcitonine concentratie <2 ng/mL in een symptomatische 
HIDS-patiënt zou dus kunnen wijzen op een koortsaanval zonder (bacteriële) 
infectie. Nader klinisch onderzoek zou moeten uitwijzen of dit bij de begeleiding 
van individuele patiënten van nut zou kunnen zijn. 
 
In hoofdstuk 6 vroegen we onszelf af waarom klassieke type HIDS families, met 
name diegenen met een V377I mutatie in het MVK gen, vooral afkomstig zijn uit 
Nederland. Met behulp van een uitgebreid haplotype onderzoek hebben we kunnen 
vaststellen dat deze V377I mutatie deel uitmaakt van een gemeenschappelijk 
voorouderlijk haplotype. Onze data suggereren dat de grondlegger van dit 
haplotype afkomstig was uit Nederland, en dat de mutatie zich hiervandaan 
verspreid heeft over de rest van de wereld. 
 
Hoofdstuk 7 onderzoekt het effect van een overmatige hoeveelheid mevalonzuur, 
het substraat van mevalonaat kinase, op geïsoleerde mononucleaire cellen uit 
perifeer bloed. Dit onderzoek laat zien dat zo’n overmatige hoeveelheid 
mevalonzuur een pro-inflammatoir effect heeft, met name in de vorm van IL-6 
secretie. Het effect wordt gemedieerd door IL-1, want het kan volledig 
geblokkeerd worden door toevoeging van de IL-1 antagonist IL-1ra. Dit effect zou 
een centrale rol kunnen spelen in de pathogenese van HIDS. 
 
De volgende twee hoofdstukken beschrijven twee klinische trials in HIDS. 
In hoofdstuk 8 hebben zes klassiek type HIDS patiënten met tenminste één 
koortsaanval iedere zes weken deelgenomen aan een gerandomiseerd, dubbelblind, 
placebo-gecontroleerd cross-over onderzoek om het effect van een dagelijkse dosis 
van 200 mg thalidomide op de periodieke koortsaanvallen te bestuderen. Het effect 
van thalidomide, een geneesmiddel waarvan bekend is dat het de productie van 
verscheidene cytokinen remt, bleef beperkt tot een lichte daling van de 
concentratie van acute fase eiwitten zonder effect op de duur, ernst of frequentie 
van de koortsaanvallen.  
Aansluitend bestudeerden we het effect van simvastatine, een remmer van HMG-
CoA reductase, één enzymstap voor mevalonaat kinase, zoals beschreven in 
hoofdstuk 9. Zes klassiek type HIDS patiënten werden geïncludeerd in een 
dubbelblind klinisch onderzoek bestaande uit twee behandelperiodes met 
simvastatine 80 mg per dag of placebo gedurende 24 weken, gescheiden door een 
uitwasperiode van 4 weken. Simvastatine gaf een daling van urine concentraties 
mevalonzuur in alle patiënten en verminderde het aantal dagen koorts in vijf van 
de zes patiënten. Er werden geen bijwerkingen waargenomen. Deze resultaten 
laten zien dat simvastatine een gunstig effect heeft op de koortsaanvallen in HIDS. 
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Ze benadrukken daarnaast nog eens de anti-inflammatoire eigenschappen van 
remming van HMG-CoA reductase. 
 
Ook al hebben alle erfelijke autoinflammatoire syndromen een gemeenschappelijk 
fenotype van levenslang terugkerende aanvallen van ontsteking, toch hebben ze  
onderscheidende kenmerken en specifieke therapeutische opties, wat het vinden 
van de specifieke diagnose in elke patiënt steeds belangrijker maakt. In hoofdstuk 
10 hebben we onderzocht of genetische screening nadere classificatie van 
voorheen ongeclassificeerde periodieke koorts patiënten mogelijk zou maken. Dit 
leverde slechts één mogelijke diagnose van FMF op in een groep van 60 voorheen 
ongeclassificeerde patiënten. Screening van alle bekende genen die betrokken zijn 
bij deze aandoeningen levert dus geen significante extra informatie op. 
Differentiële diagnostiek van de erfelijke autoinflammatoire syndromen is 
mogelijk door grondig klinisch onderzoek gevolgd door gericht genetisch 
onderzoek van één of twee van de meest waarschijnlijke syndromen. 
 
In de volgende drie hoofdstukken wordt meer aandacht besteed aan TRAPS. 
In hoofdstuk 11 beschrijven we twee Nederlandse TRAPS-patiënten met 
periodieke koortsaanvallen waarvoor gedurende meer dan 40 jaar geen diagnose 
gesteld kon worden. Toediening van een korte kuur met etanercept, een 
recombinant p75-TNFR:Fc fusie-eiwit, op het moment van een aanval resulteerde 
in een langdurige remissie in één van deze patiënten. Dit wijst erop dat het niet 
nodig is om TRAPS-patiënten continu te behandelen met etanercept injecties, 
omdat een korte kuur op het moment van een aanval voldoende is. 
Een andere TRAPS-patiënt wordt beschreven in hoofdstuk 12. Deze patiënt 
ontwikkelde de meest gevreesde complicatie van TRAPS, systemische 
amyloidose, leidend tot nierfalen. Op het moment dat haar nierfunctie ernstig 
achteruitging stopten haar koortsaanvallen. We vonden een verhoogde plasma 
concentratie van de oplosbare TNF-receptor, die normaal gesproken door de nieren 
geklaard wordt. Het is onze indruk dat deze verhoogde oplosbare TNF-receptor 
concentratie haar beschermt tegen de koortsaanvallen. 
Hoofdstuk 13 rapporteert de goede respons op het recombinante IL-1ra eiwit 
Anakinra in een jonge patiënte met een ernstige vorm van TRAPS, die tot die tijd 
nauwelijks te behandelen was. De geldende hypothese over de pathogenese van 
TRAPS luidt dat het inflammatoire effect van TNF en lymphotoxine (LT) niet 
voldoende wordt afgeremd door een tekort aan oplosbare TNF-receptor, de 
voornaamste remmer van TNF. Bezien in dat licht is het moeilijk om de 
effectiviteit van IL-1ra te verklaren, omdat IL-1 slechts verantwoordelijk is voor 
een klein deel van de biologische effecten van TNF en LT. Meer onderzoek is 
nodig om de enigmatische rol van IL-1, zelfs in TRAPS, op te helderen. 
 
Als laatste besteden we aandacht aan FMF in hoofdstuk 14. Abdominale FMF 
aanvallen presenteren zich klinisch als een ‘acute buik’ met ernstige buikpijn en 
“défense musculaire”, die binnen 3-4 dagen spontaan geneest. Het is belangrijk om 
deze aanvallen te kunnen onderscheiden van dunne darmileus ten gevolge van 
adhesies, een potentieel levensbedreigende complicatie van FMF. Dit onderscheid 
kan gemaakt worden door nauwgezette observatie van het klinisch beloop, terwijl 
een CT-scan van het abdomen hierbij behulpzaam kan zijn. 
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De resultaten beschreven in hoofdstuk 7, over de rol van mevalonzuur en IL-1 in 
HIDS, laten een aantal vragen over de pathogenese van deze aandoening 
onbeantwoord. Deze resultaten wijzen op een toxiciteit van mevalonzuur, in plaats 
van tekort aan een isoprenoid eindproduct. Op welke manier geeft mevalonzuur dit 
pro-inflammatoire effect – door beïnvloeding van het isoprenoid metabolisme, of 
op een meer directe manier? Hoe kan de pathogenese van HIDS gerelateerd 
worden aan dat van de andere erfelijke autoinflammatoire syndromen – anders 
gezegd, wat is de plaats van het inflammasoom, dat zo centraal lijkt te staan in de 
pathogenese van FMF en cryopyrine-geassocieerde syndromen? Een ander 
onderzoeksterrein waarvan interessante resultaten te verwachten zijn voor deze 
groep aandoeningen is (regulatie van) apoptose. 
Het ophelderen van de pathogenese van HIDS zal steeds nieuwe suggesties voor 
mogelijke behandeling opleveren. Simvastatine vermindert het aantal ziektedagen 
in HIDS (hoofdstuk 9), hoewel het niet leidt tot complete genezing. Het is met 
name interessant om een therapie te ontwikkelen die op het moment van een 
aanval de ontstekingssymptomen kan afremmen, en die zo nodig naast de continue 
profylactische behandeling met simvastatine gebruikt kan worden. Gelet op de 
gunstige resultaten van de TNF-remmer etanercept in twee jonge HIDS patiënten 
[172], lijkt dit een veelbelovende optie voor nader onderzoek. Naar aanleiding van 
de resultaten beschreven in hoofdstuk 7 is het ook van belang om het effect van 
IL-1ra (Anakinra) in HIDS te bestuderen. 
De ontdekking van de betrokken genen, therapeutische mogelijkheden en 
onderzoek naar de pathogenese, zoals ook beschreven in dit proefschrift, is slechts 
mogelijk geworden door de accurate fenotypische beschrijving van patiënten met 
periodieke koorts. Nauwkeurige analyse en de juiste groepering van deze patiënten 
is onmisbaar om onderzoek zowel naar de genetische achtergrond als naar 
behandeling mogelijk te maken. Dit wordt sterk bevorderd door de ontwikkeling 
van centrale periodieke koorts registers, zoals het Internationale HIDS Register in 
Nijmegen (zie de website hids.net), waardoor ook eerder niet onderkende 
symptomen ontdekt kunnen worden. Veel periodieke koorts patiënten vallen nog 
steeds niet in een van de bekende categorieën. Dit is een grote uitdaging. Het is de 
verwachting dat in de toekomst meer periodieke koorts syndromen en 
bijbehorende gen-defecten ontdekt zullen worden. 
Tot nu toe bevat het Internationale HIDS register met name gegevens verzameld 
op het moment dat patiënten geïncludeerd worden in de database. Dit maakt het 
mogelijk om dwarsdoorsnede onderzoek te doen. We zijn van plan om dit in de 
nabije toekomst aan te vullen met follow-up data, zodat we meer te weten komen 
over het natuurlijke beloop en de prognose van HIDS. Zulke informatie is tot op 
heden nog niet op een systematische manier verzameld. Eén van de interessante 
aspecten van de prognose van HIDS is de extreme zeldzaamheid van systemische 
amyloidose als een complicatie van deze chronische ontstekingsziekte; onderzoek 
op dit gebied zal naar alle waarschijnlijkheid waardevolle informatie opleveren 
over de pathogenese van systemische amyloidose in het algemeen. 
Zelfs 20 jaar na de eerste beschrijving van HIDS is de rol van IgD nog steeds 
onduidelijk (zie ook hoofdstuk 5), en IgD is nog steeds het verwaarloosde broertje 
onder de immunoglobulines. Niet alle patiënten met MVK gen mutaties en een 
verminderde MK activiteit hebben een hoge serum IgD concentratie, terwijl de 
IgD concentratie ook in andere aandoeningen (licht) verhoogd kan zijn. Daarom 
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wordt door sommige onderzoekers gesuggereerd dat de naam HIDS (Hyper-IgD 
en periodieke koorts syndroom) niet langer geschikt is om te gebruiken voor deze 
erfelijke auto-inflammatoire aandoening, omdat het te veel de nadruk legt op IgD. 
Echter, HIDS is een gevestigde naam in de medische literatuur en aangezien de 
exacte pathogenese van HIDS nog steeds onbekend is, zijn wij van mening dat een 
naamsverandering op dit moment alleen tot meer verwarring zal leiden, hetgeen 
het ziektebeeld en de patiënten niet ten goede komt.  

 Epiloog 
Samenvatting voor leken 
Epiloog 
 
178 
Dit proefschrift gaat over autoinflammatoire ziekten en dan met name over de 
zeldzame ziekte HIDS. Alle onderzoeken die we de afgelopen jaren in het UMC 
St. Radboud te Nijmegen hebben verricht komen aan bod. 
 
Autoinflammatoire ziekten zijn zeldzame erfelijke aandoeningen, die gekenmerkt 
worden door steeds terugkerende perioden met koorts en symptomen van 
ontsteking. Bij deze ziekten lijkt het alsof er regelmatig vanzelf (=”auto”) een 
ontstekingsreactie (=“inflammatie”) ontstaat die zich richt tegen het eigen lichaam. 
Er lijkt een defect te zijn waardoor ontstekingsreacties niet goed afgeremd kunnen 
worden.  
Het lichaam heeft een ingewikkeld ontstekings- en afweerapparaat, waarvan we 
nog lang niet alle details kennen. Het wordt onder andere gebruikt om stoffen die 
niet in het lichaam thuis horen snel weg te werken. Denk bijvoorbeeld aan een 
splinter in je vinger: als die blijft zitten ontstaat vaak na korte tijd een ontsteking 
op die plek om de splinter weg te krijgen. Dat merk je omdat de plek warm en 
rood wordt, en gaat kloppen. Als het nog erger wordt, kun je er zelfs koorts bij 
krijgen. Maar als de splinter er eenmaal uitgevallen is, is de ontsteking niet meer 
nodig en alleen nog maar hinderlijk. Het lichaam heeft daarom ook de 
mogelijkheid om een ontsteking weer stop te zetten als deze niet meer nodig is. 
Het lichaam is normaal zo goed ingesteld dat het de meeste dreigende problemen, 
zoals een wondje of een bacterie, kan oplossen met behulp van een kleine 
ontsteking, waar je zelf niet eens iets van merkt. Dit gebeurt vrijwel dagelijks. Pas 
als het probleem te groot is om zomaar op te lossen ga je het merken: je krijgt dan 
bijvoorbeeld verkoudheidsverschijnselen als je een virus oploopt of diarree na het 
eten van besmet voedsel.   
Schijnbaar wordt een ontstekingsreactie bij iemand met een autoinflammatoire 
ziekte zoals bijvoorbeeld HIDS niet voldoende afgeremd. Daardoor kan een 
ontsteking veel makkelijker uit de hand lopen. Pas na een langere periode dooft de 
ontstekingsreactie uit.  
 
Het hyper-IgD syndroom, ook wel HIDS genoemd, is een ziekte die gepaard gaat 
met steeds terugkerende perioden met hoge koorts met daarbij andere 
ontstekingsverschijnselen, zoals opgezette lymfklieren, vermoeidheid, hoofdpijn, 
spierpijn en buikpijn. Zo’n koortsaanval duurt meestal een paar dagen, om dan 
weer spontaan te verdwijnen. In het bloed wordt een hoge concentratie van een 
bepaald eiwit, het IgD, gevonden. (zie voor meer uitleg de website hids.net). 
In 1999 is ontdekt wáár precies in de erfelijke informatie de mutatie zit bij 
patiënten met HIDS. Het blijkt te gaan om het stuk DNA (=gen) dat informatie 
bevat voor het maken van één bepaald eiwit, dat mevalonaat kinase genoemd 
wordt. Mevalonaat kinase speelt een centrale rol in een aantal processen in de cel, 
waarbij onder andere cholesterol gevormd wordt. Bij HIDS werkt dit mevalonaat 
kinase niet goed. Hoe dit dan leidt tot de koortsaanvallen is nog niet bekend.  
 
Hoofdstuk 1 van dit proefschrift is een overzicht van de kenmerken van de 
verschillende autoinflammatoire ziekten. Ze geven allemaal koortsaanvallen, maar 
de bijkomende symptomen zijn vaak net even anders, evenals de duur van de 
koortsaanval of de manier van overerving. In de afgelopen jaren is van elk van 
deze ziekten ontdekt waar de genetische fout zit. Van deze autoinflammatoire 
ziketen is HIDS al genoemd. Twee andere ziekten uit deze groep zijn FMF en 
TRAPS.  
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Familiaire Middellandse Zeekoorts (FMF) komt het meeste voor. Zoals de naam 
al doet vermoeden komt het vooral voor bij mensen die afkomstig zijn uit landen 
rond de Middellandse Zee, bijvoorbeeld Turkije en Israël. FMF wordt eigenlijk 
nooit gevonden bij mensen van Nederlandse afkomst, maar wel bij immigranten, 
waardoor tegenwoordig ook Nederlandse artsen het regelmatig tegenkomen. Bij 
FMF staat vaak de buikpijn tijdens een koortsaanval op de voorgrond, of 
gewrichtsklachten. Aanvallen duren vaak 2 of 3 dagen. Voor FMF bestaat een 
goede behandeling: door dagelijks colchicine te gebruiken blijven de meeste 
aanvallen weg; sommige patiënten hebben zelfs helemaal geen aanvallen meer. 
TRAPS (afkorting van de Engelse naam “TNF-receptor associated periodic 
syndrome) is een ziekte met koortsaanvallen die meestal langer duren. Bij veel 
patiënten duurt een aanval 2 tot 3 weken; meestal blijft het dan wel beperkt tot 2 of 
3 aanvallen per jaar. TRAPS heeft een andere manier van overerven dan FMF en 
HIDS. Het komt ook voor in Nederland. (Meer informatie over TRAPS is te 
vinden op de website http://hids.net/TRAPS/grond.htm). 
Deze aandoeningen kunnen sterk op elkaar lijken, maar in het algemeen is het wel 
mogelijk onderscheid te maken door te letten op de kleine verschillen. 
 
De volgende 8 hoofdstukken gaan specifiek over HIDS. 
In hoofdstuk 2 wordt een studie beschreven over DNA-onderzoek waarmee de 
diagnose HIDS gesteld kan worden. We onderzochten een stukje DNA van een 
groep HIDS-patiënten. Al deze patiënten hadden fouten (=mutaties) in het gen 
voor mevalonaat kinase, maar dit waren niet altijd dezelfde mutaties. In totaal 
werden 13 verschillende mutaties gevonden. Er bleken echter twee mutaties te zijn 
die bij bijna iedere HIDS-patiënt voorkomen. Om vast te stellen of er sprake is van 
HIDS hoeft in het begin alleen gekeken te worden of de patiënt één van deze twee 
mutaties heeft. Dat maakt het DNA-onderzoek een stuk eenvoudiger. 
 
In de volgende studie wilden we weten of alle patiënten die, gezien hun klachten, 
HIDS leken te hebben ook daadwerkelijk de passende DNA-mutaties hadden 
(hoofdstuk 3). Dat bleek niet zo te zijn: van 54 patiënten die klachten hadden 
passend bij HIDS hadden 41 patiënten ook echt de mutaties in het mevalonaat 
kinase gen. De andere 13 patiënten hadden een normaal mevalonaat kinase gen 
zonder fouten, en dus een normaal werkend mevalonaat kinase eiwit. Om deze 
twee groepen te onderscheiden noemden we de eerste groep “klassieke type 
HIDS” en de laatste groep “variant type HIDS”. Toen we daarna opnieuw keken 
naar de klachten en kenmerken van de twee groepen patiënten bleken er kleine 
verschillen te zijn. Van de patiënten met “variant type HIDS” weten we nog niet 
wat de oorzaak van de koortsaanvallen is. Het is goed mogelijk dat deze patiënten 
zelfs niet allemaal dezelfde ziekte hebben. Het is opvallend dat de patiënten met 
“variant type HIDS” eigenlijk nooit familieleden hebben met dezelfde klachten. 
Mogelijk dat dit geen erfelijke ziekte is.  
 
Al jaren voor de ontdekking van de mutaties in het mevalonaat kinase gen in HIDS 
was er al een ziekte beschreven die veroorzaakt wordt door mutaties in hetzelfde 
gen. Deze ziekte wordt klassieke mevalonacidurie (letterlijk: uitplassen van 
mevalonzuur) genoemd. In klassieke mevalonacidurie hebben patiënten ook 
koortsaanvallen die veel lijken op die van HIDS. Maar ze hebben ook nog veel 
andere afwijkingen, met name aan de hersenen. De meeste van deze patiënten zijn 
verstandelijk gehandicapt en ze overlijden op jonge leeftijd. Het verbaasde ons dat 
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mutaties in hetzelfde gen konden leiden tot twee ziekten die zo veel verschillen 
van elkaar. We hadden het vermoeden dat het eigenlijk gaat om één ziekte, die 
zich meer of minder ernstig kan uiten. Dit vermoeden wordt ondersteund door het 
onderzoek beschreven in hoofdstuk 4. We vonden namelijk vijf volwassen 
patiënten met mutaties in het gen voor mevalonaat kinase, van wie het ziektebeeld 
niet echt paste bij klassieke mevalonacidurie maar ook niet helemaal bij HIDS. 
Hoe ernstig ziek iemand wordt hangt waarschijnlijk af van het soort mutatie in het 
gen, maar ook van andere, nog onbekende factoren. 
 
In de volgende studie hebben we bestudeerd wat er verandert in het bloed van een 
HIDS patiënt tijdens een koortsaanval (hoofdstuk 5). We hebben gekeken naar 
bepaalde eiwitten die met ontsteking te maken hebben. Hierbij waren we op zoek 
naar een bepaling in het bloed die zou kunnen helpen om het onderscheid te maken 
tussen een “gewone” koortsaanval, passend bij HIDS, en een infectie met een 
bacterie, die ook koorts geeft. Dit zou van belang kunnen zijn bij de behandeling 
van HIDS: door makkelijker vast te stellen dat het om HIDS gaat, kan onnodig 
gebruik van antibiotica (wat zou helpen als het om een bacterie zou gaan) 
voorkomen worden. In dit onderzoek wordt aangetoond dat een combinatie van 
een hoge concentratie van één eiwit (namelijk CRP) met een niet-verhoogde 
concentratie van een ander eiwit (namelijk procalcitonine) waarschijnlijk alleen bij 
een HIDS-aanval gevonden wordt, en niet bij een bacterie. Er is meer onderzoek 
nodig alvorens deze resultaten in de praktijk gebruikt zullen kunnen worden bij 
een individuele patiënt.  
 
In ons centrum onderhouden we een register waarin we gegevens van alle HIDS-
patiënten ter wereld proberen te verzamelen. Het viel ons op dat veel patiënten met 
HIDS afkomstig waren uit Nederland, en we vroegen ons af hoe dat kwam. Eén 
oorzaak is dat er juist in Nederland veel wetenschappelijk onderzoek gedaan wordt 
naar HIDS, onder andere in Amsterdam (vanuit een biochemisch laboratorium), 
Utrecht (vanuit de afdeling kindergeneeskunde) en Nijmegen (vanuit de afdeling 
interne geneeskunde). Hierdoor weten meer artsen in Nederland van het bestaan 
van deze zeldzame ziekte en zal de diagnose eerder gesteld worden. Er blijkt 
echter nog een andere oorzaak te zijn: door middel van DNA-onderzoek hebben 
we aangetoond dat een groot aantal patiënten met HIDS ergens in de geschiedenis, 
honderden jaren geleden, van een zelfde voorouder afstamt (hoofdstuk 6).  
 
Hoe het defect in mevalonaat kinase leidt tot koortsaanvallen is nog steeds niet 
precies bekend. In het volgende onderzoek in dit proefschrift (hoofdstuk 7) 
hebben we geprobeerd dit te onderzoeken in het laboratorium. Daarbij hebben we 
witte bloedcellen uit bloed van gezonde vrijwilligers en van verschillende HIDS-
patiënten gehaald en in een testbuisje bloot gesteld aan verschillende stoffen die 
met mevalonaat kinase en ontsteking te maken hebben. Dit heeft een aantal nieuwe 
aanwijzingen opgeleverd over het ontstaan van de koortsaanvallen. 
 
In de volgende twee hoofdstukken worden twee studies met geneesmiddelen 
beschreven met als doel een goede behandeling van HIDS te vinden. Aan beide 
studies werkten 6 patiënten met HIDS mee die zeer vaak last hadden van 
koortsaanvallen. In beide studies werd het effect van een bepaald geneesmiddel 
vergeleken met dat van een nep-pil (=placebo), waarbij de onderzoekers en de 
patiënt niet wisten wanneer ze wat gebruikten.  
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Eerst werd het effect van het geneesmiddel thalidomide onderzocht (hoofdstuk 8). 
Helaas leidde thalidomide niet tot in aantal minder aanvallen of tot minder ernstige 
aanvallen; het gaf alleen een lichte daling van de concentratie van 
ontstekingseiwitten in het bloed. Dit is dus geen goede behandeling voor HIDS. 
Daarna onderzochten we het effect van simvastatine (hoofdstuk 9). Simvastatine 
is een geneesmiddel dat meestal gebruikt wordt om het cholesterol te verlagen.  
Het remt een bepaald eiwit dat veel te maken heeft met mevalonaat kinase, en 
daarom was het interessant om dit te onderzoeken. We wisten uit ervaring dat het 
leek te helpen bij één of twee HIDS-patiënten. Dus hebben we een uitgebreider 
onderzoek gedaan gedurende een jaar, waarbij de deelnemers een half jaar 
simvastatine gebruikten en een half jaar een placebo, zonder te weten welke ze 
gebruikten. Gedurende dat jaar hielden zij bij hoe vaak ze een koortsaanval hadden 
en hoe hevig die aanvallen waren. Het resultaat was goed: vijf van de zes patiënten 
waren duidelijk minder dagen ziek tijdens het gebruik van simvastatine dan tijdens 
de nep-pil. Simvastatine heeft weinig bijwerkingen en lijkt dus een veelbelovende 
behandeling om het aantal dagen ziekte te verminderen. De komende jaren moet in 
de praktijk duidelijk worden hoe goed het werkt en wat de beste dosering is. 
Helaas onderdrukte simvastatine niet alle aanvallen. Het kan dus alleen als een 
onderhoudsbehandeling gebruikt worden om het aantal ziektedagen te 
verminderen.  
Daarnaast zou het mooi zijn als er een geneesmiddel gevonden wordt dat de 
patiënt kan gebruiken op het moment dat hij of zij een aanval voelt opkomen, om 
de aanval te stoppen. Op dit moment zijn we bezig met het onderzoeken van een 
dergelijk geneesmiddel; de resultaten hiervan zijn nog niet bekend. Binnenkort 
gaat waarschijnlijk een landelijk onderzoek van start waarbij we een ander 
geneesmiddel willen testen, dat ook gebruikt kan worden op het moment dat de 
patiënt een koortsaanval voelt aankomen 
 
In hoofdstuk 10 beschrijven we een studie naar de beste manier om de juiste 
diagnose te stellen bij patiënten met periodieke koortsaanvallen. Hierbij komt 
onder andere naar voren dat er nog steeds veel patiënten met koortsaanvallen zijn 
bij wie we geen naam aan de ziekte kunnen geven. Deze patiënten hebben dus 
bijvoorbeeld geen HIDS, FMF of TRAPS en dit zou kunnen betekenen dat er nog 
een aantal ziekten is die we niet kennen. Er is nog veel onderzoek nodig om deze 
nieuwe ziekten te ontdekken. 
 
De volgende drie onderzoeken gaan over TRAPS. In hoofdstuk 11, 12 en 13 
beschrijven we een aantal patiënten met TRAPS en het verloop van de ziekte bij 
deze mensen. Ook beschrijven we hier onze ervaringen met de behandeling van 
TRAPS met behulp van ontstekingsremmers, zoals het zogenaamde etanercept en 
anakinra.  
 
Het laatste hoofdstuk (hoofdstuk 14) gaat over FMF, en met name over de FMF-
aanvallen die gepaard gaan met hevige buikpijn. We beschrijven de kenmerken 
van zulke aanvallen, de beste manier is om onderscheid te maken tussen een FMF-
aanval en een gevaarlijke complicatie en de beste behandeling. 
 
Al deze wetenschappelijke onderzoeken hebben informatie opgeleverd over de 
autoinflammatoire syndromen; de oorzaak, de verschijnselen tijdens de 
koortsaanvallen en de behandeling. Stap voor stap komen we zo steeds meer te 
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weten. Maar er is nog veel onderzoek nodig voor we alles begrijpen en voor we 
weten hoe we patiënten en families met deze aandoeningen het beste kunnen 
behandelen. Daarom wordt het onderzoek naar HIDS en andere autoinflammatoire 
ziekten in het Universitair Medisch Centrum St. Radboud in Nijmegen voortgezet. 
Hierbij wordt zowel samengewerkt met artsen en onderzoekers in Amsterdam en 
Utrecht, als met onderzoeksinstituten in het buitenland. 
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CIAS1 gene cold induced autoinflammatory syndrome gene (= NALP3 = PYPAF) 
CINCA  chronic infantile neurological cutaneous and articular syndrome (=NOMID) 
CRP  C-reactive protein 
FCAS  familial cold autoinflammatory syndrome 
FMF  familial mediterranean fever 
HIDS  hyper-IgD and periodic fever syndrome 
HMG-CoA 3’5’-hydroxymethylglutaryl coenzyme A 
IgA  immunoglobulin A 
IgD  immunoglobulin D 
LPS  lipopolysaccharide 
MEFV gene mediterranean fever gene, associated with FMF 
MIM  Mendelian inheritance in men database 
MK  mevalonate kinase 
MVA  mevalonic acid 
MVK gene  mevalonate kinase gene 
MWS  Muckle-Wells syndrome 
NOMID  neonatal onset multisystemic inflammatory disease (=CINCA) 
NSAIDs  non-steroid antiinflammatory drugs 
PAPA  pyogenic sterile arthritis, pyoderma gangrenosum and acne 
PBMCs  peripheral blood mononuclear cells 
PCT  procalcitonin 
PFAPA  periodic fever, aphtous stomatitis, pharyngitis and adenitis 
PTX3  pentraxin-3 
SAA  serum amyloid A 
TNF  tumour necrosis factor 
TNFRSF1A TNF-receptor type 1 (= p55) 
TNFRSF1B TNF-receptor type 2 (= p75) 
TRAPS  TNF-receptor associated periodic syndrome 
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zeker hebben, bedankt voor de frequente praktische hulp, maar vooral ook voor 
alle discussies. Daarnaast alle andere arts-assistent-onderzoekers binnen de interne 
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plotseling uit het onderzoek weggeroepen werden om de Spoedeisende Hulp of 
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band.  
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Mireille, bedankt voor je hulp als grootste leek en dat is zeker bedoeld als 
compliment. 
En, last but not least, mijn ouders, voor hun onvoorwaardelijke steun en speciaal 
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De schrijver van dit proefschrift werd op 21 mei 1974 te Hilvarenbeek geboren. 
Zij behaalde haar eindexamen gymnasium aan het Jacob Roelantslyceum te Boxtel 
in 1992. In de zomer van 1992 werd zij uitgezonden als één van de twee 
Nederlandse deelnemers aan het “dr. Bessie F. Lawrence 24th International 
Summer Science Institute for pre-university students”, aan het Weizmann Institute 
of Science te Rehovot, Israel. Daarna begon zij haar studie Geneeskunde in 
Utrecht, die in 1997 werd afgesloten met het doctoraalexamen (cum laude), in 
1999 gevolgd door het artsexamen. Tijdens deze studie werkte ze twee jaar als 
student-assistent Microscopische Anatomie. Een wetenschappelijke stage op de 
afdeling Endocrinologie van het Academisch Ziekenhuis Utrecht (onder leiding 
van prof.dr. C. Lips en dr. H. Koppeschaar) werd wegens interesse een aantal 
maanden uitgebreid en leidde in 1997 tot een bezoek van 3 maanden aan het 
laboratorium van prof. M. Levine, Johns Hopkins University, Baltimore, 
Maryland, USA.  
In augustus 1999 begon zij met haar opleiding tot internist in het Canisius 
Wilhelmina Ziekenhuis te Nijmegen (opleider dr. R. de Koning). Na toekenning 
van een NWO AGIKO subsidie volgde in januari 2000 overplaatsing naar het 
UMC St. Radboud te Nijmegen (opleider prof.dr. J.W.M. van der Meer) en werd 
gestart met het onderzoek beschreven in dit proefschrift. In april 2004 zette zij 
haar opleiding tot internist voort in het Canisius Wilhelmina Ziekenhuis te 
Nijmegen (opleider dr. A.S. Dofferhoff). 
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Appendix III 
Sebright Bantam and science, 
or: Why the chickens? 
 
Just as man can give beauty, according to his standard of taste, to 
his male poultry […], can give to the Sebright bantam a new and 
elegant plumage, an erect and peculiar carriage – so it appears that 
female birds […] have by a long selection of the more attractive 
males, added to their beauty or other attractive qualities. 
Charles Darwin, 1882, in “The Descent of Man”. 
 
The cover illustration of this thesis is no random choice. I first encountered the 
Sebright bantam while working on my predoctoral research in the field of 
pseudohypoparathyroidism. It is a good example of my motto, the observation by 
William Harvey (page 5) that “nature is nowhere accustomed more openly to 
display her secret mysteries than in cases where she shows traces of her workings 
apart from the beaten path”. Observation of such traces is central to scientific 
research – and the Sebright bantam rooster has in this way inspired a whole series 
of renowned scientists since the beginning of the 19th century.  
 
First, what is so special about the Sebright bantam rooster? You can see it in the 
illustration: the Sebright bantam rooster in the foreground has the large comb of a 
rooster, but the short, upright tail feathers, called henny feathers, normally seen on 
a hen (the other chicken is a Black bantam rooster with regular long and curvy 
cocky feathers). So the Sebright bantam rooster is a genetic male with female tail 
feathers. It was discovered by Sir John Sebright, an avid animal breeder, in the 
beginning of the 19th century.   
 
Sebright’s work caught the attention of Charles Darwin, who used the Sebright 
bantam as one of the examples to support his theory of evolution. In the beginning 
of the 20th century, Thomas Hunt Morgan, who later won a Nobel prize for his 
discovery of gene linkage and the chromosomal basis of heredity, chose the 
Sebright bantam as a model system for his studies on embryonic development and 
showed that henny feathering was transmitted by an autosomal dominant gene. 
The brilliant endocrinologist Fuller Albright, who found out about the Sebright 
bantam through Morgan’s work, used it as an example of his postulation that 
hormones must have receptors in their target tissues. In 1942, he proposed that the 
female feathering was caused by a resistance to the action of the male sex 
hormone, testosterone, similar to the defect he had just demonstrated in patients 
with pseudohypoparathyroidism, whose kidneys and bone were resistant to 
parathyroid hormone. 
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Almost forty years later, this theory was proved wrong by Jean Wilson and his 
colleagues. They demonstrated that the androgen receptors in these chickens are 
perfectly normal. The problem is located at the level of aromatase, the enzyme that 
converts testosterone to estradiol. While aromatase is normally only expressed in 
very specific tissues in chickens, in the Sebright bantam the tissue specificity of 
aromatase expression is lost, and estrogen is formed in many tissues including 
skin. The feathers of the Sebright bantam rooster are thus female because of high 
local estrogen levels. Further examination revealed that this increased expression 
of aromatase is caused by the presence of a second promotor sequence for the 
aromatase gene, which is most likely due to an inadvertent retroviral insertion in 
the chicken’s DNA. And as recently as one year ago, the Sebright bantam was 
referred to again in medical literature, as three human patients were described with 
a new defect, very similar to that of the Sebright bantam – gain-of-function 
mutations in the aromatase gene leading to excess estrogen. 
 
Thus, a relatively harmless rare defect in the feathering pattern of a chicken has 
fuelled scientific minds for the last 200 years, resulting in a series of important 
discoveries. The study of rare (orphan) diseases, such as hereditary 
autoinflammatory syndromes, when brought beyond the scope of “stamp 
collecting”, may in a similar way not only benefit the patients suffering from it, 
but increase our knowledge of life in general. 
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